

# ANNUAL REPORT 2021-2022



**WATA  
CHEMICALS  
LIMITED**

# Contents ANNUAL REPORT 2021-2022

**03**

Transmittal Letter

**04**

Corporate Historical & Financial Highlights

**05-06**

Profile Of Board Of Directors

**07**

Message From The Chairman

**08**

Message From Managing Director

**09-10**

Notice Of 40th Annual General Meeting

**11-20**

Director's Report

**21-22**

Audit Committee's Report

**23-24**

Management Discussion & Analysis

**25-28**

Corporate Governance Report

**29**

NRC Report

**30-39**

Certificate on Compliance of Conditions  
of Corporate Governance Guidelines

**40**

Declaration by CEO and CFO as per  
Condition No. 1(5)(xxvi)

**42-46**

Auditor's Report

**47**

Statement of Financial Position

**48**

Statement of Profit or Loss and  
Other Comprehensive Income

**49**

Statement of Changes in Equity

**50**

Statement of Cash Flows

**51-98**


Notes & Schedules on Financial Statements

**99-112**

Some Photographs of Wata Chemicals Ltd

**LAST PAGE**

Proxy & Attendance Form





## BOARD OF DIRECTORS:

### CHAIRMAN

Mr. Razi Uddin Ahmed  
General Manager (ICB)  
(Nominated Director)

### MANAGING DIRECTOR & CEO

Mr. Md. Nazrul Islam

### DIRECTOR

Mr. A.H.M. Abdullah  
BSc. in Chemical Engineering (BUET)  
Mr. Md. Mahmudul Hasan  
MBA (DU)

### INDEPENDENT DIRECTOR

Mr. Md. Iftikhar-Uz-Zaman

### AUDIT COMMITTEE

Mr. Md. Iftikhar-Uz-Zaman  
Independent Director  
Chairman of Audit Committee

Mr. Subrata Pal- FCMA  
Non Executive Director  
Member of Audit Committee

Mr. A.T.M. Najmul Hussain  
Non Executive Director  
Member of Audit Committee

### NRC COMMITTEE

Mr. Md. Iftikhar-Uz-Zaman  
Independent Director  
Chairman of NRC

Mr. Subrata Pal- FCMA  
Non Executive Director  
Member of Audit Committee

Mr. A.T.M. Najmul Hussain  
Non Executive Director  
Member of Audit Committee

## Corporate Information

### COMPANY SECRETARY

Mr. Shamsul Huq

### CHIEF FINANCIAL OFFICER

Mr. Md. Ali Ahsan

### GENERAL MANAGER (FACTORY)

Mr. Abu Taher Bhuiyan

### GENERAL MANAGER, FINANCE & ACCOUNTS

Mr. Md. Ashraful Alam

### HEAD OF MAINTENANCE ENGINEER CIVIL

Mr. SM Farhan Ali Reza  
BSc. in Civil Engineering (KUET)

### HEAD OF MAINTENANCE ENGINEER MECHANICAL

Mr. Md. Basherul Islam  
BSc. in Mechanical Engineering (KUET)

### HEAD OF INTERNAL AUDIT

Md. Milan Hossain

### MANAGER ACCOUNTS

Mr. Tapos Chandra Sarkar

### COMMERCIAL MANAGER

Mr. Mohammad Ali

### MARKETING INCHARGE

Md. Abdul Jobbar

### PRODUCTION MANAGER

Mr. Babul Das

### ACCOUNTS OFFICER

Mr. Md. Abdul Hakim

### STATUTORY AUDITOR

MABS & J PARTNERS  
Chartered Accountants  
SMC Tower (7th Floor)  
33, Banani C/A, Road No- 17  
Dhaka-1213

### AUDITOR OF CGG

Shafiq Basak & Co.  
(4th & 6th Floor)  
292, Inner Circular Road  
Fakirapool, Motijheel, Dhaka.

### PRINCIPAL BANKERS

Agrani Bank Ltd.  
Principal Branch Motijheel C/A  
Dhaka.

### LEGAL ADVISOR

Sekander Ali & Associates  
TMC Bhabon, New Eskaton Road  
Dhaka-1000.

### CREDIT RATING AGENCY

Emerging Credit Rating Limited  
Shams Rangs, House 104, Park Road  
Level-A1 & Level-A2, Baridhara  
Dhaka-1212

### REGISTERED HEAD OFFICE

17/B, Monipuripara (3rd Floor)  
Sangshad Avenue, Dhaka-1215

### FACTORY

Murapara, Rupgonj, Narayangonj.

### PHONE

58152001, 58155206

### FAX

+880-2-5855091

### WEB SITE

[www.watachemicals.com](http://www.watachemicals.com)

### E-MAIL

[watachemicals@gmail.com](mailto:watachemicals@gmail.com)

# Transmittal Letter

08 December 2022

The Valued Shareholders  
Bangladesh Securities and Exchange Commission  
Dhaka Stock Exchange Ltd.  
Chittagong Stock Exchange Ltd.  
Central Depository of Bangladesh Ltd.  
Registrar of Joint Stock Companies & Firms

Sub: Annual Report 2021 - 2022, for the year ended on 30 June 2022.

Dear Sir(s),

We are pleased to enclose Notice of the 40th Annual General Meeting, a copy of Annual Report Containing Directors Report together with Audited Financial Statements including Statement of Financial Position as on 30 June 2022, Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year ended on 30 June 2022 along with notes thereon of WATA CHEMICALS LIMITED for your kind information & records and necessary measures.

Thanking you.

Yours faithfully,



(Shamsul Huq)  
Company Secretary

# Corporate Historical & Financial Highlights

## CORPORATE HISTORICAL HIGHLIGHTS:

	YEAR
Incorporated as a Limited Company	1981
Commencement of production in Alum Plant	1986
Establishment of Sulphuric Acid Plant	1987
Full fledged commercial production (Alum & Acid)	1991
Commercial Production in Zinc Sulphate Plant	1994
Commercial Production in BCP Plant	1997
Commercial Production in LABSA Plant	2002
Commercial Production in Magnesium Sulphate Plant	2002
Increase of Plant Capacity	2003-2004
Establishment of New Sulfuric Acid Plant	2018
Sodium Lauryl Ether Sulphate/Linear Alkyle Benzene Sulfonic Acid (under construction)	2019-2020
Offering of Public share	1992
Increase of Authorized Capital from 5 Crore to 15 Crore	1994
<b>Enlistment with Stock Exchange:</b>	
Dhaka Stock Exchange Ltd.	1992
Chittagong Stock Exchange Ltd.	1997
Listed with Central Depository Bangladesh Ltd.	2011
Offering of Right Issue	1995
Bonus Share Issued at 4:1	1997
Bonus Share Issued at 5:1	2012
Bonus Share Issued at 10:3	2013
Bonus Share Issued at 4:1	2014
Bonus Share Issued at 10:1	2015-2016
Bonus Share Issued at 20:1	2016-2017
Bonus Share Issued at 10:3	2017-2018
Bonus Share Proposed at 4:1	2018-2019

## CORPORATE FINANCIAL HIGHLIGHTS AS ON 30.06.2022

AMOUNT BDT
Tk. 15.00 Crore
Tk. 14.82 Crore
Tk. 33.62 Crore
Tk. 03.24 Crore
Tk. 50.26 Crore
Tk. 61.18

## CORPORATE OPERATIONAL RESULTS OF LAST 5 YEARS

PARTICULAR	2021-2022	2020-2021	2019-2020	2018-2019	2017-2018
Turnover	1,036,043,378	649,079,365	837,993,834	923,341,039	465,372,187
Gross Profit	279,137,551	216,830,312	283,922,156	298,979,576	138,742,236
Net Profit Before Tax	80,879,845	98,049,177	170,171,476	187,352,529	62,790,548
Net Profit After Tax	59,958,120	90,957,313	119,323,458	137,966,568	52,224,093
Paid up Capital	148,226,180	148,226,180	148,226,180	118,580,950	91,216,120
Earning Per Share	4.05	6.14	8.05	9.31 (Re-Statement)	5.72
Dividend (%)	General Shareholder 20% Cash Directors 10% Cash (Proposed)	30% Cash	35% Cash	25% Stock 30% Cash	30% Stock & 10% Cash

# Profile Of Board Of Directors



**RAZI UDDIN AHMED  
CHAIRMAN**

Mr. Razi Uddin Ahmed was inducted as a ICB Nominated Director of Wata Chemicals Limited on 20 November 2021. Since 1990 he has been serving in Investment Corporation of Bangladesh (ICB) for last 31 years in various important positions. Presently Mr. Razi has been holding the position of General Manager of Admin and Operation Division, ICB.

Mr. Razi Uddin Ahmed obtained BSc (Honors) and Masters Degree in Economics in 1989, from Jahangirnagar University.

In his long career, Mr. Razi has worked in important areas like Appraisal Department, Special Fund Unit, Merchandising Division, AML/CFT Unit, Internal Control and Compliance Division, ICB Khulna Branch as Branch Manager of Investment Corporation of Bangladesh (ICB). In addition, he has also performed his responsibility as the Deputy Chief Executive Officer of ICB Asset Management Company Ltd., a subsidiary company of ICB and Deputy General Manager of establishment Division of ICB. He has participated in various programs, seminars and workshops. Mr. Razi is a life member of Bangladesh Economic Association.



**MD. NAZRUL ISLAM  
MANAGING DIRECTOR & CEO**

Mr. Md. Nazrul Islam, son of Late Alhaj Shakhawat Hossain and Late Motijan Nessa, is a reputed businessman. He has wide Experience in Management of Chemical Industry, Construction & Survey Firm and Import businesses. He is the functional head of the company who manages the affairs of WATA with appropriate delegation of authority and accountability while the Chief Executives of all strategic business units directly report to him. His business strategy and various backward and forward linkages have diversified the business in manifold resulting WATA a largest turnover based chemical company in Bangladesh. He is also Chairman of Board of Trustee of Sakhawat H. Memorial Trust having under it different educational organizations named S.M. Institute of Medical Technology & MATS, Sakhawat H. Memorial Nursing College. He has also established Autism Centre to bring Autistic Children in the main stream of society. He has traveled different countries of the World for business development purposes.

# Profile Of Board Of Directors



**MD. IFTIKHAR-UZ-ZAMAN**  
INDEPENDENT DIRECTOR

Mr. Md. Iftikhar-Uz-Zaman is an Independent Director of WATA Chemicals Limited, appointed by Board of Directors of the Company vide decision of the meeting of the Board of Directors held on 15.11.2020, and subsequently confirmed at 38th AGM held on 24.12.2020.

He is the Chairperson of the Nomination and Remuneration Committee and also the Audit Committee of WATA Chemicals Limited. He also serves as a Member of the Board of Directors this Company.

He was born in 09th June, 1957 and completed Hon's and Master's degree from University of Rajshahi. Mr. Md. Iftikhar-Uz-Zaman has more than 33 years of experience in service at Investment Corporation of Bangladesh (ICB) and Janata Bank Limited. He was the Managing Director of Investment Corporation of Bangladesh & Deputy Managing Director of Janata Bank Limited. He was previously discharge his responsibilities as Chairman of different Govt. /Non-Govt. Organization such as ICB Securities Trading Company Ltd., ICB Capital Management Ltd., ICB Asset Management Company Ltd., Jago Corporation Ltd. and as Director with Central Depository Bangladesh Ltd., British American Tobacco Ltd., Glaxo Smith Klien Bangladesh Ltd. Linde Bangladesh Ltd, Reneta Ltd., ACI Limited, Bangladesh Institute of Capital Market (BICM), Credit Rating Informations & Service Ltd. ,Credit Rating Agency of Bangladesh Ltd., Lafarge Surma Cement Ltd., Energypac Power Generation Ltd., Apex Tannery Ltd., Appex Footwear Ltd. and many more. He has also completed training courses of Capital Market Development from abroad.



**A.H.M. ABDULLAH**  
DIRECTOR

A.H.M. Abdullah is a Director of the Company. He is a BSc. in Chemical Engineering from BUET, Dhaka. He has completed HSC from Notre Dame College and SSC from Dhaka Residential Model College in Science Discipline. He has wide experience on Technology of Chemical Plant/Industries. He performs as member of the board's audit committee. He has significant contribution in the advancement of industrial as well as import sector of the company. He is also engaged in social work and has established a Autism Centre, Medical Assistant Training School, Nursing College at Sirajgonj for poor people of that area.



**MD. MAHMUDUL HASAN**  
DIRECTOR

Md. Mahmudul Hasan is a Director of the Company. He has completed MBA from University of Dhaka, BA (Hon's) in English, HSC from Notre Dame College, Dhaka, SSC from Dhaka Residential Model College and Engaged with foreign correspondences relating to procurement & Import of Chemical Raw Materials, Capitated Machineries of WATA CHEMICALS LIMITED. Md. Mahmudul Hasan has continued to maintain management style in WATA, with special emphasis on quality, productivity and customers services. He is currently serving as the head of the administration department. He is also engaged in social work and with Autism Center, Nursing College at Sirajgonj.

# MESSAGE FROM THE CHAIRMAN DIRECTOR

Dear Shareholders,  
Assalamu Alikum

I am pleased to write to you and present to you our 40th Annual Report for Financial Year (FY) 2021-22. This year has been a remarkable year for all of us. I am grateful to our partners, team members, and other stakeholders for their relentless collaboration to make this happen. I firmly believe that the global economy continues to operate under uncertainty and Wata Chemicals Ltd. will endeavor to navigate this uncertainty with due prudence, caution and forethought.

Our company has earned Net Profit after Tax of Tk. 59,958,120 in 2021-2022 despite facing many constraints like post Covid-19 pandemic effect, the war between Russia and Ukraine, devaluation of BDT compared to US Dollar and unprecedented cost push. For FY 2021-2022, 20% cash Dividend for General Shareholders (other than Directors) and 10% cash dividend for Directors has been recommended which is subject to approval by the Honorable Shareholders at the 40th Annual General Meeting. We will continue to drive ahead in building a more sustainable specialty in chemical business for enhancing our stakeholders' value.

Our commitment to responsible growth has always been the focal point of everything. It has been our belief that sustainable and purposeful businesses will stand the test of time and drive superior long-term performance more effectively than ever before.

I would once again like to express my gratitude to all of our team members for valiantly fighting through the challenges posed by this unprecedented crisis and extend my sincere gratitude to the Board for its continued Guidance and Support. I also convey heartfelt appreciation to all of our business partners, vendors and other business associates who have firmly stood by our Company amidst adversity. We deeply value the faith, guidance and support of all our shareholders and would continue to do so as we attempt to emerge stronger from the challenges and look ahead to brighter times.



  
Razi Uddin Ahmed  
Chairman

# MESSAGE FROM THE MANAGING DIRECTOR

Dear Shareholders,

Assalamu Alikum

I am delighted to welcome all the shareholders to the 40th Annual General Meeting of our company.

We are pleased to inform you that we have ended another year with satisfactory results although there has been global crisis. Despite the increasingly challenging environment, we continue to achieve our business profitably.

Our company has earned Net Profit after Tax of Tk. 59,958,120 in 2021-2022 despite facing many constraints like post Covid-19 pandemic effect, the war between Russia and Ukraine, devaluation of BDT compared to US Dollar.



Our company has earned Net Profit after Tax of Tk. 59,958,120 in 2021-2022 despite facing many constraints like post Covid-19 pandemic effect, the war between Russia and Ukraine, devaluation of BDT compared to US Dollar.

Gross Sales during 2021-2022 has been increased by Tk. 38,69,64,013 compared to the year of 2020-2021 but EPS reduced to tk.4.05 from tk.6.14. During 2021-2022 sales of Sulfuric Acid, Aluminium Sulphate, Zinc Sulphate and Magnesium Sulphate has been increased. But Cost of Goods Sold has also been increased by Tk. 32,16,85,014. Unexpectedly huge Exchange Loss in 4th quarter affected negatively in the net profit ratio despite increased gross profit ratio and thus finally affected in EPS ratio.

The company has installed a project namely Sodium Lauryl Ether Sulphate and Linear Alkyl Benzene Sulphonic Acid which will help in maximizing the revenue & profit as well as bringing the pace of growth of our company. We already knew that COVID-19 situation in China is not overcome because of which machineries supplier of China unable to come for commissioning, test operation/trial production. But in the meantime, we have conducted Test production by our technical team. But for few technical errors, we need support from Machineries Supplier Expert Team. They have already ensured us to provide this support as soon as possible. We hope, technical errors will be solved by China Expert Team and the project will come into commercial production very soon.

We are in the early stages of our growth story, with remarkable runway ahead of us. We will continue to build on the strong initiatives that are in place while exploring new opportunities and enhancing our future readiness.

We believe that success is largely due to 'Hard Working', 'Creative Vision', 'Timely Delivery'. These values extend to all of our relationships with customers, employees and business partners. Hopefully, we will create new possibilities by enhancing value, improving returns and contributed to national economy and wealth.

I am very grateful to all our shareholders for your belief and trust in this journey and look forward to your continued support towards the development of our company.

A handwritten signature in black ink, appearing to read 'Md. Nazrul Islam'.

Md. Nazrul Islam  
Managing director



# ওয়াটা কেমিক্যালস লিঃ ৪০ তম বার্ষিক সাধারণ সভার বিজ্ঞপ্তি

এতদ্বারা ওয়াটা কেমিক্যালস লিমিটেড- এর সম্মানিত শেয়ারহোল্ডারগণের জ্ঞাতার্থে জানানো যাচ্ছে যে, কোম্পানীর ৪০ তম বার্ষিক সাধারণ সভা নিম্নলিখিত বিষয়াদি সম্পাদনকল্পে আগামী ২৯ ডিসেম্বর, ২০২২ইং (বাংলা- ১৪ই পৌষ, ১৪২৯) রোজ বৃহস্পতিবার, অপরাহ্ন ৪:০০ ঘটিকায় ভার্চুয়াল প্লাটফর্মে অনুষ্ঠিত হবে:

## আলোচ্য সূচিঃ

০১. ৩০.০৬.২০২২ইং তারিখে সমাপ্ত কোম্পানীর নিরীক্ষিত আর্থিক হিসাব বিবরণী, নিরীক্ষকের প্রতিবেদন, পরিচালক মন্ডলীর প্রতিবেদন গ্রহণ, বিবেচনা ও অনুমোদন করা,
০২. ৩০.০৬.২০২২ইং তারিখে সমাপ্ত আর্থিক হিসাব বছরের লভ্যাংশ অনুমোদন করা,
০৩. কোম্পানীর সংখ্যিক অনুযায়ী পরিচালক নিয়োগ/পুনঃ নিয়োগ করা,
০৪. ৩০.০৬.২০২৩ইং তারিখে সমাপ্ত ২০২২ - ২০২৩ হিসাব বছরের জন্য সংবিধিবদ্ধ নিরীক্ষক নিয়োগ ও তাদের পারিষ্মিক অনুমোদন করা,
০৫. ৩০.০৬.২০২৩ইং তারিখে সমাপ্ত ২০২২ - ২০২৩ হিসাব বছরের জন্য কর্পোরেট গভার্ন্যাল কমিট্যায়েল নিরীক্ষিক নিয়োগ ও তাদের পারিষ্মিক অনুমোদন করা,
০৬. চেয়ারম্যান মহোদয়ের অনুমতিক্রমে সাধারণ সভায় আলোচনাযোগ্য অন্যান্য যে কোন বিষয়াদি সম্পাদন করা।

তারিখঃ ০৮.১২.২০২২ইং  
ঢাকা।

## দ্রষ্টব্যঃ

০১. ৱেকর্ডেট ২২.১১.২০২২ইং। ৱেকর্ড ডেট অনুযায়ী সিডিবিএল ৱেকর্ডে এবং শেয়ার রেজিস্ট্রারে যে সকল শেয়ারহোল্ডারগনের নাম নথিভৃত থাকবে কেবল মাত্র তাহারাই ৪০তম বার্ষিক সাধারণ সভায় অংশ গ্রহণ এবং অনুমোদিত লভ্যাংশ পাবার যোগ্য হবেন।
০২. বার্ষিক সাধারণ সভায় চূড়ান্ত অনুমোদনের জন্য পরিচালনা পর্ষদের সর্বসম্মতিক্রমে ২৭.১০.২০২২ইং তারিখের সিদ্ধান্ত মোতাবেক সকল শেয়ারহোল্ডারবন্দের জন্য পরিশোধিত মূলধনের ২০% হারে এবং পরিচালকবন্দের জন্য ১০% হারে নগদ লভ্যাংশ প্রদানের সুপারিশ করেছে।
০৩. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন (বিএসই) এর নির্দেশনা মোতাবেক কোম্পানীর ৪০ তম বার্ষিক সাধারণ সভা ডিজিটাল প্লাটফর্ম (ভার্চুয়াল মিটিং) এ অনুষ্ঠিত হবে। স্বাস্থ্য বুকি বিবেচনায় অনলাইন লাইভ পোর্টাল এর মাধ্যমে ৪০ তম বার্ষিক সাধারণ সভায় উপস্থিত হওয়ার জন্য অনুরোধ করা হলো।
০৪. বার্ষিক সাধারণ সভা শুরুর ২৪ ঘন্টা পূর্বে ও সভা চলাকালীন শেয়ারহোল্ডারবন্দ তাহাদের নাম, বিও হিসাব নম্বর/ফলি ও নম্বর, শেয়ার সংখ্যা নির্দিষ্ট লিংক এ প্রদান করে তাহাদের ভোটাধিকার, প্রশ্ন ও মন্তব্য প্রদান করতে পারবেন। <https://agmbd.live/WATACHEMICALS40ThAGM22> লিংক এর মাধ্যমে বার্ষিক সাধারণ সভায় যোগদান করতে পারবেন।



০৫. শেয়ারহোল্ডারবন্দ ভয়েস ৱেকর্ডিং করে তাহাদের মন্তব্য ই-মেইল নম্বর [watachemicals@gmail.com](mailto:watachemicals@gmail.com) এ ২৬.১২.২০২২ অপরাহ্ন ৪:০০ ঘটিকার মধ্যে প্রেরণ করতে পারবেন। মন্তব্য/বক্তব্য অবশ্যই সংক্ষিপ্ত হতে হবে যেন তাহা আপলোড করা সম্ভব হয়।
০৬. বার্ষিক সাধারণ সভা শুরুর ২৪ ঘন্টা আগে পোর্টাল খুলে দেয়া হবে।
০৭. বার্ষিক সাধারণ সভার নোটিশ, ডিজিটাল প্লাটফর্মে সংযুক্ত হবার লগ-ইন প্রক্রিয়া শেয়ারহোল্ডারবন্দকে ই-মেইল এর মাধ্যমে জানিয়ে দেয়া হবে।
০৮. ভার্চুয়াল সভায় অংশগ্রহনের প্রক্রিয়া সমূহ কোম্পানীর ওয়েব সাইটে [www.watachemicals.com](http://www.watachemicals.com) পাওয়া যাবে।
০৯. ভার্চুয়াল সভা সংক্রান্ত লগ ইন প্রক্রিয়া ও যে কোন প্রয়োজনে মোবাইল নম্বর- +৮৮০ ১৬৪৩-২৪৯৮৬০, +৮৮০ ১৭০৩-৮৪৬১০৯ এ যোগাযোগ করার জন্য অনুরোধ জানানো যাচ্ছে।
১০. বার্ষিক সাধারণ সভায় অংশ গ্রহণ ও ভোট প্রদানের জন্য প্রক্সী (প্রক্সীকে অবশ্যই একজন শেয়ারহোল্ডার হতে হবে) নিয়োগ করতে পারবেন রেভিনিউ স্ট্যাম্প সম্বলিত প্রক্সী ফরম কোম্পানীর রেজিস্টার্ড অফিসে/প্রধান কার্যালয়ে সভার নির্ধারিত সময়ের ৪৮ ঘন্টা পূর্বে অবশ্যই জমা দিতে হবে। শেয়ারহোল্ডার কোম্পানী/কর্পোরেশন হলে তাদের মনোনীত প্রতিনিধি সভায় অংশগ্রহন করতে পারবেন।
১১. বার্ষিক প্রতিবেদন এর কপি শেয়ারহোল্ডারবন্দের ই-মেইল ঠিকানায় প্রেরণ করা হবে। আগ্রহী শেয়ারহোল্ডারবন্দ কোম্পানীর প্রধান কার্যালয় ১৭/বি মনিপুরীপাড়া, সংসদ এভিনিউ, ঢাকা-১২১৫ হতে “বার্ষিক প্রতিবেদন” এর কপি লিখিত আবেদনের মাধ্যমে সংগ্রহ করতে পারবেন। বার্ষিক প্রতিবেদন কোম্পানীর ওয়েব সাইট এ পাওয়া যাবে।
১২. শেয়ারহোল্ডারগণকে কাণ্ডে শেয়ার ডিমেট করাতে, ব্যাংক হিসাব নম্বর কমপক্ষে ১৩ ডিজিট এবং ব্যাংকের রাউটিং নম্বর, টিআইএন, মোবাইল নম্বর ও ই-মেইল ঠিকানা ইত্যাদি সিকিউরিটিজ হাউজে হালনাগাদ করেন অনুরোধ করা হলো।

বিষয়ঃ বার্ষিক সাধারণ সভায় অংশগ্রহণকারীদের কোন ধরনের খাবার, উদ্ঘার সামগ্রী বা বেনিফিট প্রদান করা হবে না।



# WATA CHEMICALS LIMITED

## NOTICE OF THE 40th ANNUAL GENERAL MEETING

Notice is hereby given that the 40th Annual General Meeting of WATA CHEMICALS LIMITED will be held at 4:00 PM, Thursday, 29th December- 2022 at the virtual platform to transact the following businesses:

### AGENDA:

01. To receive, consider and adopt the Audited Financial Statements for the year ended on 30th June' 2022 together with Reports of the Auditors and the Directors there on.
02. To declare/approve dividend for the year ended on 30 June, 2022.
03. To elect/re-elect Director(s) of the Company as per the Articles of Association of the Company.
04. To appoint Statutory Auditors for the Accounting year 2022-2023 ended on 30.06.2023 and to fix up their remuneration.
05. To appoint Corporate Governance Compliance Auditor for the year 2022-2023 and to fix up their remuneration.
06. Others, on approval of Chairman of the Meeting.

Dhaka  
December 08, 2022

By order of the Board  
*Shamsul Huq*  
(Shamsul Huq)  
Company Secretary

### NOTES:

01. The Shareholders as per CDBL record or names in Share Register on the 'Record Date' (November 22, 2022) will be entitled to attend the meeting and for Dividend subject to approval at the 40th AGM.
02. The Board in its meeting dated 27.10.2022 has recommended 20% Cash Dividend for General Public/Investor and 10% Cash Dividend for Directors on the paid-up capital of the Company.
03. In view of the order of Bangladesh Securities & Exchange Commission (BSEC), the ensuing 40th AGM of the company would be conducted through digital platform (Virtual meeting). Therefore, the Shareholders are requested to attend the 40th AGM through online live portal.
04. The Members will be able to submit their questions/comments electronically 24 hours before commencement of the AGM and during the AGM. For logging into the system, the Members need to put their Beneficial Owner BO ID number/Folio number and other credentials as proof of their identity by visiting the link <https://agmbd.live/WATACHEMICALS40ThAGM22>



05. The Members may also send their comments/queries through recording via email to [watachemicals@gmail.com](mailto:watachemicals@gmail.com) on or by 4:00 PM, December 26, 2022. The content must be briefed otherwise it is difficult for uploading.
06. Portal will be opened for Shareholders 24 hours before at 4.00 PM on 29th December, 2022. The Members may also send their comments/queries through Portal.
07. AGM Notice will be mailed to the respective Member's email address available with us.
08. The detailed procedures to participate in the virtual meeting are available on the Company's website at: <http://www.watachemicals.com>
09. We encourage the Members to login to the system prior to 4:00 PM on December 29, 2022. Please allow ample time to login and establish your connectivity. The webcast will start at 4:00 PM. Please contact +880 1643-249460, +880 1703-446109 for Login procedure and others. Please join 5 minutes before commencement of the Meeting for avoiding any technical difficulties in accessing the Virtual Meeting.
10. Shareholders are eligible to attend the Annual General Meeting (AGM) is entitled to appoint a Proxy (Proxy must be a Shareholder of the Company) to attend and vote on his/her behalf (through digital platform). The "Proxy Form" must be affixed with requisite Revenue Stamp and deposited it at the Registered Office of the Company not later than 48 hours before the time fixed for the meeting. If Shareholder is a Company/Corporation, they can be nominated representative to attend the meeting.
11. The softcopy of the Annual Report 2021-2022 of the company will be sent to the Shareholder's respective e-mail addresses. However, interested Shareholders may collect hard copy of the Annual Report from the company's Head office at 17/B, Monipurpara, Sangshad Avenue, Dhaka-1215 by submitting a written requests. The Annual Report is available on the Company's website: [www.watachemicals.com](http://www.watachemicals.com)
12. Shareholders are requested to Demat their Paper Shares, to update Bank A/C number 13 digit minimum, their Bank's Routing Number, TIN Number, Mobile Number & E-mail address with Brokerage House on top priority basis.

**N.B.: FOOD, GIFT OR BENEFIT IN CASH OR KIND SHALL NOT BE GIVEN AT THE ANNUAL GENERAL MEETING.**



## Director's Report to the Shareholders

Bismillaher Rahmanir Rahim

Dear Shareholder,  
Assalamu Alaikum,

The Directors of Wata Chemicals Ltd. take the pleasure in presenting Annual Report together with the report of the Board of Directors and the Auditor's Report on Audited Financial Statements of the Company for the year ended on 30.06.2022 for your valued consideration, adoption and Approval.

We welcome you all at the 40th Annual General Meeting of WATA Chemicals Limited. Reports of the Board of Directors for accounting period ended on 30.06.2022 are hereby presented before gentlemen shareholders. Audited Financial Statements have been prepared complying Companies Act, concerned laws, Regulation, Orders, Notifications of Bangladesh Securities & Exchange Commission, International and Bangladeshi Accounting Standard, BFRS, IFRS, duly accepted by Institute of Chartered Accountants of Bangladesh .Company's success even in Covid-19 situation, future possibilities, Financial results and other potential , legal aspect, information on its compliances etc; presented for providing of suggestions of all other respectable Shareholders.

WATA chemicals Limited became listed with Dhaka Stock Exchange in 1992 with Tk. 16.20 million paid-up Capital .Paid up prevailing now is Tk.148.20 million has been increased from profit earning .Production; its dimension has been diversified by raising capacity and by set up new plants. We are happy to inform you that 512% dividend has been paid to the Shareholder till 30.06.2022 .The Board of Directors devoted themselves for continuous development of Company's prospect in co-operation of Shareholders and others concerned with the company.

### Operating Results for year 2021-2022 ended on 30.06.2022:

After long effect Covid-19 Pandemic, Management have been utilizing best effort to increase production & Sales. During the year production of WCL Product has been increased by 10.66% in terms of Quantity and 67.38% in terms of value. But post Covid situation, price of Raw Materials have been increased much more than the previous year due to shortage of container, increase of freight, port charges, and unavailability of regular liner vessels and thus increased cost of Goods Sold by Tk. 321,685,041. Besides these, the war between Russia & Ukraine and devaluation of taka in comparison with US dollar, resulting huge exchange loss which causes significant deviation in EPS. Comparative figure of two financial years are furnished below:

PARTICULARS	AMOUNT IN TAKA	
	30.06.2022	30.06.2021
Revenue (Net of VAT)	953,804,600	569,812,320
Cost of Sales	(674,667,049)	(352,982,008)
Gross Profit	279,137,551	216,830,312
Administrative Selling and Distribution Expenses	(68,569,557)	(47,063,922)
Operating Profit	210,567,995	169,766,390
Finance Expenses	(129,909,518)	(73,734,448)
Non-operating Income	4,265,360	6,919,694
Profit before contribution to WPPF & Welfare fund	84,923,837	102,951,636
Contribution WPPF & Welfare fund	4,043,992	(4,902,459)
Profit before Tax	80,879,845	98,049,177
Income Tax Expenses	20,921,725	(7,091,864)
Profit after Tax	59,958,120	90,957,313
Other Comprehensive Income /Expenses ( Deferred Tax on Revaluation of PPE)	(1,226,325)	(1,340,484)
Total Comprehensive Income	58,731,795	89,616,829
Earnings per Share(EPS) in Taka	4.05	6.14

### Main Activities of the Company:

WATA Chemicals Ltd. produce basic chemicals namely Sulfuric Acid, Aluminium Sulphate, Zinc Sulphate and Magnesium Sulphate. Moreover, SLES ( Sodium Lauryl Ether Sulphate ),LABSA (Linear Alkyle Benzene Sulphonic Acid ) plant set up works have been completed and waiting for foreign experts to come for starting production being delayed for Covid-19 effect. The above Products used in different manufacturers/sectors named below:

Saidabad Water Treatment Plant, Phase-I, Saidabad Water Treatment Plant Phase-II, Saidabad Water Treatment Plant Phase-III., Lalbagh Water Works, Sonakandi Water Works, Godnail Water Works under Dhaka WASA, Sheikh Hasina Water Treatment Plant, Mohara Water Treatment Plant, Sheikh Russel Water Treatment Plant under Chattogram WASA, Asugonj Fertilizer and Chemical Co. Ltd, Asugonj Power Station, Ghorashal Power Station, Ghorashal Urea Fertilizer Co. Ltd., Polash Urea Fertilizer Co. Ltd., Jamuna Fertilizer Co. Ltd.,

Mixed Fertilizer factories, Battery Industries, Steel & Rerolling Mills, Textile ,Garments and it's linkage factories, Tannery Industries, Paper Industries, Effluent Treatment Plants (ETP), Soap and Detergent manufacturing industries, Medicine industries, Gold processing industries, Color ,glue, Ether, Rubber etc; industries, Other Engineering and Chemical sectors and many more.

## Industry Outlook:


Bangladesh is the 39th largest economy in the world, in nominal terms, and 29th largest by purchasing power parity. It is classified among the next eleven emerging market middle income economies and a frontier market. Bangladesh is one of the world's fastest growing economies. Per capita GDP and per capita national income are continuing the upward trend. GDP growth increased until 2019 but it declined in 2020 due to Covid-19. Bangladesh has a well-established manufacturing sector with a contribution of manufacturing value added (MVA) of 20.6% to GDP and MVA per capita of \$356 (2015 constant US\$) in 2021. While MVA contribution to GDP increased 1.72 times, MVA per capita increased by 4.62 times between 2000 and 2021. There is abundant empirical evidence to show that the manufacturing sector plays an important role in socio-economic growth globally, particularly when countries are at a relatively lower-income level. Manufacturing offers the possibility of higher levels of productivity, more rapid productivity growth and greater technological change than agriculture, or below a certain income level, in many parts of services sectors. In addition, it can create jobs that offer higher wages due to a higher level of productivity. Hence, there is usually an association between the growth of an economy and the size and growth of its manufacturing sector.

The overall economy of Bangladesh is going through a challenging time since the 3rd quarter of 2019-2020 as the country was under the lockdown severely including various restriction imposed by Government . Both manufacturing and selling activities were frustrated . The chemical industry has witnessed a recovery since the 2nd Quarter of 2021-2022, with demand increasing from the major end markets. This was driven partly by a rebound in Bangladesh GDP, which will likely grow during 2021 after declining by 2020-2021. During the first half of 2021 and up to September, 2021 the industry experienced supply chain disruption caused by extreme Covid-19 spreading. With supply chain challenges easing, idled capacity should come back online and support inventory buildup. In fact, chemicals have already achieved pre pandemic sales levels in Q2, 2021-2022. 2022 could mark the full recovery for the Bangladeshi chemical industry post pandemic. As the industry moves into 2022, strong demand for BASIC CHEMICALS should keep prices robust throughout the year. The industry should also experience increased capital expenditure as industry players focus on building capacity and expanding into growing end markets. At present, the chemical industry are facing pressures amid raw material cost inflation, devaluation of Taka against US Dollar and crisis of US Dollar for payment of LC value is the main challenge. WATA Chemicals Produces Basic chemicals like Sulfuric Acid, Aluminium Sulphate (Alum), LABSA & SLES and fertilizers and its uses are in the sectors as stated in previous paragraph so demand of our chemicals should increase.

## Comparisons of Financial Result :

The key financial results of WATA Chemicals Ltd. for five years including current year are presented below:

PARTICULAR	2021-2022	2020-2021	2019-2020	2018-2019	2017-2018
Turnover	1,036,043,378	649,079,365	837,993,834	923,341,039	465,372,187
Gross Profit	279,137,551	216,830,312	283,922,156	298,979,576	138,742,236
Net Profit Before Tax	80,879,845	98,049,177	170,171,476	187,352,529	62,790,548
Net Profit After Tax	59,958,120	90,957,313	119,323,458	137,966,568	52,224,093
Paid up Capital	148,226,180	148,226,180	148,226,180	118,580,950	91,216,120
Earning Per Share	4.05	6.14	8.05 (Re-Statement)	9.31 (Re-Statement)	5.72
Dividend (%)	General Shareholder 20% Cash Directors 10% Cash (Proposed)	30% Cash	35% Cash	25% Stock 30% Cash	30% Stock & 10% Cash





### Segment-wise or product-wise performance :

Production, sales and marketing have been increased after severe Covid-19 pandemic. Sulfuric Acid is our principal product its yearly production capacity is about 48,000 MT but in 2021-2022 capacity utilization is 43,612.800 MT which is 90.86% of yearly capacity. Aluminium Sulphate measuring 6,468 MT has been manufactured out of yearly capacity 18,000 MT, percentage achieve 35.93%. Achievement of other product has been increased such as Zinc Sulphate (Fertilizer) & Megnisium Sulphate (Fertilizer) to 52.59% & 40.33% respectfully though production and Sale value has been increased as compared with the previous year but price of Raw Materials is more higher than the same period of the previous year due to post Covid-19 situation and for Russia – Ukraine war, devaluation of taka in comparison with US Dollar resulting increase of cost of production as well as decrease of EPS.

### Possible future developments in the industry:

Our Board of Directors, it's Management have been utilizing best efforts in support and suggestion of the shareholders for strengthening and widening field of production, Capacity Building for the wellbeing of the economy of the country and so for the SLES/LABSA plant has been completed and efforts are being utilized for quick starting trial production. Our Director Mr. A.H.M Abdullah, Graduate in Chemical Engineering from BUET with his team have been utilizing their best efforts for set up more basic chemical plants for more contribution to the economy of the country as well as for WATA chemicals Ltd.

### Risks and concerns including internal and external risk factors, threat to sustainability:

Coronavirus pandemic sweeping through the world up to last year is likely to have a heavy impact on the world as well as Bangladesh not just economically but almost in every area of life. From the perspective of our business we can see quite a few short term challenges on supply chain disruptions, volatility of international trade and currency markets, general economic downturn across the world and Bangladesh impacting consumer confidence and affecting consumption patterns etc.

In the medium to long term we expect a larger focus on health and hygiene from consumers, public institutions and governments alike that may lead to lasting changes in consumer and business behaviours. We also expect changes in public policies towards Health and Hygiene in most countries. Company will continue to navigate all these challenges.

Risks and concerns including internal and external risk factors of WATA chemicals Limited are shown on page-18 in Annexure-4

### **Extra-ordinary gain and Losses :**

In Year 2021-2022 there were few significant extra ordinary gain or losses in the business. The Devaluation of the local currency against the US dollar is taking a heavy toll on business in Bangladesh for the last Quarter of 2021-2022 which has been continued till date. In the year ended on 30.06.2022 the exchange loss was Tk. 1,86,41,248. In the current global scenario, we are also experiencing massive price increase in the purchase (Import) of raw materials specially for "Sulphur". Although the crisis mostly started later due to Corona Virus situation, its increase day by day which is beyond our control. As the raw material is a petroleum bye product, the war between Russia and Ukraine caused prices to raise further. Price of raw materials imported from Middle East and Russia are increased much more than the previous year.

### **Environmental Issues:**

Rules-Regulations of the Directorate of Environment are being fully complied with by using Air Treatment Plant (ATP) and Effluent Treatment Plant (ETP). The Treatment Plants are being very effectively utilized so that laboratory test report of the department is found satisfactory, acceptable and remain within standard parameters. Zero discharge treatment Plant has been planning to set up for more effective control.

### **Discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin:**

Gross Sales during 2021-2022 has been increased by Tk.38,69,64,013 in comparison with that of year 2020-2021, EPS reduces to Tk.4.05 from Tk.6.14. During 2021-2022. Sales of Sulfuric Acid, Aluminium Sulphate, Zinc Sulphate and Magnesium Sulphate has been increased. Net sales and Cost of Goods Sold have also been increased by Tk.38,39,92,280 and Tk.32,16,85,014 respectively.

Gross Profit has been increased in 2021-2022 in comparison with preceding year by Tk.6,23,07,239 but unexpected huge Exchange Loss in 4th quarter and increase of Financial Expenses affect negatively in the net profit ratio despite increased gross profit ratio and thus finally affected in EPS ratio.

### **Statement of Remuneration paid to the directors including independent directors:**

Detailed are shown in Audited Financial Statements- Page- 68 of this Annual Report

### **Accounting Policies and Estimation:**

Accounting policies are determined by applying the relevant IFRS. Where there is no available guidelines of IFRS, management uses its judgment in developing and applying an accounting policy that results in information that is relevant and reliable. The company selects and applies its accounting policies for a period consistently for similar transactions, other events and conditions, unless a IFRS or specifically requires or permits categorization of items for which different policies may be appropriate. The accounting policies set out below have been applied consistently in all material respects to all periods presented in these financial statements. We have followed International Financial Reporting Standards (IFRSs) and the Companies Act, 1994 in preparation of financial statements. These financial statements follow the requirements of IFRSs which are to some extent different from the requirement of the Companies Act, 1994. The company changes its accounting policy only if the change is required by a IFRS or results in the financial statements providing reliable and more relevant information about the effects of transactions, other events or conditions on the company financial position, financial performance or cash flows. Changes in accounting policies is made through retrospective application by adjusting opening balance of each affected components of equity i.e. as if new policy has always been applied and Estimates arise because of uncertainties inherent within them, judgment is required but this does not undermine reliability. Effect of changes of accounting estimates is included in profit or loss account. The preparation of the financial statements are in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. However, the Company also complied with the requirements of following laws and regulations from various Government bodies: i. Bangladesh Securities and Exchange Rules 1987; ii. The Income Tax ordinance, 1984; and iii. The Value Added Tax Act, 1991; iv. The Value Added Tax and Supplementary Duty Act, 2012. In preparing financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively. Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the financial statements is included in note 1, Page- 52 of this Annual Report.

### **Internal Control Systems :**

The Company's internal control procedures which include internal financial controls ensure compliance with various policies, practices and statutes and keeping in view the organization's pace of growth and increasing complexity of operations. The internal auditors' team carries out extensive audits throughout the year across all locations and across all functional areas and submits its reports to the Audit Committee of the Board of Directors.

### **Human Resource and Welfare Development:**

WATA Chemicals Ltd maintain preference for Development of Human Resource and Welfare of all involved with the Company, 5% profit before Tax is being maintained with "Workers Profit Participation Fund & Welfare Fund" yearly. Guidelines of Directorate General of Health Services, World Health Organization for protection from Covid-19 and other issues relating to Health and Hygiene are being maintained and regular follow up has been there.

### **Board Meeting & attendance :**

The total number of Board meetings held during the year and attendance by each director are shown in ANNEXURE :02, Page-17

## **Shareholding Patern :**

Pattern of shareholding disclosing the aggregate number of shares (along with name-wise details) held by: (a) Parent or Subsidiary or Associated Companies and other related parties (name-wise details); (b) Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name-wise details); (c) Executives; and (d) Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details); are shown in ANNEXURE :03, Page-17 of this Annual Report.

## **Dividend :**

The Board of Directors is pleased to recommend 20% cash dividend for General Investor (Excluding Directors of Board of Directors) and @ 10% for Directors on paid up Capital for the year ended 30 June 2022 to those share owners whose names were appeared in the Share Register of Members of the Company or in the Depository list of CDBL on the Record Date which is 22 November, 2022. No Stock Dividend was declared during the year.

## **Contribution to the National Exchequer:**

For the year ended 30 June 2022, the company paid/deposited Taka 148.63 million to the National Exchequer in the form of corporate tax, custom duty and Value Added Tax (VAT) only. This is equivalent to 15.58% of the Company's gross sales revenue for the year 2021-2022.

## **Appointment of Director as per Article of Association of the Company:**

ELECTION OF DIRECTORS as per Articles of Association of the Company, Mr. A H M Abdullah and Md. Mahmudul Hasan will retire from the Board of Directors and being eligible offer themselves for re-election. The elections of new Directors are subject to approval in the 40th Annual General Meeting.

## **Statutory Auditor:**

As per requirements of law, the current statutory auditors, M/S MABS & J Partners, Chartered Accountants, will retire at the 40th Annual General Meeting. As they are completed last 3 years tenure, they are not considered eligible as per the rules. M/S. Khan Wahab Shafique Rahman & Co. Chartered Accountant have expressed their willingness for being appointed for the year 2022-2023. Based on suggestions of the Audit Committee, the Board recommends the appointment of M/S. Khan Wahab Shafique Rahman & Co., Chartered Accountants, as the statutory auditors of the Company for the year 2022-2023 and continuation up to the next AGM at a fee of Tk. 3,50,000 (Taka Three Lac Fifty thousand) only Excluding VAT and requests shareholders to approve the appointment.

## **Compliance Auditor:**

Pursuant to code 9.2 of the codes of corporate governance issued by BSEC, shareholders at the 39th Annual General Meeting (AGM) had appointed M/S Shafiq Basak & Co., Chartered accountants, as the Compliance Auditor of the Company for the year 2021-2022 ended on 30.06.2022. As proposed by the Audit Committee and recommended by the Board of Directors, the matter of appointment of MABS & J Partners, Chartered accountants, as Compliance Auditor of the Company for the year 2022-2023 would be placed before the shareholders at the 40th AGM of the Company for approval at a fee Tk. 75,000 (Seventy Five Thousand) only excluding VAT.

## **Audit Committee:**

The Audit Committee at present consists of Independent Directors with Mr. Md. Iftikhar Uz-zaman as Chairman and Mr. Subrata Pal – FCMA, Non-executive Director and Mr. A.T.M. Najmul Husain, Non-executive Director as members. The Committee inter alia reviews the Internal Control System, Reports of Internal Auditors, Key Audit Matters presented by the Statutory Auditors and compliance of various regulations. The Committee also reviews the audited financial statements before those are placed before the Board of Directors. Audit Committee Report for the year ended on 30th June, 2022 is shown in ANNEXURE : 5, PAGE- 21 - 22.

## **Nomination and Remuneration Committee:**

The Nomination and Remuneration Committee at present consists of Mr. Md. Iftikhar Uz-zaman, Independent Director as Chairman and Mr. Subrata Pal – FCMA, Non-executive Director and Mr. A.T.m. Najmul Husain, Non-executive Director as members. The Nomination and Remuneration Committee Report for the year ended on 30th June, 2022 is shown in ANNEXURE : 6, PAGE: 29.

## **Disclosure for Significant Deviation:**

For the year ended 30 June 2022, total revenue of WATA Chemicals Limited was Taka 95.380 million (Net of VAT) against Taka 569.81 million of financial year 2020-2021, resulting 167.38% higher revenue over FY 2020-2021. Due to post Covid pandemic Corona Virus (COVID-19) digaster which is unavoidable and beyond our control, the Company utilized efforts to continue consistency in production process. Through value of sales has been increased, price of Raw Materials imported are proportionately increased much more than previous year due to shortage of container, freight of ship, higher port charge and unavailability of regular liner ship and lastly Russia & Ukraine war. Moreover devaluation of taka in comparison with US dollar, resulting huge exchange loss which are the major caused for significant deviation in EPS.

## **Management Discussion & Analysis:**

The discussion and analysis duly signed by the Managing Director of the Company presenting, among others, the detailed analysis of the company's operations, financial position, performance, risk and concern, accounting policies & estimation to the financial statements, any changes thereof have been disclosed on page- 23 - 24 in Annexure III of this report.

## **Corporate Governance:**

Our Company has complied with notifications, instructions, Guide lines etc of the Bangladesh Securities and Exchange Commission in respect of Corporate Governance for protecting interests of investors, investor companies and of the regulatory /controlling authorities. Compliance Report of M/S Shafiq Basak & Co., Chartered Accountants and their certificate has been incorporated in page- 30 of this report.

Moreover, Compliance Report as per BSEC notification has been in page- 31 to 39 of this report. Other inclusions in the report are : Curriculum Vitae (CV) of the Directors been recommended by the Board of Directors for appointment of next one year term Page # 06, Report of the Audit Committee Page # 21, Report of the NRC Page # 29, Certificate of CEO and CFO Page # 40, Certificate on Compliance of Corporate Governance Page # 25 to 28.

### **Explanation on Qualified opinion:**

Regarding qualified opinion no. 01 we would like to state that since those plant are out of production from 2004 as such no depreciation were charged in line with paragraph-55 IAS 16. If depreciation of both the plant would have been charged, then there would have adverse impact on cost of production of all other products of running units. Regarding Qualified opinion 02, we complied with this observation from 2012 onward. According to BAS-16 Para 82 of Bangladesh Financial Reporting Standard 2013 Volume II -"An entity shall apply this standard for annual periods beginning on or after 1st January 2013. Earlier application is encouraged, if an entity applies this standard for a period beginning before 1st January 2013, it shall be disclosed that date". Regarding Qualified opinion 03, Trust deed has already executed and disbursement process will be started soon.

### **Related party transactions:**

Related party transactions entered into during the financial year were on arm's length basis and were in ordinary course of business. The Company has entered into transactions with the related party as mentioned in Note No. 52 of Notes to financial statements.

There are no related party transactions made by the Company which may have potential conflict with the interest of the Company. There are no material related party transactions which are not in ordinary course of business or which are not on arm's length basis and hence there is no information to be provided as required.


### **We would like to confirm that:**

- The financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity.
- Proper books of account of the issuer company have been maintained.
- Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment.
- International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS) as applicable in Bangladesh have been followed in preparation of the financial statements and any departure there from has been adequately disclosed.
- The system of internal control is sound in design and has been effectively implemented and monitored.
- Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;
- There are no significant doubts upon the Company's ability to continue as a going concern.
- Significant deviations from last year's operating results of the Company have been highlighted in the report and reasons thereof have been explained.
- Key operating and financial data of preceding five years have been provided on page- 17 in Annexure- 1
- During the year five Board meetings were held and the attendance by each director is given on page-17 in Annexure-2
- The pattern of shareholding is provided on pages- 17 in Annexure- 3
- A management discussion and analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with brief discussion of changes in the financial statements, is provided on page- 23 to 24.
- Declaration or certification by the CEO and the CFO to the Board as required under condition no. 3(3)(c) of Corporate Governance Code; is provided on page- 40.
- In accordance with the requirement of the Bangladesh Securities and Exchange Commission, "Compliance of conditions of Corporate Governance Code as required under condition no. 9 " is provided on page- 30.
- During the year the company did not pay any remuneration to its Independent Director. Only meeting attendance fees were paid.

### **Acknowledgment:**

The Board of Directors of WATA Chemicals Limited would like to extend its foremost regard and appreciation to the valued Shareholders and other stakeholders of the Company for their persistent support and guidance to the company that led to the cumulative achievements. The Board also expresses their gratitude to Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange (DSE), Chittagong Stock Exchange (CSE), Registrar of Joint Stock Companies and Firms (RJSC), Ministry of Home , National Board of Revenue (NBR), Central Depository Bangladesh Limited (CDBL), Office of the Deputy Commissioner of District Narayanganj, Office of the Deputy Commissioner of District Chattogram, Department of Explosives , Department of Environment , Department of Inspection for Factories and Establishments (DIFE), Fire Service and Civil Defense, Company's bankers, and other business alliances for their cooperation, positive support, and guidance. We record deep appreciation for all WATA employees who have adjusted their way of working to continue supporting our valued customers and partners; finally we extend thanks to our valued clients who play the most significant role in our success story. We promise that we will continue our journey towards a bright future. We look forward to your continued support in 2022-23 and the days ahead.

For the Board of Directors of WATA Chemicals Limited.

(Razi Uddin Ahmed)  
  
Chairman

## Annexure-1

KEY OPERATING AND FINANCIAL DATA OF LAST FIVE YEARS:

[FIGURE IN TAKA EXCEPT DIVIDEND]

PARTICULAR	2021-2022	2020-2021	2019-2020	2018-2019	2017-2018
Turnover	1,036,043,378	649,079,365	837,993,834	923,341,039	465,372,187
Gross Profit	279,137,551	216,830,312	283,922,156	298,979,576	138,742,236
Net Profit Before Tax	80,879,845	98,049,177	170,171,476	187,352,529	62,790,548
Net Profit After Tax	59,958,120	90,957,313	119,323,458	137,966,568	52,224,093
Paid up Capital	148,226,180	148,226,180	148,226,180	118,580,950	91,216,120
Earning Per Share	4.05	6.14	8.05 (Re-Stated)	9.31 (Re-Stated)	5.72
Dividend (%)	General Shareholder 20% Cash Directors 10% Cash (Proposed)	30% Cash	35% Cash	25% Stock 30% Cash	30% Stock & 10% Cash

## Annexure-2

THE NUMBER OF BOARD MEETING HELD ,THE ATTENDENCE BY EACH DIRECTOR DURING THE PERIOD JULY 2021 TO JUNE 2022

NAME OF DIRECTORS	POSITION	Number of Meeting Held	NUMBER OF ATTENDANCE
Mr. Razi Uddin Ahmed General Manager- I.C.B. (Nominated Director)	Chairman	5	5
Mr. Md. Nazrul Islam	Managing Director	5	5
Mr. Md. Iftikhar Uz-zaman	Independent Director	5	5
Mr. A.H.M. Abdullah	Director	5	5
Mr. Md. Mahmudul Hasan	Director	5	5

## Annexure-3

SHARE HOLDING PATTERN

NAME	STATUS	SHARES HELD
A) PARENT/SUBSIDIARY/ASSOCIATED COMPANIES AND OTHER RELATED PARTIES	NONE	NONE
<b>B) DIRECTORS,CHIEF EXECUTIVE OFFICERS,COMPANY SECRETARY,CHIEF FINANCIAL OFFICER,HEAD OF INTERNAL AUDIT AND THEIR SPOUSE AND CHILDREN :</b>		
Mr. Razi Uddin Ahmed, (ICB Nominated Director)	Chairman	NIL
Mr. Md. Nazrul Islam	Managing Director	48,04,032
Mr. Md. Iftikhar-Uz-zaman	Independent Director	NIL
Mr. A H M Abdullah, (Son of Mr. Md. Nazrul Islam)	Director	2,96,453
Md. Mahmudul Hasan, (Son of Mr. Md. Nazrul Islam)	Director	2,96,453
Mrs. Amina Khatun, (Wife of Mr. Md. Nazrul Islam)	Spouse	NIL
Mr. Md. Ali Ahsan	Chief Financial Officer	1,000
Mr. Shamsul Huq	Company Secretary	NIL
Mr. Milan Hossain	Head of Internal Audit	NIL
<b>C) EXECUTIVE :</b>		
Mr. Abu Taher Bhuiyan	General Manager (Factory)	NIL
Mr. Md. Ashraful Alam	General Manager (Finance & Accounts)	NIL
Mr. Tapos Chandra Sarkar	Accounts Manager	NIL
Mr. Mohammad Ali	Manager -Commercial	NIL
<b>D) SHAREHOLDERS HOLDING 10% OR MORE :</b>		
Md. Nazrul Islam	48,04,032	
M/S Investment Corporation of Bangladesh (ICB)	39,84,091	

# Annexure-4

## Risk Factors And Management Perception About The Risks At Wata Chemicals Limited

Most entrepreneurs are risk taker by nature or at minimum calculated visionaries with a clear plan of action to launch product or fill a gap in the industries.

Risks are always associated with investments and investing in the company involves inherent risk factors. There are a number of factors, both specific to Wata Chemicals Ltd (Here in after shown as WCL) and of a general nature, which may affect the future operating and financial performance of the WCL and the value of an investment in WCL. Some of these factors can be mitigated by the use of safeguards and appropriate risk management action. However, some are outside the control of WCL and cannot be mitigated. The objective of risk management system of WCL is to identify measure and manage risks there upon and protect our stakeholders.

The information given below does not assert to be exhaustive. Additional risks or uncertainties are presently not known to the company or that are currently deemed immaterial may also have a material adverse effect on WCL's business, financial condition and operating results. The order in which the risks presented below is not intended to provide an indication of the likelihood of their occurrence nor of their severity or significance.

### INTEREST RATE RISKS:

Interest rate is always a concern of the management. Higher rate of interest increases costs of fund of a company and consequently its profit is squeezed.

### MANAGEMENT PERCEPTION:

The management of the Company is always aware of interest rate, which is connected to the cost of fund of the Company. The Management prefers procuring long-term fund with minimum fixed interest rate and the short-term fund with reasonable competitive rate. On the other hand management of the Company is emphasizing on equity based financing.

### EXCHANGE RATE RISK:

The company uses raw materials by importing from Asian & European countries. Taka may be devalued significantly against dollar and WCL may suffer due to exchange rate fluctuation in case of import of raw materials.

### MANAGEMENT PERCEPTION:

Appropriate and responsible mechanisms exercised by WCL in the past in case of significant taka devaluation in order to keep the costs minimum and same will be followed in future. However, if the price of US dollar rises so sharply against Taka, this will be a nationwide phenomenon to experience by the whole industrial sector, the company cover such possibilities by adjusting price of its products.

### LIQUIDITY RISKS:

This is the risk that cash may not be available to pay obligations when fall due. The Risk Primarily arise due to the maturity mismatch associated with Assets and liabilities.

### MANAGEMENT PERCEPTION:

The company has regular sale of its products to Govt. Organization/industries and to other in Private Sector. Items have very wide market. Generally Goods are not sold on Credit. As per experience of last 30 years. Products became sold immediately on Production and with good profit margin. After full completion of newly installed plants the project shall become more profitable and sale value shall attain/find at a new dimension.

### MANAGEMENT RISKS:

There may arise Management Risk in the Company which associates ineffectiveness, destructive or underperforming management which may hurts the smooth operation of the company resulting a loss.

### MANAGEMENT PERCEPTION:

WCL has well established management structure with diverse knowledge, skills, experience and expertise in core area of business in its bid to attain optimal utilization of available resources. Company Management is headed by General Manager of ICB. One of its Director is a Graduate in Chemical Engineering from Bangladesh University of Engineering & Technology(BUET). The company has also a well proven track record of having strong and effective leadership which already has shown an effect on the Chemical Business of the country. Under this circumstance management risk is not a concerning factor for the WCL.

### OPERATIONAL RISK:

Operational risk of the company is directly related to performance of Machineries, Power supply, Technical man power, Raw material supply continuity, Natural calamities, Political situation and availability of labor etc.

### MANAGEMENT PERCEPTION:

Management is aware of and maintenance of machineries are has been done regularly. The company has adequate electric & GAS supply arrangement from REB & Titas Gas Transmission & Distribution Company Ltd. Two Gas generators has been setup within thefactory to ensure uninterrupted supply. More powerful Steem Turbine Generator has installed for greater power requirement of plants. The company has sufficient & experienced technical manpower for smooth running of the existing plants and also new plants.

The company maintains excellent relationship with several suppliers is Asian and European countries and continuous supply of rawmaterials can be maintained for the existing and new plants. The company maintain adequate stock of Raw Materials to cover possible risk of supplier's failure to comply with contractual terms of shipment.

CONTINUED



The project is situated on a high land near Dhaka, adjacent to a wide concrete road and all its machineries and stocks of Raw materials, finished products, and spare parts are stored within pucca, wide & strong buildings. During last 29 years of its setup, the company never experienced any loss/damage by natural calamity.

Since we maintain adequate stock of Raw-materials, productions do not become frustrated on political unrest. Referring to marketing- ALUM is sold mainly to Dhaka WASA, Chattogram WASA, Industries under BCIC do not face problem in supply process. Acid and others materials are sold to nearby industries and trade companies. So it has very little risk in supply processes during political unrest.

#### **BUSINESS RISKS:**

Business risk is the possibility that a company will have lower than anticipated profits, or that it will experience a loss rather than a profit. Business risk is influenced by various factors, including business environment, economic situation and Government Regulations.

#### **MANAGEMENT PERCEPTION:**

Business Risk for this company is very minimum for its products are compulsory for the Government Organization ie; Dhaka & Chittagong WASA, Fertilizer Factory under Govt. Control, Power Plant etc. need Aluminium Sulphate and Sulfuric Acid for their Operational Processes. Leather, Textile and other export oriented Industries use our products to meet their requirement in their production process. In agriculture sector sulphate fertilizer uses are growing day by day. So the management find very minimum Risk on it's business.

#### **INDUSTRY RISKS:**

The company mainly produce and sale sulfuric acid. Major consumers of the products of WCL are Fertilizer Factories, leather industry, soap, detergent, battery industry, glue, rubber, paints, dyes, plastics, water treatment plant, paper mill, iron pickling, steel mill, Textiles and its backward linkage industry etc. ETP plants and other chemical & Engineering sectors. There are a huge demand for the product of the Company in the Industrial sectors. Its main product Sulfuric Acid is of toxic character and has effects including water and environmental Pollution.

#### **MANAGEMENT PERCEPTION:**

The Company has internal risk Mitigate system like using the modern equipped Water Treatment Plant (ETP), Air Treatment Plant (ATP) and using of experience technician for hazard identification, risk analysis and risk management. It has ETP and ATP for environment pollution control. Workers and Employees of the factory use appropriate Uniform, Musk, Gloves, shoes etc. for security & safe guard of their life and these are effectively monitored by the management.

#### **MARKET & TECHNOLOGY RELATED RISK & MANAGEMENT PERCEPTION:**

WCL's product is Sulfuric Acid, Aluminium Sulphate, Zinc & Magnesium Sulphate, LABSA & SLES etc. Consumption of sulfuric acid is a main indicator of Industrial development of a country. Its demand is being increased day by day. It has very few competitors in market yet. Aluminium sulphate is the most essential item in Water Purification. Its demand is being increased day by day. It also has very few competitors in market. At rising of production of high yielding variety of all agricultural products, sulphate fertilizer use has also similar rising trend all over the country. Market risk for the product is as good as nil. Political unrest may have a factor on overall market position of the country.

The technology being utilized for its products are the latest standard. It has technical manpower and the company never faced any technological difficulties during life of the plant units. Management always has intention to adopt developed technologies in future and when it is found innovative in productivity.

#### **RISK RELATED TO POTENTIAL OR EXISTING GOVERNMENT REGULATIONS:**

The business activities of WCL is fully controlled by Policies, Rules and Regulations framed by Regulatory Authorities of the Government, Sudden change in Government policies in this regard may impact business operation.

#### **MANAGEMENT PERCEPTION:**

The Company operates under Company's Act-1994, Taxation Policy adopted by NBR, Bangladesh Security And Exchange Commission (BSEC)'s, Dhaka Stock Exchange (DSE),Chittagong Stock Exchange Ltd. (CSE) Rules Regulations adopted by other Regulatory organizations. Any abrupt change of the policies formed by those bodies may impact the business of the Company.

WCL maintain its production and marketing processes in full compliance with Act, Rules, Regulations of the regulatory authorities like Ministry of Home, Department of Explosive ,DC Office of Narayangonj & Chittagong (Licensing Authority) etc;



### **RISK RELATED TO POTENTIAL CHANGES IN GLOBAL OR NATIONAL POLICIES:**

The performance of the company may be affected by the political and economical instability both in Bangladesh and worldwide. Any instance of political turmoil and disturbance in the country may adversely affect the economy in general. Since our products are of basic and fundamental uses in developing/developed countries, there is very little risk for changes in Global & National Policies.

### **MANAGEMENT PERCEPTION:**

The company can prosper in a situation of political stability and a congenial business environment. Political turmoil and disturbance have adverse effect on the economy and so also on this sector. This is why WTO and Asian Development Bank emphasize development of chemical sector in chalking out their respective policies. The Company is always aware of all types of turmoil and even though if the smooth supply of raw material is hampered or faces any kind of disruptions, it will try to keep the production smooth. The global and national policies for production of sulfuric acid are favorable since long and at present.

Though the Government has strict monitoring and follow up the retail use of any type of acid due to abusing inhuman way, there is no restriction on production considering the dire necessity of sulfuric acid as raw materials of various local & export oriented industries in Bangladesh. So, the demand of sulfuric acid will increase day by day with the increase of the relevant industries those who are using sulfuric acid.

### **RISK RELATED TO COVID- 19 SITUATIONS:**

The Corona Virus is a Novel Virus and a Novel risk resulting in Industry, logistical and financial issuer never seen before Most of the factor are like that

- (1) Supply Chain Disruption
- (2) Interruption of operation
- (3) Effect on consumer demand
- (4) Work related measure
- (5) Market volatility, Credit risk and financial performance

### **MANAGEMENT PERCEPTION:**

During unavoidable COVID- 19 (Corona Virus) Pandemic situation guideline on COVID- 19 has been introduced and as such no employee & workers at factory has been affected by corona virus yet. As our basic chemicals used in all WASA, Govt. Enterprise and huge member of local Industries in Bangladesh, So far we have not had to close our Factory. We have continued our production at a smaller scale.

### **SUPPLY RISK:**

WCL is dependent on import for its raw materials. The company imports major raw material i.e Sulphur from Russia and UAE, Saudi Arabia, India. The company maintains import relationship with several suppliers. So, it thinks very minimum supply risk.

Raw materials are imported from different Asian and European countries. Risk has been there for procurement/import of raw materials for Covid 19 pandemic has affected almost all countries around the Globe. Container crisis, ship's unavailability, insufficient feeder vessel, congestion at port of transshipment etc; have been reason for import lots taking much long time from port of loading to reach destination.

Management is aware of the risk and has been importing sufficient quantity so that risk of raw material supply is minimized and production continuation is maintained properly. The risk is being covered by effective supervision, timely purchase and by utilizing experience of the Management.

# **AUDIT COMMITTEE REPORT FOR THE YEAR ENDED 30TH JUNE, 2022**

**Annexure: 05**

We, the members of Audit Committee of Wata Chemicals Ltd. have reviewed the Audited Financial Statement as well as performance of the company for the year covering from 1st July, 2021 to 30th June, 2022.

Based on our study and review of draft audited accounts as well as annual performance of company for the year covering from 1st July, 2021 to 30th June, 2022 following facts along with observations and recommendations on the variations, if any, came to our notice are appended in the undernoted paragraphs:

## **SCOPE OF AUDIT:**

We have conducted our audit and review on financial statements for the year from 1st July, 2021 to 30th June, 2022 in line with Generally Accepted Auditing Standards in order to obtain reasonable assurance on the accounts whether financial statements are free of material misstatement.

We have discussed with Managing Director, Head of Accounts and Head of Internal Audit in the matter where clarifications were necessary. We have also made check with all relevant records and books of accounts on test basis. Our review work includes assessing of accounting systems and principles used for preparation of financial

## **CONSTITUTION OF AUDIT COMMITTEE:**

The present Audit committee had been constituted as per guidelines issued by BSEC as well as subsequently Corporate Governess Code brought by BSEC with following members:

- (i) Mr. Md. Iftikhar-Uz-Zaman, Independent Director and Chairman of Audit Committee, Wata Chemicals Ltd.
- (ii) Mr. A.T.M. Najmul Hussain, Non-Executive Director, Wata Chemicals Ltd. and Member of Audit Committee
- (iii) Mr. Subrata Pal- FCMA, Non-Executive Director, Wata Chemicals Ltd. and Member of Audit Committee
- (iv) Mr. Shamsul Huq, Company Secretary, Wata Chemicals Ltd. and Secretary of Audit Committee.

We, the members of Audit Committee met together in a meeting held on 26.10.2022 to review of draft audit report & accounts and performance of company for the period from 1st July, 2021 to 30th June, 2022.

## **ROLE OF AUDIT COMMITTEE:**

The assignments and responsibility of Audit Committee are laid down as under:

- (a) To oversee the financial reporting process and comments on significant deviations, if any, found.;
- (b) To monitor and study the Accounting Policy and Principles as followed by the company;
- (c) To monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan review of the Internal Audit and Compliance Report;
- (d) To oversee performance of external auditors;
- (e) To hold meeting with the external or statutory auditors for review of the Annual Financial Statements before submission to the Board for approval or adoption;
- (f) To review along with the management, the Annual Financial Statements before submission to the Board for
- (g) To review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;
- (h) To review the adequacy of internal audit function;
- (i) To review the Management's Discussion and Analysis before disclosing in the Annual Report;
- (j) To review statement of all related party transactions submitted by the management;
- (k) To review Management Letters or Letter of Internal Control weakness issued by statutory auditors ;
- (l) To oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors; and
- (m) To review and study first quarterly, second quarterly and third quarterly unaudited Financial Statements as well as draft Audit Report and Accounts and submit before the Board alongwith committee's observations and comments on deviations, if any. Discussion with Management should also be held about significant deviations,

The duties and responsibilities of Audit Committee are clearly set forth in writing by the Board in the Audit Committee's chart of responsibilities. Accordingly audit committee are responsible to the Board of Directors.

## **THE SALIENT ISSUES TO BE COVERED BY AUDIT COMMITTEE'S REPORT:**

The audit committee's report would cover following issues for reporting to the Board of Directors as per BSEC's

- (a) Report on conflict of interest, if any.
- (b) Report on any suspected transactions, fraud or misappropriation of fund, irregularity or material financial impact involved in any transaction, weakness in internal control system.
- (c) To identify the risks, if any, in internal control system and management process.
- (d) To review and study the appointment process of external auditor.
- (e) To review management letter on internal control weakness issued by auditor.
- (f) Deviations, if any, in compliance of company laws, security related laws and other rules and regulations.
- (g) Any other matters involving financial adverse impact to be disclosed in the report for knowledge of Board of
- (h) To review statement of significant related party transactions, if any.

### **Committee meetings and attendance**

The Committee held 04 (four) meetings for review of financial statements including among others.

At least one meeting to be held every quarter, in which the Committee reviewed issues relating to business operations, compliance, finance and accounts, among others. The Managing Director & Chief Executive Officer, Chief Financial Officer and Head of Internal Audit and Compliance were permanent invitees to the meeting. Relevant departmental heads and other members of the management also attended the meetings as required. The proceedings of the meetings are properly recorded in minutes and regularly reported to the Board of Directors. All members of Audit Committee were present in all meeting ie; attendance percentage is 100%.

### **COMMITTEE'S OBSERVATION AND RECOMMENDATIONS :**

The committee has laid down the following observations alongwith recommendations regarding compliance of corporate laws and the Financial Affairs of the Company for the period 2021 - 2022 as under:

- a) Laws and regulations relating to business and internal policies/guidelines should have been carefully complied.
- b) VAT Department had raised claim for amount of Tk. 414.28 lac against which company has filed appeal on payment of 10% of claim amounts.

In financial statements for the year ended 30th June, 2022 against which contingent liability have been disclosed in disclosure by the management in accordance with International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS) as adopted by the Institute of Chartered Accountants of Bangladesh.

- c) Appropriate Management Information Systems (MIS) and budgetary control system should be properly introduced and reviewed from time to time.
- d) Physical inventory at end of each financial year have been carried out through inventory committee. Difference, if any, have also be accounted for.
- e) Fixed assets register should be maintained properly.
- f) To mitigate financial risk, management should take effective steps and reviewed from time to time.
- g) Company's staff organogram with responsibility chart should be prepared more effectively and reviewed whether deficit or surplus staff/workers carrying on pay roll.
- h) Management should consider the recommendations of statutory auditor of the company in their respective reports as well as recommendations of audit committee.

The findings and recommendations of the committee are reported to the Board of Directors meeting and the Board of Directors may take appropriate measures thereof. The minutes of all Audit Committee meetings are circulated among head of all concerned department and Managing Director of company.

### **APPRECIATION:**

We thanks to Managing Director, Directors and all Officers and staff of office and factory who had extended then best co-operation and necessary assistance through necessary papers and data as and when required, to accomplish our



**Md. Iftikhar-Uz-Zaman**

**Independent Director and Chairman of Audit Committee**

**Wata Chemicals Ltd.**

# Management Discussion and Analysis

The year, 2021-22 was unique in many ways and the financials reported for the year truly reflect the challenges that the business faced. Major part of up to 2021 with various restriction of Government / lockdown of the economy in the Bangladesh, and recording lower revenue. During this unprecedented period, there were three key areas that we focused on. The highest priority was for ensuring employees' wellbeing and protecting their jobs. Next, was to support customers' needs amidst the challenging environment. The third was for ensuring the health of the business and the interest of the stakeholders. After post effect of Covid- 19 and the war between Russia & Ukraine and devaluation of taka in comparison with US dollar, resulting huge exchange loss.

## Accounting policies and estimation:

Accounting policies are determined by applying the relevant IFRS. Where there is no available guidelines of IFRS, management uses its judgment in developing and applying an accounting policy that results in information that is relevant and reliable. The company selects and applies its accounting policies for a period consistently for similar transactions, other events and conditions, unless a IFRS or specifically requires or permits categorization of items for which different policies may be appropriate. The accounting policies set out below have been applied consistently in all material respects to all periods presented in these financial statements. We have followed International Financial Reporting Standards (IFRSs) and the Companies Act, 1994 in preparation of financial statements. These financial statements follow the requirements of IFRSs which are to some extent different from the requirement of the Companies Act, 1994. The company changes its accounting policy only if the change is required by a IFRS or results in the financial statements providing reliable and more relevant information about the effects of transactions, other events or conditions on the company financial position, financial performance or cash flows. Changes in accounting policies is made through retrospective application by adjusting opening balance of each affected components of equity i.e. as if new policy has always been applied and Estimates arise because of uncertainties inherent within them, judgment is required but this does not undermine reliability. Effect of changes of accounting estimates is included in profit or loss account. The preparation of the financial statements are in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. However, the Company also complied with the requirements of following laws and regulations from various Government bodies: i. Bangladesh Securities and Exchange Rules 1987; ii. The Income Tax ordinance, 1984; and iii. The Value Added Tax Act, 1991; iv. The Value Added Tax and Supplementary Duty Act, 2012. In preparing financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively. Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the financial statements is included in note-1, Page- 52 of this Annual Report.

## Changes in Accounting Policies and Estimation:

WATA Chemicals has been following consistent policies and estimations and there have been no such changes in accounting policies or estimations that have had a material impact on financial statements.

## Financial Results (BDT) for last five years :

Particulars	2021-2022	2020-2021	2019-2020	2018-2019	2017-2018
Gross Turnover	1,036,043,378	649,079,365	837,993,834	923,341,039	465,732,187
Net Turnover	953,804,600	569,812,320	770,452,978	872,437,857	425,030,219
Cost of Goods Sold	(674,667,049)	(352,982,008)	(486,530,822)	(573,458,281)	(286,287,982)
Gross Profit	279,137,551	216,830,312	283,922,156	298,979,576	138,742,236
Administrative Selling & Distribution Expense	(68,569,557)	(47,063,922)	(41,141,121)	(36,174,225)	(36,872,873)
Operating Profit	210,567,995	169,766,390	242,781,035	262,805,351	101,869,363
Finance Expense	(129,909,518)	(73,734,448)	(65,461,886)	(68,391,981)	(44,745,788)
Non-Operating income	4,265,360	6,919,694	1,360,900	2,306,785	8,806,500
Profit before Contribution to WPPF& welfare fund	84,923,837	102,951,636	178,680,049	196,720,155	65,930,075
Contribution to WPPF	(4,043,992)	(4,902,459)	(8,508,574)	(9,367,626)	3,139,527
Profit before Tax	80,879,845	98,049,177	170,171,475	187,352,529	62,790,548
Income Tax Expense	(20,921,725)	(7,091,864)	(50,848,018)	(49,385,960)	(12,518,786)
Profit after Tax	59,958,120	90,957,313	119,323,457	137,966,568	50,271,762

During the year, there was a gross sale of Tk. 1,036,043,378. Gross Sales during 2021-2022 has been increased by Tk.38,69,64,013 compare to the year of 2020-2021. Gross Profit has been increased in 2021-2022 in compare to with preceding year by Tk.6,23,07,239 but unexpected huge Exchange Loss in 4th quarter and increase of Financial Expenses affect negatively in the net profit ratio despite increased gross profit ratio.

## Ratios Analysis of performance table 2021-22 and 2020-21 are described below:

Particulars	2021-2022	2020-2021	Variance
Gross Profit ratio (%)	29.27	38.05	(8.78)
Operating profit ratio (%)	22.08	29.79	(7.71)
Net Profit ratio (%)	6.29	15.96	(9.67)
Inventory turnover ratio (days)	66.00	69	(3.00)
Debt equity ratio Long Term Debt Equity Ratio	49.30:50.70	49.91:50.09	-
Current ratio	0.79	0.75	0.04
Interest coverage ratio (Times)	1.62	2.33	(0.71)
Debtors turnover /Trade Receivables turnover ratio (Days)	218	242	(24.00)

## Dividend:

In view of the performance of the company and considering the current liquidity position, the Board of Directors has recommended a cash dividend of 20% per share for General Investor (Other than Director) and 10% cash dividend for Directors the year ended 30 June 2022, to be approved at the ensuing 40th Annual General Meeting.

With this recommendation of proposed cash dividend, the summary of the dividend in last five years represented below:

Particulars	2021-2022	2020-2021	2019-2020	2018-2019	2017-2018
Profit after tax	59,958,120	90,957,313	119,323,457	137,966,568	50,271,762
Earnings per share	4.05	6.14	8.05	9.31 (Restated)	5.51
Cash dividend %	20% for General/Investors (Proposed) 10% for Sponsor/Director (Proposed)	30%	35%	30%	10%
Stock Dividend %	-	-	-	25%	30%

**Comparison of financial performance with peer industry:**

WATA Chemicals Limited is the BASIC CHEMICAL MANUFACTURING INDUSTRIES in Bangladesh. Also, the nature of the Chemicals business is different from the other Chemical industries in the capital market and hence it is not possible to compare the financial and cash flow position with peer companies.

**Finance:**

The gross revenue of the Company was Tk. 1,036,043,378 for the year under review as compared to Tk. 649,079,365 for the year ended 30th June 2021. The Company registered a net profit of Tk 59,958,120 as compared to net profit of Tk 90,957,313 for the previous year ended 30th June 2021. For the year ended 30 June 2022, total revenue of WATA Chemicals Limited was Tk. 1,036,043,378 against Tk 649,079,365 of financial year 2020-2021, resulting 59.61% more revenue over FY 2020-2021. Though Sales volume has been increased as compared with the corresponding period of previous year. After post effect of Covid- 19 and the war between Russia & Ukraine and devaluation of taka in comparison with US dollar & inflation of raw materials price is much more higher than corresponding period of previous year resulting huge exchange loss resulting increase of cost of production as well as decrease of EPS.

**Cash flow Movement (BDT thousand):**

Particulars	2021-2022	2020-2021	2019-2020	2018-2019	2017-2018
Net Cash flow from Operating Activities	86,395,426	68,409,867	97,259,642	172,001,657	50,085,592
Net Cash flow from Investing Activities	(62,645,356)	(111,585,061)	(177,547,314)	(583,243,661)	(210,328,893)
Net Cash flow from Financing Activities	(25,357,927)	68,905,756	87,332,853	413,489,822	161,792,492
Net Increase/(Decrease) in cash & cash Equivalents (A+B+C)	(1,607,857)	25,730,562	7,045,181	2,247,818	1,549,191
Effect of Movement in exchange rate on cash held	(18,641,248)	(2,194,524)	(226,301)	(1,969,987)	(1,951,775)
Opening cash & Cash Equivalents	(31,368,347)	7,832,309	1,013,429	735,599	1,138,182
Closing Cash & Cash Equivalents at Reporting Date	11,119,242	31,368,347	7,832,309	1,013,429	735,599
Net Operating Cash flow per Share in Taka	5.83	4.62	6.56	14.50	5.49

**Financial and economic scenario of the country and the global economy:**

The virulent outbreak continues to worry investors, especially given the already significant disruption of a wide range of global industries, including manufacturing, automobiles, technology, pharmaceuticals, apparel, transportation, retail and tourism etc. Despite the pandemic, Bangladesh is set to post the third-highest growth in the world and the highest in Asia in 2020, according to the International Monetary Fund. Of the 190 IMF member countries, only 23 are forecast to post a positive growth in the outgoing year. The Prime Minister of Bangladesh had taken effective measures that fuelled domestic demand and helped people survive the crisis. As a result, Bangladesh has been able to keep up the growth trajectory during the crisis; the economy has weathered the impacts of the pandemic and is now on track for a recovery." The government's massive stimulus package helped the economy, but it is yet to recover fully, "Most of the countries are likely to have negative growth this year." The economy is recovering, but it is not yet back on track to a faster and sustainable growth with investments still depressed and external demand wavering. The war between Russia & Ukraine and devaluation of taka in comparison with US dollar & inflation of raw materials price has a severe effect. We hope 2023 will get us back to a sustainable growth track as the world economy and domestic demand turns around. Government takes necessary steps timely that Bangladesh's agriculture, manufacturing and service sectors will achieve more in the near future.

**Risks and concern issues related to the financial statements:**

The Managing Director and Chief Finance Officer is required to confirm annually that all information relevant to the audit has been provided to the Board of Directors through the Audit Committee and that reasonable steps have been taken to ensure full disclosure in response to requests for information from the external auditor. In addition, The Finance and Accounts Department to fully review account reconciliations on a annual basis. The integrity of the Company's public financial reporting is further supported by several processes and steps to provide assurance over the completeness and accuracy of the content including review and recommendation by the Audit Committee and review and approval by the Board. The Company has policies, practices and controls in place in relation to the financial reporting.

**Future plan :**

Our Board of Directors, it's Management have been utilizing best efforts in support and suggestion of the shareholders for strengthening and widening field of production, Capacity Building for the wellbeing of the economy of the country and so for the SLES and LABSA plant set against finance provided by Agrani Bank Ltd. , has been completed and efforts are being utilized for quick starting trial production. After successful commercial production of the newly set up SLES and LABSA turnover of the company will be significantly increased and we hope profit as well as EPS will increase accordingly. Our Director Mr. A.H.M Abdullah Graduate in Chemical Engineering from BUET with his team have been utilizing their best efforts for set up more basic chemical plants for more contribution to the economy of the country as well as for WATA chemicals Ltd.

Declaration or certification by the CEO and the CFO to the Board as required shall be disclosed as per Annexure-A, Page- 40; and The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 were disclosed as per Page # 30 & 31 to 39.



(Md. Nazrul Islam)  
Managing Director

# Corporate Governance Report

Corporate Governance is the system of directing & controlling listed companies by its Management in the best interest of all stakeholders to ensure greater transparency, better and timely financial reporting. Board of Directors is responsible for proper Governance in setting out company's strategic aims, providing appropriate leadership in implementing aims, supervising business Management and reporting to the shareholder.

WATA CHEMICALS LTD (later on mentioned as 'WCL') is committed to continuous reviewing all Corporate Governance policies and practices to ensure transparency of the company's business and to deliver high standards and quality information to stakeholders.

Maintenance of effective corporate governance remains a key priority of the Board of WCL. To exercise clarity about Directors' responsibilities towards the shareholders, Corporate Governance must be dynamic and remain focused on the business objectives of the Company and create a culture of openness and accountability. Keeping this in mind, clear structure and accountabilities supported by well understood policies and procedures to guide the activities of the Company's Management have been instituted.

## STATEMENTS OF COMPLIANCE:

Bangladesh Securities and Exchange Commission's notification on Corporate Governance:

As WCL is listed on the Stock Exchanges in Bangladesh provision contain with BSEC's notification on Corporate Governance (BSEC/CMRRCD/2006-158/207/Admin/80, Dated: 03 June, 2018) are being complied with.

## CORPORATE GOVERNANCE FRAMEWORK

### ROLE OF THE BOARD

The Directors of the Board are appointed by the Shareholders at the Annual General Meeting (AGM) and accountable to the Shareholders. The Board is responsible for ensuring that the business activities are soundly administered and effectively controlled. The Directors of the Board keep themselves informed about the Company's financial position and ensure that its activities, accounts and asset management are subject to adequate control.

In addition to the other legal guidelines, the Board has also adopted "Governance Guidelines" for the Board for ensuring better Governance. The Code on Corporate Governance of the company sets out the principles and best practices to be applied by the company in its operations towards achieving the optimal governance framework.

The Board of Directors is responsible for protecting the rights and interests of all shareholders and also accountable for the overall Management of the entity. Besides its usual legal and statutory responsibilities, the Board is responsible for the following:

- Reviewing and adopting a strategic plan for the company;
- Overseeing the conduct of the company's business to evaluate whether the business is being properly managed;
- Identifying principal risks and ensuring the implementation of appropriate systems to manage these risks;
- Succession planning, including appointing, training, fixing the compensation and where appropriate, replacing senior management;
- Developing and implementing an investor relations program or shareholder communications policy for the company;
- Reviewing the adequacy and the integrity of the company's internal control systems and management information systems, including systems for compliance.
- Approving the financial statements and accounting policies of the company;
- Approving changes in the policy;
- Recommending dividend for declaration in AGM;
- Establishing committees, including the Audit Committee, Nomination & Remuneration Committee and the Compensation Committee and determining the authorities to be delegated to committees of the Board;
- Receiving and reviewing reports from committees of the Board;
- Establishing and monitoring compliance with the company's standards of business conduct and other policies of the company;
- Establishing appropriate systems of corporate Governance in the company;
- Considering and approving other relevant matters.
- Constantly guide and assist the company in external stakeholder management.

### BOARD COMPOSITION

At present the Board in WCL is comprised of 5 Directors. The post of Chairman and Managing Director are filled by two different Directors. Managing Director acts as Chief Executive Officer. The Board of Directors define respective roles responsibilities of the Chairman, Managing Director and Independent Director.

**THE NAME OF THE BOARD OF DIRECTORS:**

01.	Mr. Razi Uddin Ahmed General Manager- I.C.B.	Chairman (Director- Nominated by I.C.B)
02.	Mr. Md. Nazrul Islam	Managing Director
03.	Mr. Md. Iftikhar-Uz-Zaman	Independent Director
04.	Mr. Md. A.H.M. Abdullah	Director
05.	Mr. Md. Mahmudul Hasan	Director

**BOARD MEETINGS**

The meetings of the Board of Directors of WCL are normally held at the Registered Head Office of the Company. The meetings are held at least once in a quarter, to discharge its responsibilities and functions as mentioned above. Meeting is scheduled well in advance and the notice of each Board meeting is given in writing to each Director.

The WCL Board meeting 5 times during the period from July 2021 to June 2022 and took decisions on key matters.

The details of Board Meeting and attendance are given in Annexure- 2 of this report.

**ELECT AND RE-ELECT OF DIRECTORS**

As per the Articles of Association of the company, one-third of the Directors to retire in every year shall be those who have been longest in office since their last election.

**INDEPENDENT DIRECTOR**

Management vide meeting of Board of Directors dated 15.11.2020 considering evaluation report from NRC appoint Mr. Md. Iftekhar-Uz-Zaman, Ex-Managing Director of ICB as Independent Director of WATA Chemicals Limited for One tenure confirmed by 38th Shareholder meeting will be held on 24.12.2020.

**DIVISION OF WORK FOR THE BOARD AND MANAGING DIRECTOR**

The roles of the Board and Managing Director are separate and delegation of responsibilities is clearly established set out in writing and agreed by the Board to ensure transparency and better corporate governance. To that end, WCL has also adopted "Governance Guidelines for Managing Director". The Managing Director is the authoritative head for day-to-day management. He acts as Chief Executive Officer of WCL to ensure that WCL operates business as per the Articles of Association, decisions made by the Board and Shareholders and according to WCL Policies, Procedures and relevant regulatory legislations.

**ROLE OF THE CHAIRMAN**

The Chairman leads the Board in determination of its strategy and achievement of its objectives. The Chairman is responsible for organizing the business of the Board, ensuring its effectiveness and setting its agenda. The Chairman is also responsible for ensuring that the Directors receive accurate, timely and clear information. The Chairman has no engagement in the day-to-day business of the Company. The Chairman facilitates the effective contribution of Independent Directors and ensures that constructive relations exist amongst the Directors. Minutes of Board meeting are signed by the Chairman.

**ROLE OF THE MANAGING DIRECTOR & CEO**

The Managing Director & CEO is responsible for running the business and for formulating and implementing Board strategy and policy. He exercises overall control of the Company on a day-to-day basis and is accountable to the Board for the financial and operational performance of the Company.

**ROLE OF COMPANY SECRETARY**

To ensure effective integration and timely flow of information required by the Board and to maintain necessary liaison with internal resources as well as external agencies, the Board has appointed a Company Secretary. The Corporate Governance Guidelines issued by the Bangladesh Securities and Exchange Commission (BSEC) also require a listed company to appoint a full fledged Company Secretary, as distinct from other managers of the Company. In pursuance of the same, the Board of Directors has appointed Company Secretary and defined his following roles & responsibilities:

Assist the members of the Board under the Companies Act, BSEC & Stock Exchange requirements .

Acts as a channel of communication and information

Ensures that the Board's decisions are properly implemented and communicated by assisting in the implementation of corporate strategies and policies.

Ensures proper compliance with all relevant statutory and regulatory requirements.

Communicates with the stakeholders of the company

In addition he attends all Board Meetings and presents and reviews all quarterly and periodical results.

**ROLE OF CHIEF FINANCIAL OFFICER:**

The chief financial officer (CFO) is the officer of the company that has primary responsibility for managing the company's finances, including financial planning, management of financial risks, record-keeping, and financial reporting. In some sectors, the CFO is also responsible for analysis of data.

The CFO is a senior manager with the primary role of overseeing the management of the company's finances and financial activities, including financial risk management, financial planning, financial reporting, recordkeeping, and analysis of data. The chief financial officer usually reports to the CEO, as well as the board of directors and to Shareholder. They may also seat on the board. They are the head of the company's finance personnel and are also the key financial spokesperson. They normally support on both tactical and strategic matters concerning cost-benefit analysis, securing of new funding, forecasting needs, and budget management.

The CFO is in charge of the financial support of the corporate strategy, meaning they ensure that sufficient cash is available to cover strategic needs and alleviate risk.

The CFO also plays an important liaison role, since they build relationships with lenders, banks, investors, regulators, and other financial institutions.

#### **ROLE OF THE HEAD OF INTERNAL CONTROL & COMPLIANCE**

The Head of Internal Control is responsible for reporting to the Board Audit Committee regarding any deviation from accounting and internal control systems of the Company. He is also responsible for ensuring regulatory compliance of the Company.

#### **PRICE SENSITIVE INFORMATION**

The Board of WCL through the Company Secretary always ensures it's any or all price sensitive information by Fax and or email within 30 minutes of the decision or immediately upon getting such information to the BSEC and the Stock Exchanges and to other concerned. In special cases by publishing the same in two widely circulated daily newspapers, one in Bangla and the other in English and upload PSI in Companies Website.

#### **DISCLOSURE ON THE PERFORMANCE AND PROSPECT OF THE COMPANY**

WCL attaches high priority on timely publication of quarterly, Quarterly and annual report as per regulatory requirements. Price Sensitive Information is released to the regulators within half an hour of the decision. The Financial Statements are prepared in accordance with IAS and IFRS and other applicable laws.

#### **DIVIDEND POLICY**

The Board of Directors has a Dividend Policy which is based on company's performance and company's objectives.

#### **BOARD COMMITTEES**

##### **Audit Committee:**

The Board of Directors has constituted an Audit Committee of the Board Consisting of three Directors, At present The Audit Committee headed by the Independent Director, Mr. Md. Iftikhar-Uz-Zaman, Independent Director and Mr. Subrata Pal- FCMA, Non Executive Director and Mr. A.T.M. Najmul Hussain, Non Executive Director. The Audit Committee carries out its responsibilities as per the provisions of law and submits its report to the Board of Directors from time to time. The Audit Committee shall also Co-Ordinate with the Internal and External Auditor's as and when required. The Audit Committee also ensures compliance of requirements of BSEC and others agencies. Mr. Shamsul Huq Company Secretary has been working as Secretary of the Audit Committee.

#### **NOMINATION AND REMUNERATION COMMITTEE:**

At present Nomination and Remuneration Committee (NRC) Comprising of three members namely the audit committee headed by the Independent Director, Mr. Md. Iftikhar-Uz-Zaman, Independent Director and Mr. Subrata Pal- FCMA, Non Executive Director and Mr. A.T.M. Najmul Hussain, Non Executive Director. is the Chairman of NRC. NRC committee carries out its responsibilities as per provision of BSEC Notification.

##### **A. Purpose**

- (i) The objective of the Nomination and Remuneration Committee ("NRC") is to assist the Board of WATA CHEMICALS LIMITED in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executives;
- (ii) The Committee shall ensure that the Board and Executive Committee's retain an appropriate structure, size and balance of skills to support the strategic objectives and values of the company.

##### **B. Constitution**

- (i) The Committee shall comprise of at least three members including an independent director;
- (ii) All members of the Committee shall be non-executive directors;
- (iii) Members of the Committee shall be nominated and appointed by the Board;
- (iv) The Board of Wata Chemicals Limited shall have authority to remove and appoint any member of the Committee;
- (v) In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;
- (vi) The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;
- (vii) The Committee shall have delegated authority from the Board in respect of the functions and powers set out in these Terms of Reference;
- (viii) The Committee shall have the authority to investigate any matter within its Terms of Reference and to obtain such information as it may require for such investigation.

##### **C. Chairperson**

- (i) The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;
- (ii) In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;

(iii) The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders: Provided that in absence of Chairperson of the NRC, any other member from the NRC shall be selected to be present in the annual general meeting (AGM) for answering the shareholder's queries and reason for absence of the Chairperson of the NRC shall be recorded in the minutes of the AGM.

**D. Secretary**

(i) The company secretary shall act as the secretary of the Committee;

**E. Frequency of Meetings**

(i) The NRC shall conduct at least one meeting in a financial year;  
(ii) The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC.

**F. Quorum**

(i) The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher;  
(ii) The quorum of the NRC meeting shall not constitute without attendance of at least one independent director.  
(iii) A duly convened meeting of the Committee at which a quorum is present shall be competent to exercise all or any of the authorities, powers and discretions vested in or exercisable by the Committee.

**F. Proceedings of Meetings**

(i) The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC;  
(ii) The Secretary shall minute the proceedings and resolutions of all committee meetings, including the names of those present and in attendance and shall circulate the minutes of meetings of the Committee to all members of the Committee.  
(iii) All the observations/ findings/ recommendations of the Committee shall be recorded in the minutes of meetings of the Committee.  
(iv) Minutes of the Committee's meetings shall be kept by the secretary of the committee;

**G. Remuneration / Fees**

(i) No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than meeting fees or honorarium from the company.

**H. Role & Major Responsibilities of NRC are as under:**

(i) Recommend a policy on Board's diversity taking into consideration age, gender, experience, education and nationality;  
(ii) Formulate the criteria for determining qualification and independence of Directors;  
(iii) Identify persons who are qualified to become Directors and in top level executives and recommend their appointment and removal;  
(iv) Formulate the criteria for evaluation of performance of Independent Directors and the Board;  
(v) Recommend a policy to the Board relating to the Selection, Appointment, Remuneration of the Directors, and top level executives;  
(vi) Assess that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable Directors to run the company successfully;  
(vii) Evaluate that remuneration to Directors and top level executives involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;  
(viii) Identify the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;  
(ix) Recommend and review annually the Company's human resources and training policies;  
(x) Recommend the remuneration policy of the Company, particularly in relation to the yearly increment principle; and  
(xi) Recommend the Code of Conduct for the Chair of the Board, other Board Members and Chief Executive Officer of the Company.

**I. REPORTING**

(i) NRC shall be independent and responsible or accountable to the Board and to the shareholders;  
(ii) The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report;  
(iii) Minutes of each Committee meeting will be disclosed at the next meeting of the Board unless there are privacy and confidentiality reasons that prevent disclosure beyond the members of the Committee;  
(iv) Periodically the Chairperson of the Committee shall report to the Board on matters within its roles and responsibilities.

**J. REVIEW OF THE TERMS OF REFERENCE**

(i) The Committee shall review annually its Terms of Reference and may recommend to the Board any amendments to its Terms of Reference.  
(ii) The Board shall have the authority to make amendment to this Terms of Reference at any time.

**EXTERNAL /STATUTORY AUDITORS**

M/S. MABS & J Partners, Chartered Accountants is the External /Statutory Auditors of the company. They carry out systematic examination of books & records and ascertain, verify and report upon the facts regarding the financial operation and results of the company maintaining compliance of the BSEC Notification.

**CORPORATE GOVERNANCE COMPLIANCE AUDITORS**

The Compliance Auditor is responsible in certification on Compliance of Conditions of Corporate Governance code 2018 of Bangladesh Securities and Exchange Commission as well as the provisions of relevant Bangladesh Secretarial Standards of Institute of Chartered Secretaries of Bangladesh.

M/S. Shafiq Basak & Co., Chartered Accounts is the Corporate Governance Compliance Auditor of WATA CHEMICALS LIMITED for the year ended on 30.06.2022.

**SUBSIDIARY COMPANY**

WCL do not have any subsidiary or Associate or Parent company.

### Report Of The Nomination & Remuneration Committee- 2021-2022 Of Wata Chemicals Ltd.

Pursuant to Code 6.5(c) of Codes of Corporate Governance, the policy and report of the Nomination and Remuneration Committee (NRC) are presented hereunder at a glance.

Considering the magnitude and also to discharge its entrusted responsibilities, the Board of Directors of WATA Chemicals has duly constituted a Nomination and Remuneration Committee, as per the requirements of the BSEC Codes of Corporate Governance.

NRC assists the Board in formulating the nomination criteria for determining qualifications, positive attributes, experiences and independence of Directors and other top-level executives, as well as a policy for the formal process of considering the remuneration of Directors and senior level executives of the Company. Nomination and Remuneration Committee Composition along with Company Secretary.

At present the Nomination and Remuneration Committee consist of following members:

1. Mr. Md. Iftikhar Uz-zaman, Independent Director as Chairman
2. Mr. Subrata Pal – FCMA, Non-executive Director as member
3. Mr. A.T.M. Najmul Husain, Non-executive Director as member.
4. Shamsul Huq , Company Secretary as Secretary of NRC

In 2021-2022 committee met once on 16.10.2021 at the Head Office of the company.

The key activity summary of NRC during the year:

“Determining qualifications, positive attributes, experiences and independence and others for recommendation to the Board for appointment of Non-Executive Director.”



Md. Iftikhar Uz-zaman

Chairman

the Nomination and Remuneration Committee



# শফিক বসাক এন্ড কোং SHAFIQ BASAK & CO.

CHARTERED ACCOUNTANTS

**Partners:**

Md. Shafiqul Islam, FCA  
Sampad Kumar Basak, FCA  
Sarwar Mahmood, FCA  
Sheikh Zahidul Islam, MBA, FCA

**DHAKA OFFICE-(1):**

Shatabdi Centre (4th & 6th Floor)  
292, Inner Circular Road.  
Fakirapool, Motijheel, Dhaka.  
Phone/Fax: 880-2-7192098,  
Cell : +88 01730-080666  
E-mail: skzislam86@gmail.com  
skz4sbc@gmail.com  
Web: www.shafiqbasak.com

**CHATTOGRAM OFFICE:**  
National House (1st Floor),  
109, Agrabad Commercial Area,  
Chattogram -4100, Bangladesh.  
Phone: 880-31-711561  
Pho/Fax: 880-31-723680  
Web: www.shafiqbasak.com  
E-mail: basak\_sbc@yahoo.com  
basak@shafiqbasak.com

## Report to the Shareholders of WATA Chemicals Limited on compliance on the Corporate Governance Code [Certificate as per condition No. 1(5) (xxvii)]

We have examined the compliance status to the Corporate Governance code by WATA Chemicals Limited for the year ended on 30 June 2022. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- (a) The Company have complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission;
- (b) The Company have complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this;
- (c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws; and
- (d) The Governance of the company is satisfactory subject to the remarks and observations as reported in the attached corporate governance compliance status.

Signed for & on behalf of  
Shafiq Basak & Co.  
Chartered Accountants

Sheikh Zahidul Islam, FCA, MBA  
Partner

Place: Dhaka  
Dated: November- 24, 2022



INDEPENDENT MEMBER OF

**ABACUS**  
WORLDWIDE

DHAKA OFFICE - (2) : House - 42 (1st Floor), Road - 01, Block - A, Niketan, Gulshan - 01, Dhaka.

Phone: 88-02-99859602-3, 01819-285196, E-mail.mahmoods.bd@gmail.com

**In Practice Since 1993**

**WATA CHEMICALS LIMITED**  
**CORPORATE GOVERNANCE COMPLIANCE STATUS**

[AS PER CONDITION NO. 1(5)(XXVII)]

Status of compliance with the conditions imposed by the Commission's Notification No. SEC/CMR-RCD /2006-158/207/Admin/80 dated 3 June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

(REPORT UNDER CONDITION NO. 9)

Condition No.	TITLE	Compliance status (Put ✓ in the Appropriate Column)		Remarks (if any)
		Complied	Not complied	
1.0	<b>Board of Directors</b>			
1(1)	<b>Size of the Board of Directors:</b> The total number of members of a company's Board of Directors (hereinafter referred to as "Board") shall not be less than 5 (five) and more than 20 (twenty).	✓		
1.2	<b>Independent Directors:</b>			
1(2)(a)	At least one-fifth (1/5) of the total number of directors in the company's Board shall be independent directors; any fraction shall be considered to the next integer or whole number for calculating number of independent director(s);	✓		
1(2)(b)(i)	"Independent Director" means a director- who either does not hold any share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company;	✓		
1(2)(b)(ii)	who is not a sponsor of the company or is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares of the company on the basis of family relationship and his or her family members also shall not hold above mentioned shares in the company: Provided that spouse, son, daughter, father, mother, brother, sister, son-in-law and daughter-in-law shall be considered as family members;	✓		
1(2)(b)(iii)	who has not been an executive of the company in immediately preceding 2 (two) financial years;	✓		
1(2)(b)(iv)	who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies;	✓		
1(2)(b)(v)	who is not a member or TREC (Trading Right Entitlement Certificate) holder, director or officer of any stock exchange;	✓		
1(2)(b)(vi)	who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	✓		
1(2)(b)(vii)	who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this Code;	✓		
1(2)(b)(viii)	who is not independent director in more than 5 (five) listed companies;	✓		
1(2)(b)(ix)	who has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or any advance to a bank or a Non-Bank Financial Institution (NBFI); and	✓		
1(2)(b)(x)	who has not been convicted for a criminal offence involving moral turpitude;	✓		
1(2)(c)	The independent director(s) shall be appointed by the Board and approved by the shareholders in the Annual General Meeting (AGM);	✓		
1(2)(d)	The post of independent director(s) cannot remain vacant for more than 90 (ninety) days; and	✓		
1(2)(e)	The tenure of office of an independent director shall be for a period of 3 (three) years, which may be extended for 1 (one) tenure only: Provided that a former independent director may be considered for reappointment for another tenure after a time gap of one tenure, i.e., three years from his or her completion of consecutive two tenures [i.e. six years]: Provided further that the independent director shall not be subject to retirement by rotation as per Companies Act, 1994.	✓		

Condition No.	TITLE	Compliance status (Put ✓ in the Appropriate Column)		Remarks (if any)
		Complied	Not complied	
1.3	<b>Qualification of Independent Director.</b>			
1(3)(a)	Independent director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws, regulatory requirements and corporate laws and can make meaningful contribution to the business;	✓		
1(3)(b)(i)	Independent director shall have following qualifications: Business Leader who is or was a promoter or director of an unlisted company having minimum paid-up capital of Tk. 100.00 million or any listed company or a member of any national or international chamber of commerce or business association; or	✓		
1(3)(b)(ii)	Corporate Leader who is or was a top level executive not lower than Chief Executive Officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid-up capital of Tk. 100.00 million or of a listed company; or	✓		
1(3)(b)(iii)	Former official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics or commerce or business or Law; or	✓		
1(3)(b)(iv)	University Teacher who has educational background in Economics or Commerce or Business Studies or Law; or			Not Applicable
1(3)(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;	✓		
1(3)(c)	The independent director shall have at least 10 (ten) years of experiences in any field mentioned in clause (b);	✓		
1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission.			No such incident happened
1.4	<b>Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer.</b>			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director (MD) and/or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	✓		
1(4)(b)	The Managing Director (MD) and/or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	✓		
1(4)(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the company;	✓		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and/or Chief Executive Officer;	✓		
1(4)(e)	In the absence of the Chairperson of the Board, the remaining members may elect one of themselves from nonexecutive directors as Chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	✓		
1.5	<b>The Directors' Report to Shareholders</b>			
1(5)(i)	The Board of the company shall include the following additional statements or disclosures in the Directors' Report prepared under section 184 of the Companies Act, 1994 (Act No. XVIII of 1994): An industry outlook and possible future developments in the industry;	✓		
1(5)(ii)	The segment-wise or product-wise performance;	✓		
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	✓		
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	✓		
1(5)(v)	A discussion on continuity of any extraordinary activities and their implications (gain or loss);	✓		
1(5)(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	✓		
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;			Not Applicable

Condition No.	TITLE	Compliance status (Put ✓ in the Appropriate Column)		Remarks (if any)
		Complied	Not complied	
1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing, etc.;			Not Applicable
1(5)(ix)	An explanation on any significant variance that occurs between Quarterly Financial performances and Annual Financial Statements;	✓		
1(5)(x)	A statement of remuneration paid to the directors including independent directors;	✓		
1(5)(xi)	A statement that the financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	✓		
1(5)(xii)	A statement that proper books of account of the issuer company have been maintained;	✓		
1(5)(xiii)	A statement that appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	✓		
1(5)(xiv)	A statement that International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;	✓		
1(5)(xv)	A statement that the system of internal control is sound in design and has been effectively implemented and monitored;	✓		
1(5)(xvi)	A statement that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	✓		
1(5)(xvii)	A statement that there is no significant doubt upon the issuer company's ability to continue as a going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	✓		
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained;	✓		
1(5)(xix)	A statement where key operating and financial data of at least preceding 5 (five) years shall be summarized;	✓		
1(5)(xx)	An explanation on the reasons if the issuer company has not declared dividend (cash or stock) for the year;			Not Applicable
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;	✓		
1(5)(xxii)	The total number of Board meetings held during the year and attendance by each director;	✓		
1.5(xxiii)(a)	A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details where stated below) held by: Parent or Subsidiary or Associated Companies and other related parties (name-wise details);	✓		
1.5(xxiii)(b)	Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name-wise details);	✓		
1.5(xxiii)(c)	Executives; and	✓		
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details);	✓		
1(5)(xxiv)(a)	In case of the appointment or reappointment of a director, a disclosure on the following information to the shareholders: A brief resume of the director;	✓		
1(5)(xxiv)(b)	Nature of his or her expertise in specific functional areas; and	✓		
1(5)(xxiv)(c)	Names of companies in which the person also holds the directorship and the membership of committees of the Board;	✓		
1(5)(xxv)(a)	A Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on: Accounting policies and estimation for preparation of financial statements;	✓		
1(5)(xxv)(b)	Changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	✓		

Condition No.	TITLE	Compliance status (Put ✓ in the Appropriate Column)		Remarks (if any)
		Complied	Not complied	
1(5)(xxv)(c)	Comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	✓		
1(5)(xxv)(d)	Compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	✓		
1(5)(xxv)(e)	Briefly explain the financial and economic scenario of the country and the globe;	✓		
1(5)(xxv)(f)	Risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company; and	✓		
1(5)(xxv)(g)	Future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	✓		
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A; and	✓		
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9	✓		
1(6)	<b>Meetings of the Board of Directors:</b> The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	✓		
1.7	<b>Code of Conduct for the Chairperson, other Board members and Chief Executive Officer</b>			
1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6, for the Chairperson of the Board, other board members and Chief Executive Officer of the company;	✓		
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.	✓		
2.0	<b>Governance of Board of Directors of Subsidiary Company</b>			
2(a)	Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company;			Not Applicable
2(b)	At least 1 (one) independent director on the Board of the holding company shall be a director on the Board of the subsidiary company;			Not Applicable
2(c)	The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company;			Not Applicable
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;			Not Applicable
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.			Not Applicable
3.0	<b>Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS).</b>			
3(1)(a)	<b>Appointment:</b> The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	✓		
3(1)(b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	✓		
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time;	✓		
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	✓		
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).			No such incidence arose

Condition No.	TITLE	Compliance status (Put ✓ in the Appropriate Column)		Remarks (if any)
		Complied	Not complied	
3(2)	Requirement to attend Board of Directors' Meetings: The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board: Provided that the CS, CFO and/or the HIAC shall not attend such part of a meeting of the Board which involves consideration of an agenda item relating to their personal matters.	✓		
3.3	<b>Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO)</b>			
3(3)(a)(i)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief: These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and	✓		
3(3)(a)(ii)	These statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	✓		
3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board or its members;	✓		
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	✓		
4.0	<b>Board of Directors' Committee.</b>			
4(i)	For ensuring good governance in the company, the Board shall have at least following sub-committees: Audit Committee; and	✓		
4(ii)	Nomination and Remuneration Committee.	✓		
5.0	<b>Audit Committee</b>			
5(1)(a)	<b>Responsibility to the Board of Directors:</b> The company shall have an Audit Committee as a sub-committee of the Board;	✓		
5(1)(b)	The Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	✓		
5(1)(c)	The Audit Committee shall be responsible to the Board; the duties of the Audit Committee shall be clearly set forth in writing.	✓		
5(2)(a)	<b>Constitution of the Audit Committee:</b> The Audit Committee shall be composed of at least 3 (three) members;	✓		
5(2)(b)	The Board shall appoint members of the Audit Committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least 1 (one) independent director;	✓		
5(2)(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	✓		
5(2)(d)	When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 1 (one) month from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;			No such vacancy arose
5(2)(e)	The company secretary shall act as the secretary of the Committee;	✓		
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director.	✓		
5(3)(a)	<b>Chairperson of the Audit Committee:</b> The Board shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an independent director;	✓		
5(3)(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes.			No such incidence arose

Condition No.	TITLE	Compliance status (Put ✓ in the Appropriate Column)		Remarks (if any)
		Complied	Not complied	
5(3)(c)	Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM): Provided that in absence of Chairperson of the Audit Committee, any other member from the Audit Committee shall be selected to be present in the annual general meeting (AGM) and reason for absence of the Chairperson of the Audit Committee shall be recorded in the minutes of the AGM.	✓		
5(4)(a)	<b>Meeting of the Audit Committee:</b> The Audit Committee shall conduct at least its four meetings in a financial year: Provided that any emergency meeting in addition to regular meeting may be convened at the request of any one of the members of the Committee;	✓		
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two-third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	✓		
5(5)(a)	<b>Role of Audit Committee</b> <b>The Audit Committee shall:</b> Oversee the financial reporting process;	✓		
5(5)(b)	Monitor choice of accounting policies and principles;	✓		
5(5)(c)	Monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;	✓		
5(5)(d)	Oversee hiring and performance of external auditors;	✓		
5(5)(e)	Hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	✓		
5(5)(f)	Review along with the management, the annual financial statements before submission to the Board for approval;	✓		
5(5)(g)	review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;	✓		
5(5)(h)	Review the adequacy of internal audit function;	✓		
5(5)(i)	Review the Management's Discussion and Analysis before disclosing in the Annual Report;	✓		
5(5)(j)	Review statement of all related party transactions submitted by the management;	✓		
5(5)(k)	Review Management Letters or Letter of Internal Control weakness issued by statutory auditors;	✓		
5(5)(l)	Oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors; and	✓		
5(5)(m)	Oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission: Provided that the management shall disclose to the Audit Committee about the uses or applications of the proceeds by major category (capital expenditure, sales and marketing expenses, working capital, etc.), on a quarterly basis, as a part of their quarterly declaration of financial results: Provided further that on an annual basis, the company shall prepare a statement of the proceeds utilized for the purposes other than those stated in the offer document or prospectus for publication in the Annual Report along with the comments of the Audit Committee.			Not Applicable
5.6	Reporting of the Audit Committee			
5(6)(a)(i)	<b>Reporting to the Board of Directors:</b> The Audit Committee shall report on its activities to the Board;	✓		
5(6)(a)(ii)(a)	The Audit Committee shall immediately report to the Board on the following findings, if any: Report on conflicts of interests;			No such incident happened
5(6)(a)(ii)(b)	Suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process or in the financial statements;			No such incident happened
5(6)(a)(ii)(c)	Suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations; and			No such incident happened

Condition No.	TITLE	Compliance status (Put ✓ in the Appropriate Column)		Remarks (if any)
		Complied	Not complied	
5(6)(a)(ii)(d)	Any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately;			No such incidence arose
5(6)(b)	<b>Reporting to the Authorities:</b> If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.	✓		
5(7)	<b>Reporting to the Shareholders and General Investors:</b> Report on activities carried out by the Audit Committee, including any report made to the Board under condition No. 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	✓		
6(1)(a)	<b>Nomination and Remuneration Committee (NRC).</b> <b>Responsibility to the Board of Directors:</b> The company shall have a Nomination and Remuneration Committee (NRC) as a sub-committee of the Board;	✓		
6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	✓		
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5) (b).	✓		
6(2)(a)	<b>Constitution of the NRC:</b> The Committee shall comprise of at least three members including an independent director;	✓		
6(2)(b)	All members of the Committee shall be non-executive directors;	✓		
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	✓		
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;	✓		
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;			If arise, will be complied
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;	✓		
6(2)(g)	The company secretary shall act as the secretary of the Committee;	✓		
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	✓		
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.	✓		
6(3)(a)	<b>Chairperson of the NRC:</b> The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	✓		
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;			If arise, will be complied
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders: Provided that in absence of Chairperson of the NRC, any other member from the NRC shall be selected to be present in the annual general meeting (AGM) for answering the shareholder's queries and reason for absence of the Chairperson of the NRC shall be recorded in the minutes of the AGM.	✓		

Condition No.	TITLE	Compliance status (Put ✓ in the Appropriate Column)		Remarks (if any)
		Complied	Not complied	
6(4)(a)	<b>Meeting of the NRC:</b> The NRC shall conduct at least one meeting in a financial year;	✓		
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;			If arise, will be complied
6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	✓		
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	✓		
6(5)(a)	<b>Role of the NRC:</b> NRC shall be independent and responsible or accountable to the Board and to the Shareholders	✓		
6(5)(b)(i)(a)	Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following: The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;	✓		
6(5)(b)(i)(b)	The relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and	✓		
6(5)(b)(i)(c)	Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;	✓		
6(5)(b)(ii)	Devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	✓		
6(5)(b)(iii)	Identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	✓		
6(5)(b)(iv)	Formulating the criteria for evaluation of performance of independent directors and the Board;	✓		
6(5)(b)(v)	Identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria; and	✓		
6(5)(b)(vi)	Developing, recommending and reviewing annually the company's human resources and training policies;	✓		
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report.	✓		
7.0	External or Statutory Auditors			
7(1)(i)	The issuer company shall not engage its external or statutory auditors to perform the following services of the company, namely:- Appraisal or valuation services or fairness opinions;	✓		
7(1)(ii)	Financial information systems design and implementation;	✓		
7(1)(iii)	Book-keeping or other services related to the accounting records or financial statements;	✓		

Condition No.	TITLE	Compliance status (Put ✓ in the Appropriate Column)		Remarks (if any)
		Complied	Not complied	
7(1)(iv)	Broker-dealer services;	✓		
7(1)(v)	Actuarial services;	✓		
7(1)(vi)	Internal audit services or special audit services;	✓		
7(1)(vii)	Any service that the Audit Committee determines;	✓		
7(1)(viii)	Audit or certification services on compliance of corporate governance; and	✓		
7(1)(ix)	Any other service that creates conflict of interest.	✓		
7(2)	No partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company: Provided that spouse, son, daughter, father, mother, brother, sister, son-in-law and daughter-in-law shall be considered as family members.	✓		
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (Annual General Meeting or Extraordinary General Meeting) to answer the queries of the shareholders.	✓		
8.0	<b>Maintaining a website by the Company.</b>			
8(1)	The company shall have an official website linked with the website of the stock exchange.	✓		
8(2)	The company shall keep the website functional from the date of listing.	✓		
8(3)	The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s).	✓		
9.0	<b>Reporting and Compliance of Corporate Governance.</b>			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report.	✓		
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the annual general meeting.	✓		
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not.	✓		



## WATA CHEMICALS LIMITED Declaration by CEO and CFO TO THE BOARD

Date: 27 October, 2022

The Board of Directors,  
WATA Chemicals Limited  
Registered Office: 17/B, Monipuripara,  
Sangshad Avenue, Dhaka-1215.

Subject: Declaration on Financial Statements for the year ended on 30 June 2022.

Dear Sirs,

Pursuant to the condition No.1 (5)(xxvi) imposed vide the Commission's Notification No. BSEC/CMRRC-D/2006-158/207/Admin/80 Dated 3 June 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

- 1) The Financial Statements of WATA Chemicals Limited for the year ended on 30 June 2022 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh and any departure therefrom has been adequately disclosed;
- 2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
- 3) The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
- 4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
- 5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
- 6) The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. In this regard, we also certify that:-
  - (i) We have reviewed the financial statements for the year ended on 30 June 2022 and that to the best of our knowledge and belief:
    - (a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
    - (b) These statements collectively present a true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
  - (ii) There are, to the best of knowledge and belief, no transaction entered into by the Company during the year which is fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,

A handwritten signature in black ink.

(MD. NAZRUL ISLAM)  
Chief Executive Officer (CEO)

A handwritten signature in black ink.

(MD. ALI AHSAN)  
Chief Financial Officer (CFO)



## AUDITOR'S AND FINANCIAL STATEMENTS

<b>42-46</b>	Auditor's Report
	Statement of Financial Position <b>47</b>
<b>48</b>	Statement of Profit or Loss and Other Comprehensive Income
	Statement of Changes in Equity <b>49</b>
<b>50</b>	Statement of Cash Flows
	Notes and Schedules <b>51-98</b>



## INDEPENDENT AUDITOR'S REPORT

TO THE SHAREHOLDERS OF WATA CHEMICALS LIMITED

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

QUALIFIED OPINION

We have audited the financial statements of Wata Chemicals Limited (the Company), which comprise the statement of financial position as at 30 June 2022, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the effects of the matters described in the Basis for Qualified Opinion section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at 30 June 2022, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

### BASIS FOR QUALIFIED OPINION

1. Reference to Note # 02 to the financial statements, no depreciation has been charged on LABSA plant and BCP plant of the company on the ground that these plants have not been in use since 2008. However, as per Para 55 of IAS 16, a company should not cease the depreciation when the assets become idle or is retired from active use unless the assets are fully depreciated. As a result, depreciation for the current year has been undercharged by Taka 6,056,250.
2. Reference to Note # 12 to the financial statements, the Company has revalued its Property, Plant and Equipment in 2008 but the amount of surplus between depreciation based on the revalued carrying amount of the assets and depreciation based on the asset's original cost was not transferred from Revaluation Surplus to Retained Earnings for a total of 04 (Four) years from 2008-2011 as per Para 41 of IAS 16. Moreover, the Company has not maintained fixed assets register properly.
3. Reference to Note # 23 to the financial statements, provision for WPPF of Taka 44,117,864 has been provided by the company and the same is shown under the head of "Workers Profit Participation Fund and Welfare Fund" as current liabilities in the financial statements as on 30 June 2021. However, the amount has not been distributed yet with a proportion of 80:10:10 to the Participatory Fund, Welfare Fund and Workers' Welfare Foundation Fund respectively as per the Labor Act 2006 as amended in 2013 although the company has executed Trust Deeds for the same. Moreover, the fund amount has been used by the company in its operation as internal source of financing without providing any interest for such usage as per section 240 (3) of the said Act.



Corporate Office:  
SMC Tower (7th Floor)  
33, Banani C/A, Road 17  
Dhaka- 1213, Bangladesh  
Phone : +880-2-222275057-58  
: +880-2-222275365-66  
E-mail : [info@mabsj.com](mailto:info@mabsj.com)  
Web : [www.mabsj.com](http://www.mabsj.com)

Motijheel Branch Office:  
21, Purana Paltan Line (4th & 7th Floor)  
Dhaka- 1000, Bangladesh  
Phone : +880-2-58315469 / 58315471  
Fax : +880-2-48320936  
E-mail : [info@mabsj.com](mailto:info@mabsj.com)  
Web : [www.mabsj.com](http://www.mabsj.com)

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the Institute of Chartered Accountants of Bangladesh (ICAB) Bye Laws. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

## EMPHASIS OF MATTERS

Without modifying our opinion, we draw attention on the following matters:

1. Reference to Note # 1.14.00 of the financial statements, the company has translated its unsettled foreign currency liabilities (USD) at the exchange rate (BC Selling rate of Bangladesh Bank) of BDT 93.5/\$1 on 30 June 2022 as per the requirements of IAS 21 — The Effects of Changes in Foreign Exchange Rate. Subsequently, up to 30 September 2022, foreign currency liabilities have been settled at the average rate of BDT 102.15/\$1 as disclosed under Event after Reporting Period as per IAS 10 in note # 54.01 to the financial statements of the company.
2. Reference to Note # 51 to the financial statements, the company has disclosed the "Contingent Liabilities" of Taka 41,427,896 against the claim from Commissioner of Customs Excise and VAT Directorate. The Company has filed an appeal to the Appellate Tribunal which is still pending.
3. As per Section 99 of the Labor Act 2006 as amended in 2013, it is required that "In the establishments wherein minimum of 100 permanent workers are employed, must introduce group insurance in the manner prescribed by rules". However, the company has not introduced yet group insurance for permanent employees despite being employed more than 100 permanent employees. This indicates non-compliance of the provision of the section 99 of the Labor Act 2006 as amended in 2013.

## KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matters described in the Basis for Qualified Opinion section we have determined the matters described below to be communicated in our report. For each matter below our description of how our audit addressed the matters provided in that context.

### 01. REVENUE RECOGNITION

#### SEE NOTE 27.00 TO THE FINANCIAL STATEMENTS

The Key Audit Matter	How The Matter Was Addressed In Our Audit
<p>At the year end the Company reported the net sales revenue of Taka 953,804,600 are recognized when the Company transfers control over goods to the customer or satisfies the performance obligation to a customer. Recognition of the revenue of Wata has been considered complex due to several types of contract from local customers and the government for different product as well as high level comparing to last few years' performance.</p>	<p>We have reviewed the Company's revenue recognition policies, accounting guidelines and disclosures to assess conformity with IFRS 15 "Revenue from Contract with Customers". We have tested relevant internal control used to ensure the completeness, accuracy and timing of revenue recognized including sales during the year end to ensure cut off has been properly maintained. We have applied analytical and substantive procedure to establish, whether any revenue had been recognized where no corresponding accounts receivables or proceeds have been recorded in the general ledger.</p>

## 02. VALUATION OF PROPERTY, PLANT AND EQUIPMENT

See Note 02 to the Financial Statements

The Key Audit Matter	How The Matter Was Addressed In Our Audit
<p>The carrying value of the PPE was Taka 896,188,486 as at 30 June 2022. Expenditures are capitalized if they create new assets or enhance the existing assets, and expensed if they relate to repair or maintenance of the assets. Classification of the expenditures involves judgment. The useful lives of PPE items are based on management's estimates regarding the period during which the assets or its significant components will be used. The estimates are based on historical experience and market practice and take into consideration the physical condition of the assets.</p> <p>The valuation of PPE was identified as a key audit matter due to the significance of this balance to the financial statements and that there is significant measurement uncertainty involved in this valuation</p>	<p>Our audit included the following procedure:</p> <p>We assessed whether the accounting policies in relation to the capitalization of expenditures are in compliance with IAS and found them to be consistent.</p> <ul style="list-style-type: none"> <li>• We inspected a sample of invoices and L/C documents to determine whether the classification between capital and revenue expenditure was appropriate.</li> <li>• We evaluated whether the useful lives determined and applied by the management were in line with historical experience and the market practice.</li> </ul> <p>We checked whether the depreciation of PPE items was commenced timely, by comparing the date of the reclassification from capital work in progress to ready for use, with the date of the act of completion of the work.</p>

## OTHER INFORMATION

Management is responsible for the other information. The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

## RESPONSIBILITIES OF MANAGEMENT AND THOSE CHARGED WITH GOVERNANCE FOR THE FINANCIAL STATEMENTS

Management is responsible for the preparation of financial statements in accordance with IFRSs, the Companies Act 1994, the Security and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

## AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law and regulation preclude public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987, we also report the following:

- a) We have obtained all the information and explanation which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of those books;
- c) The statement of financial position and statement of profit or loss with the report are in agreement with the books of account and returns; and
- d) The expenditure incurred was for the purpose of the Company's business.

Dated: 27 October 2022  
Dhaka, Bangladesh

Signed for & on behalf of  
**MABS & J Partners**  
Chartered Accountants



Nasir Uddin Ahmed  
FCA, FCS, CGMA, ACMA (UK), FCA (ICAEW)  
Deputy Managing Partner  
ICAB Enrolment No: 535  
DVC No: 2210270535AS393268



**WATA CHEMICALS LIMITED**  
**STATEMENT OF FINANCIAL POSITION**  
As at 30 June, 2022

PARTICULARS	NOTES	AMOUNT IN TAKA	
		30-Jun-22	30-Jun-21
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>		<b>1,747,568,114</b>	<b>1,735,737,576</b>
Property, Plant and Equipment (PPE)	2.00	896,188,486	943,466,378
Capital Work-in-Progress (CWIP)-BMRE	3.00	845,988,799	786,110,248
Right-of-Use (ROU) Asset	4.00	5,390,830	6,160,950
<b>CURRENT ASSETS</b>		<b>1,097,216,697</b>	<b>888,335,379</b>
Inventories	5.00	174,092,613	109,239,794
Trade Receivables	6.00	627,414,177	435,570,160
Advance Income Tax	7.00	35,976,756	17,654,979
Advances, Prepayments & Deposits	8.00	248,613,909	294,502,098
Cash & Cash Equivalents	9.00	11,119,242	31,368,347
<b>TOTAL ASSETS</b>		<b>2,844,784,812</b>	<b>2,624,072,956</b>
<b>SHAREHOLDER'S EQUITY &amp; LIABILITIES</b>			
<b>SHAREHOLDER'S EQUITY</b>		<b>906,918,960</b>	<b>892,655,019</b>
Share Capital	10.00	148,226,180	148,226,180
Share Premium	11.00	32,400,000	32,400,000
Revaluation Reserve	12.00	390,090,087	396,766,745
Retained Earnings	13.00	336,202,693	315,262,094
<b>LIABILITIES</b>			
<b>NON-CURRENT LIABILITIES</b>		<b>557,534,096</b>	<b>546,159,138</b>
Long Term Loan	14.00	502,631,077	494,136,963
Deferred Tax Liability	15.00	49,932,717	45,982,632
Lease Liability	16.00	4,970,302	6,039,543
<b>CURRENT LIABILITIES</b>		<b>1,380,331,756</b>	<b>1,185,258,799</b>
Bank Overdraft & Loans	17.00	1,162,301,848	954,295,861
Current Portion of Long Term Loan	18.00	116,930,416	112,117,776
Short term Loan (Unsecured)	19.00	2,453,403	(916,397)
Lease Liability	16.00	656,441	875,040
Trade Payables	20.00	8,502,742	27,776,472
Deposit against Sales	21.00	-	1,040,829
Liabilities for Expenses	22.00	24,422,127	25,202,635
Workers Profit Participation Fund & Welfare Fund	23.00	44,117,864	40,073,872
Provision for Taxation	24.00	18,198,265	22,061,365
Unclaimed Dividend Account	25.00	2,748,651	2,731,346
<b>TOTAL LIABILITIES</b>		<b>1,937,865,852</b>	<b>1,731,417,937</b>
<b>TOTAL SHAREHOLDER'S EQUITY &amp; LIABILITIES</b>		<b>2,844,784,812</b>	<b>2,624,072,956</b>
<b>Net Assets Value (NAV) Per Share in Taka</b>	26.00	61.18	60.22

The annexed notes **1 to 54** and schedule **1 to 11** from an integral part of these financial statements.

  
Razi Uddin Ahmed  
Chairman

  
Md. Nazrul Islam  
Managing Director

  
A.H.M. Abdullah  
Director


  
Md. Ali Ahsan  
Chief Finance Officer

  
Shamsul Huq  
Company Secretary

*Signed in terms of our separate report of even date annexed*

Dated: 27 October 2022  
Dhaka, Bangladesh


*Signed for & on behalf of  
MABS & J Partners  
Chartered Accountants*

  
Nasir Uddin Ahmed  
FCA, FCS, CGMA, ACMA (UK), FCA (ICAEW)  
Deputy Managing Partner  
ICAB Enrolment No: 535  
DVC No: 2210270535AS393268

**WATA CHEMICALS LIMITED**  
**STATEMENT OF PROFIT OR LOSS & OTHER COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED 30 JUNE 2022**

PARTICULARS	NOTES	AMOUNT IN TAKA	
		30-Jun-22	30-Jun-21
Revenue (Net of VAT)	27.00	953,804,600	569,812,320
Cost of Sales	28.00	(674,667,049)	(352,982,008)
<b>Gross Profit</b>		<b>279,137,551</b>	<b>216,830,312</b>
Administrative, Selling and Distribution Expenses	29.00	(68,569,557)	(47,063,922)
<b>Operating Profit</b>		<b>210,567,995</b>	<b>169,766,390</b>
Finance Expenses	30.00	(129,909,518)	(73,734,448)
Non Operating Income	31.00	4,265,360	6,919,694
<b>Profit before contribution to WPPF &amp; Welfare Fund</b>		<b>84,923,837</b>	<b>102,951,636</b>
Contribution to WPPF & Welfare Fund		(4,043,992)	(4,902,459)
<b>Profit before Tax</b>		<b>80,879,845</b>	<b>98,049,177</b>
<b>Income Tax Expenses</b>	32.00	<b>(20,921,725)</b>	<b>(7,091,864)</b>
<b>Profit after Tax</b>		<b>59,958,120</b>	<b>90,957,313</b>
<b>Other Comprehensive Income / Expenses</b>			
Deferred Tax on Revaluation of PPE		(1,226,325)	(1,340,484)
<b>Total Comprehensive Income</b>		<b>58,731,795</b>	<b>89,616,829</b>
<b>Earning Per Share (EPS) in Taka</b>	33.00	<b>4.05</b>	<b>6.14</b>

The annexed notes **1 to 54** and schedule **1 to 11** from an integral part of these financial statements.



Razi Uddin Ahmed  
Chairman




Md. Nazrul Islam  
Managing Director



A.H.M. Abdullah  
Director



Md. Ali Ahsan  
Chief Finance Officer




Shamsul Huq  
Company Secretary

*Signed in terms of our separate report of even date annexed*

Dated: 27 October 2022  
Dhaka, Bangladesh

Signed for & on behalf of  
MABS & J Partners  
Chartered Accountants



Nasir Uddin Ahmed  
FCA, FCS, CGMA, ACMA (UK), FCA (ICAEW)  
Deputy Managing Partner  
ICAB Enrolment No: 535  
DVC No: 2210270535AS393268

**WATA CHEMICALS LIMITED**  
**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED 30TH JUNE 2022**

Particulars	Amount in Taka				
	Share Capital	Share Premium	Revaluation Reserve	Retained Earning	Total
<b>Balance as at 01 July 2021</b>	<b>148,226,180</b>	<b>32,400,000</b>	<b>396,766,745</b>	<b>315,262,094</b>	<b>892,655,019</b>
Profit after Tax during the period	-	-	-	59,958,120	59,958,120
Cash dividend for the year 20-21	-	-	-	(44,467,854)	(44,467,854)
Adj. of Realized Depreciation on Revaluation		-	(5,450,333)	5,450,333	-
Deferred Tax on Revaluation transferred to Revaluation Reserve			(1,226,325)	-	(1,226,325)
<b>Balance as at 30th June'2022</b>	<b>148,226,180</b>	<b>32,400,000</b>	<b>390,090,087</b>	<b>336,202,693</b>	<b>906,918,960</b>

FOR THE YEAR ENDED 30TH JUNE 2021

Particulars	Amount in Taka				
	Share Capital	Share Premium	Revaluation Reserve	Retained Earning	Total
<b>Balance as at 01 July 2020</b>	<b>148,226,180</b>	<b>32,400,000</b>	<b>404,064,937</b>	<b>290,191,549</b>	<b>874,882,666</b>
Profit after Tax during the period	-	-	-	90,957,313	90,957,313
Cash dividend for the year 19-20	-	-	-	(51,879,163)	(51,879,163)
Adj. of Realized Depreciation on Revaluation		-	(5,957,708)	5,957,708	-
Adjustment of Previous Years Deferred Tax Expenses				(19,965,313)	(19,965,313)
Deferred Tax on Revaluation transferred to Revaluation Reserve			(1,340,484)	-	(1,340,484)
<b>Balance as at 30th June'2021</b>	<b>148,226,180</b>	<b>32,400,000</b>	<b>396,766,745</b>	<b>315,262,094</b>	<b>892,655,019</b>

The annexed notes **1 to 54** and schedule **1 to 11** from an integral part of these financial statements.



Razi Uddin Ahmed  
Chairman



Md. Nazrul Islam  
Managing Director



A.H.M. Abdullah  
Director



Md. Ali Ahsan  
Chief Finance Officer



Shamsul Huq  
Company Secretary

Dated: 27 October 2022  
Dhaka, Bangladesh

**WATA CHEMICALS LIMITED**  
**STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 30TH JUNE 2022**

<b>PARTICULARS</b>	<b>NOTES</b>	<b>AMOUNT IN TAKA</b>	
		<b>30-Jun-22</b>	<b>30-Jun-21</b>
<b>Cash Flows from Operating Activities:</b>			
Cash receipts from Customers and others	34.00	900,553,142	563,664,302
Cash paid to Suppliers and others	35.00	(435,812,218)	(186,637,443)
Cash paid to employees and for expenses	36.00	(248,482,817)	(192,586,791)
Cash paid for VAT & Tax	37.00	(129,862,681)	(116,030,201)
<b>Net Cash (used in)/generated from Operating Activities (A)</b>		<b>86,395,426</b>	<b>68,409,867</b>
<b>Cash Flows from Investing Activities:</b>			
Acquisition of Fixed Assets	38.00	(61,576,115)	(110,405,348)
Paid of Lease Liability	38.00	(1,069,241)	(1,179,713)
<b>Net Cash (used in)/generated from Investing Activities (B)</b>		<b>(62,645,356)</b>	<b>(111,585,061)</b>
<b>Cash Flows from Financing Activities:</b>			
Loan Received	39.00	77,529,603	233,717,923
Loan Repaid	40.00	(58,436,982)	(111,585,803)
Dividend Paid	41.00	(44,450,548)	(53,226,364)
<b>Net Cash (used in)/generated from financing activities ( C)</b>		<b>(25,357,927)</b>	<b>68,905,756</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)</b>		<b>(1,607,857)</b>	<b>25,730,562</b>
Effect of movements in exchange rate on cash held		(18,641,248)	(2,194,524)
Opening Cash & Cash Equivalents		31,368,347	7,832,309
<b>Closing Cash &amp; Cash Equivalent at Reporting Date</b>		<b>11,119,242</b>	<b>31,368,347</b>
<b>Net Operating Cash Flow Per Share (NOCFPS) in Taka</b>	42.00	5.83	4.62
<b>(Previous year's NOCFPS has been restated based on 14,822,618 shares)</b>			

The annexed notes **1 to 54** and schedule **1 to 11** from an integral part of these financial statements.



Razi Uddin Ahmed  
Chairman




Md. Nazrul Islam  
Managing Director



A.H.M. Abdullah  
Director



Md. Ali Ahsan  
Chief Finance Officer



Shamsul Huq  
Company Secretary

Dated: 27 October 2022  
Dhaka, Bangladesh

**WATA CHEMICALS LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**AS AT AND FOR THE PERIOD ENDED 30TH JUNE' 2022**

**1.00.00 Reporting Entity**

**1.01.00 Company Profile**

"WATA CHEMICALS LIMITED" hereinafter referred as to the Company was incorporated in Bangladesh on August 19, 1981 under Companies Act, 1913 (Subsequently amended in 1994). Its shares are listed with Dhaka Stock Exchange Limited since 1992 & Chittagong Stock Exchange Limited since 1997.

The registered office of the company is at 17/B, Monipuripara (3rd Floor), Sangshad Avenue, Dhaka-1215. Its factory is situated at Murapara, Rupgonj, Narayanganj, Bangladesh.

**1.02.00 Nature of Business**

The Company produces Alum, Zinc Sulphate, Magnesium Sulphate, Sulphuric Acid, Basic Chrome Powder (BCP) and Linear Alkyl Benzene Sulphonic Acid (LABSA) for 100% local consumption.

**1.03.00 Basis of Preparation of the Financial Statements**

**1.03.01 Statement of Compliance**

In accordance with the requirement of the gazette notification issued by The Financial Reporting Council (FRC) on 22 November 2020, the financial statements have been prepared in accordance with International Financial Reporting Standards (IFRSs)

The Company also complied with the requirements of following laws and regulations from various Government bodies:

- i. Bangladesh Securities and Exchange Rules 1987;
- ii. The Companies Act, 1994;
- iii. The Income Tax Ordinance, 1984; and
- iv. The Value Added Tax and Supplementary Duty Act, 2012.

The title and format of this financial statements follow the requirements of IFRSs which are to some extent different from the requirement of the Companies Act, 1994. However, such differences are not material and in the view of management, IFRS format gives a better presentation to the shareholders.

According to the International Accounting Standards (IAS)-1 "Presentation of Financial Statements" the complete set of Financial Statements includes the following components":

- i. Statements of Financial Position as at 30 June 2022
- ii. Statement of Profit or Loss and Other Comprehensive Income for the year ended 30 June 2022
- iii. Statement of Changes in Equity for the year ended 30 June 2022
- iv. Statement of Cash Flows for the year ended 30 June 2022
- v. Notes to the Financial Statements and Other Explanatory Information

**1.03.02 Authorisation for Issue**

This financial statement is authorised for issue by the Board of Directors in its First Board of Directors meeting for the year 2022-2023 held on 27 October, 2022.

**1.03.03 Reporting Period**

These financial statements of the Company covers from **01 July 2021 to 30th June'2022**.

**1.03.04 Comparative and Reclassification**

Comparative information has been disclosed for all numerical, narrative and descriptive information where it is relevant for understanding of the current period financial statements. Comparative figures have been rearranged/reclassified wherever considered necessary, to ensure better comparability with the current period financial statements and to comply with relevant IFRSs.

**1.03.05 Functional and Presentation Currency**

This financial statements are presented in Bangladeshi Taka (Taka/TK/BDT) which is the Company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

**1.03.06 Use of judgements and estimates**

In preparing this financial statement, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognised prospectively.

**a) Judgements**

Information about judgements related to lessee accounting under IFRS 16 made in applying accounting policies that have the most significant effects on the amounts recognised in the financial statements is described in note 4.

**b) Assumptions, Estimation and Uncertainties**

Information about assumptions and estimation uncertainties at 30 June 2022 that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities in the next financial year is included in the following notes:

Note 02: Property, Plant and equipment

Note 05: Inventory

Note 24: Current Tax Liabilities

Note 15: Deferred Tax Liabilities

Note 51: Contingent Liabilities

**1.04.00 Basis of Measurement**

Measurement is the process of determining the monetary amounts at which the elements of the financial statements are to be recognized and carried in the financial statements. The measurement basis adopted by the Company is historical cost except for plant & machinery & equipment, building, land & land development and other assets which are stated in accordance with the policies mentioned in the respective notes.

**1.05.00 Going Concern**

When preparing financial statements, management makes an assessment of the Company's ability to continue as a going concern. The Company prepares financial statements on a going concern basis. In spite of working capital constant, the Company has adequate resources to continue in operation for the foreseeable future. For this reasons the directors continue to adopt going concern basis in preparing the financial statements.

**1.06.00 Accrual Basis of Accounting**

The Company prepares its financial statements, except for cash flow information, using the accrual basis of accounting. Since the accrual basis of accounting is used, the Company recognizes items as assets, liabilities, equity, income and expenses (the elements of financial statements) when they satisfy the definitions and recognition criteria for those elements in the Framework.

**1.07.00 Materiality and Aggregation**

The Company presents separately each material class of similar items. The Company presents separately items of a dissimilar nature or function unless they are immaterial. Financial statements result from processing large numbers of transactions or other events that are aggregated into classes according to their nature or function.

**1.08.00 Statement of Cash Flows**

Cash Flow Statement is prepared in accordance with IAS 7-"Statement of Cash Flows". The Statement shows the structure of changes in cash and cash equivalents during the financial year. Statement of Cash Flows is prepared principally in accordance with IAS-7 "Cash Flow Statement" and the cash flow from the operating activities have been presented under direct method, paragraph 19 of IAS-7 which provides that "Enterprises are Encouraged to Report Cash Flow from Operating Activities Using the Direct Method".

**1.09.00 Statement of Changes in Equity**

Statement of Changes in Equity has been prepared in accordance with IAS 1 -"Presentation of Financial Statements".

**1.10.00 Changes in Accounting Policies**

The company changes its accounting policy only if the change is required by a IFRS or results in the financial statements providing reliable and more relevant information about the effects of transactions, other events or conditions on the company financial position, financial performance or cash flows. Changes in accounting policies is made through retrospective application by adjusting opening balance of each affected components of equity i.e. as if new policy has always been applied.

**1.11.00 Changes in Accounting Estimates**

Estimates arise because of uncertainties inherent within them, judgment is required but this does not undermine reliability. Effect of changes of accounting estimates is included in profit or loss account. The preparation of the financial statements are in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies.

**1.12.00 Segment Reporting**

No segmental reporting is applicable for the company as required by IFRS 8: "Operating Segments" as the company operates in a single industry segment and within a single geographical territory.

**1.13.00 Summary of Significant Accounting Policies**

Accounting policies are determined by applying the relevant IFRS. Where there is no available guidelines of IFRS, management uses its judgment in developing and applying an accounting policy that results in information that is relevant and reliable. The company selects and applies its accounting policies for a period consistently for similar transactions, other events and conditions, unless a IFRS or specifically requires or permits categorization of items for which different policies may be appropriate. The accounting policies set out below have been applied consistently in all material respects to all periods presented in these financial statements.

**1.14.00 Foreign Currency Transaction**

Transactions in foreign currencies are translated to the respective functional currency (BDT) of the company at exchange rates at the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated to the functional currency at the exchange rates ruling at the statement of financial position date. Non-monetary assets and liabilities denominated in foreign currencies, stated at historical cost, are translated into (BDT) at the exchange rate ruling at the date of transaction. Foreign exchange differences arising on translation are recognised in profit or loss.

**1.15.00 Revenue Recognition**

The core principle of IFRS 15 is that an entity will recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This core principle is delivered in a five-step model framework as follows;

- i. Identify the contract(s) with a customer
- ii. Identify the performance obligations in the contract
- iii. Determine the transaction price
- iv. Allocate the transaction price to the performance obligations in the contract
- v. Recognise revenue when (or as) the entity satisfies a performance obligation. However, the company has complied with the applicable requirements of IFRS 15 in recognizing revenue.

Moreover, the entity assesses whether it transfers control over time by following prescribed criteria for satisfying performance obligation. If none of the criteria is met then the entity recognizes revenue at point of time at which it transfers control of the goods to the customer.

Revenue is measured net of value added tax, trade discount, returns and allowances (if any). In case of cash delivery, revenue is recognised when delivery is made and cash is received by the Company

## **1.16.00 Financial Instruments**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

### **Recognition and Initial Measurement**

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset (unless it is a trade receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at Fair value through profit or loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue. A trade receivable without a significant financing component is initially measured at the transaction price.

### **Classification and Subsequent Measurement**

#### **Financial Assets**

On initial recognition, a financial asset is classified as measured at:

- Amortised Cost;
- FVOCI – debt investment; and
- FVOCI – Equity Investment; or FVTPL.

#### **Financial liability**

All financial liabilities are recognised initially on the transaction date at which the Company becomes a party to the contractual provisions of the liability. The Company derecognises a financial liability when its contractual obligations are discharged or cancelled or expired. Financial liabilities include trade and other payables etc.

## **1.17.00 Cash and Cash Equivalents**

Cash and cash equivalents include notes and coins in hand and at bank, which are not ordinarily susceptible to change in value. For the purpose of Balance Sheet and Cash Flow Statement, Cash in Hand and Bank balances represent cash and cash equivalents considering the IAS-1 "Presentation of Financial Statements" and IAS-7 "Cash Flow Statement", which provide that Cash and Cash equivalents are readily convertible to known amounts of Cash and are subject to an insignificant risk of changes in value and are not restricted as to use.

## **1.18.00 Non-current Assets [Property, Plant & Equipment and Intangibles]**

### **1.18.01 Recognition**

The cost of an item of property, plant and equipment is recognized as an asset if, and only if, it is probable that future economic benefits will flow to the Company and the cost of the item can be measured reliably.

### **1.18.02 Measurement at Recognition**

An item of property, plant and equipment that qualifies for recognition as an asset is measured at its cost. The cost of an item of property, plant and equipment is the cash price equivalent at the recognition date. The cost of a self-constructed asset is determined using the same principles as for an acquired asset.

### **1.18.03 Elements of Costs and Subsequent Costs**

Cost includes purchase price (including import duties and non-refundable purchase taxes), directly attributable costs to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by the management and the initial estimate of the cost of dismantling and removing the item and restoring the site on which it is located. Costs of day to day servicing (repairs and maintenance) are recognized as expenditure as incurred. Replacement parts are capitalized, provided the original cost of the items they replace is derecognized.

### **1.18.04 Measurement of Property, Plant & Equipment after Recognition**

#### **Cost model**

After recognition as an asset, an item of property, plant and equipment shall be carried at its cost less any accumulated depreciation.

#### **Revaluation model**

The revaluation model requires an asset, after initial recognition, to be measured at a revalued amount, which is its fair value less subsequent accumulated depreciation.

Where an asset's carrying amount is increased as a result of a revaluation, the increase is recognized in equity under the heading of revaluation reserve. However, the increase is recognized in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognized in profit or loss.

Where an asset's carrying amount is decreased as a result of a revaluation, the decrease is recognized in profit or loss. However, the decrease is recognized in equity to the extent of any credit balance existing in the revaluation reserve in respect of that asset. The decrease recognized in equity reduces the amount accumulated under the heading of revaluation reserve.

The revaluation reserve included in equity in respect of an item of property, plant and equipment is transferred directly to retained earnings when the asset is derecognized. However, some of the surplus is transferred as the asset is used by the Company. In such a case, the amount of the revaluation reserve transferred would be the difference between depreciation based on the revalued carrying amount of the asset and depreciation based on the asset's original cost.

### **1.18.05 Derecognition of Property, Plant and Equipment**

The carrying amount of an item of property, plant and equipment is derecognized on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of an item of property, plant and equipment is included as other income in profit or loss when the item is derecognized.

### **1.18.06 Impairment of Assets**

Entity applies periodic review to ensure that its assets are carried at no more than their recoverable amount. Which is hunger of an asset's or Cash generating unit's fair value less costs to sell and its value in use as prescribed in IAS36 "Impairment of Assets". However, the company has measured the carrying amount of non-financial assets considering possible impairment of assets and performed the impairment testing of assets under the scope of International Accounting Standards (IAS) 36 at the reporting date. In conducting asset impairment testing, the company has considered all the non-current assets under the scope of Impairment as single cash generating unit and Value in Use has been considered as its recoverable value. However, no impairment loss has been made on such assets in its financial statements for the year ended 30 June 2022 as the carrying amount of assets or its cash-generating unit did not exceed its recoverable amount.

#### 1.18.07 Depreciation

The depreciation charge for each period is recognized in profit or loss unless it is included in the carrying amount of another asset. Depreciation of an asset begins when it is installed and available for use, i.e. when it is in the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale and the date that the asset is derecognized. Depreciation has been charged using Reducing Balance Method (RBM) on additions from the date of acquisition, when the related assets are put into use and no depreciation is charged on assets disposed of during the year. Expenditure for maintenance and repairs are expensed, major replacements, renewals and betterment are capitalized.

Depreciation is calculated based on the cost/revalued amount of items of fixed assets [property, plant & equipment] less their estimated residual values using reducing balance method (RBM) over their useful lives and recognized in profit and loss. Land is not depreciated. Rates of depreciation considering the useful life of respective assets are as follows:

Particulars	Rate
Plant & Machinery	10%
Factory Building	5%
Boundary Wall	15%
Motor Vehicles and Bi-cycle	10%
Furniture & Fixtures	10%
Office Equipments	10%
Laboratory Equipments	15%
Computer	10%
Generator	10%

Depreciation has been charged to Statement of Profit or Loss and other Comprehensive Income consistently.

#### 1.19.00 Valuation of Inventories

Inventories are assets held for sale in the ordinary course of business, in the process of production for such sale or in the form of materials or supplies to be consumed in the production process. Inventories are stated at the lower of cost or net realizable value in compliance to the requirements of Para 10 of IAS-2. Costs including an appropriate portion of fixed and variable overhead expenses are assigned inventories by the method most appropriate to the particular class of inventory. Net realizable value represents the estimated selling price for the inventories less all estimated cost of completion and cost necessary to make the sale. Item wise valuation is as follows:

Category of Inventories	Basis of Valuation
Raw & Packing Materials	At Weighted average cost
Work-in Progress	At Weighted average cost
Finished Goods	At Weighted average cost

#### 1.20.00 Other Provisions, Accruals and Contingencies

##### 1.20.01 Recognition of Provisions, Accruals and Contingencies

A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; a reliable estimate can be made of the amount of the obligation. Accruals are liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amount due to employees.

##### 1.20.02 Measurement of Provision

The amount recognized as a provision is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period.

#### 1.21.00 Workers' Profit Participation Fund (WPPF) & Welfare Fund

As per Bangladesh Labour Law, 2006 as amended in 2013 all companies fall within the scope of WPPF (which includes Company) are required to provide 5% of its profit after charging such expense to their eligible employees within the stipulated time. As required by Law, the Company has maintained WPPF and kept sufficient provision against profit participation fund.

#### 1.22.00 Taxation

The tax expense for the period comprises current tax and deferred tax. Tax is recognized in the income statement, except in the case it relates to items recognized directly in equity.

##### 1.22.01 Current Tax

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantially enacted at the reporting date and any adjustment to the tax payable in respect of previous years. Provision for current income tax has been made on taxable income of the company as per following rates: The Company is "Publicly Traded Company" as per the Finance Act, 2019 and the rate of Minimum tax applicable is .60%.

Type of Income	2021-2022	2020-21
Business income	22.50%	22.50%
Capital gain	10% to 15%	10% to 15%
Minimum Tax Section 16BBB+82C(4)	0.60%	0.60%

## 1.22.02 Deferred Tax

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit and are accounted for using the Statement of Financial Position as liability method. Deferred tax liabilities are generally recognized for all taxable temporary differences and deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized.

### Principles of Recognition

Deferred tax is recognized as income or an expense amount within the tax charge, and included in the net profit or loss for the period. Deferred tax relating to items dealt with directly in equity is recognized directly in equity.

## 1.23.00 Share Capital and Reserves

### 1.23.01 Capital

#### Authorized Capital

Authorized Capital is the maximum amount of share capital that the Company is authorized to raise as per its Memorandum and Articles of Association.

#### Paid-up Capital

Paid-up Capital represents total amount of shareholders' capital that has been paid in full by the shareholders. Shareholders are entitled to receive dividend as approved from time to time in the Annual General Meeting.

### 1.23.02 Share Premium

Premium received amounting of Tk. 32,400,000 as against 162,000 ordinary share of Tk. 200 each of the share in the year 1997.

The Share Premium shall be utilized in accordance with provisions of the Companies Act, 1994 and as directed by the Securities and Exchange Commission in this respect. The section 57 of the Companies Act, 1994 provides that the Company may apply the Share Premium Account as follows:

- i. in paying up un-issued shares of the Company to be issued to members of the Company as fully paid bonus shares;
- ii. in amortized off the preliminary expenses of the Company;
- iii. in amortized off the expenses or the commission paid or discount allowed on any issue of shares or debentures of the Company; and
- iv. in providing for the premium payable on the redemption of any redeemable preference shares or of any debenture of the Company.

### 1.23.03 Assets Revaluation Reserve

This represents the difference between the book value and the re-valued amount of Building and other Construction and Plant & Machineries of the Company as assessed by professional valuers in the year 2008. The reserve is not distributable.

## 1.24.00 Expenses

### 1.24.01 Management and Other Expenses

Expenses incurred by the Company are recognized on an accrual basis.

## 1.25.00 Earnings Per Share (EPS)

#### Measurement

The Company calculates basic earnings per share amounts for profit or loss attributable to ordinary equity holders of the parent entity. Basic earnings per share is calculated by dividing profit or loss attributable to ordinary equity holders of the parent entity (the numerator) by the weighted average number of ordinary shares outstanding (the denominator) during the period.

#### Presentation

The Company presents in the statement of profit or loss and comprehensive income earnings per share. The Company present earnings per share with equal prominence for all periods presented. The Company presents earnings per share, even if the amounts are negative (i.e. a loss per share).

## 1.26.00 Employee Benefits

According to para-05 of IAS 19, employee benefits are given below :

#### a) Short-term Employee Benefits

- i) Paid Wages, Salaries and no Social Security Contributions;
- ii) Paid 20 (Twenty) days Annual (Casual Leave), 14 (Fourteen) days Medical (Sick Leave), 06 (Six) days Earn Leave, 120 (One Hundred Twenty) days Maternity Leave and General Holidays as per Govt declaration;
- iii) Paid Festival Bonuses and 05 (Five) percent WPPF(Workers Profit Participation Fund) as profit-sharing; and
- iv) No non-monetary benefit for current employees except lunch facility and accidental medical facilities at work station.

#### b) Post-employment Benefits

- i) No retirement benefit; and
- ii) No other post employment benefits such as post-employment life insurance and post-employment medical care.

#### c) Other Long-term Employee Benefits, such as the followings

- i) No long-term paid absences such as long-service leave or sabbatical leave;
- ii) No jubilee or other long-service benefits; and
- iii) No long-term disability benefits; and

#### d) Termination Benefits

No termination benefits but paid onetime financial benefit due to death of any employee on the basis of financial condition of employee but not less than 06 (six) months salary avail in the last month.

#### 1.27.00 Leases

Implementation of IFRS 16 and its relevant assumptions and disclosures IFRS 16: "Leases" has come into force on 1 January 2019, as adopted by the Institute of Chartered Accountants of Bangladesh (ICAB). Wata Chemicals Limited applied IFRS 16 where the Company measured the lease liability at the present value of the remaining lease payments, discounted it using incremental borrowing rate at the date of initial application, and recognised a right-of-use asset at the date of the initial application on a lease by lease basis.

##### Right-of-use assets

The Company recognises right-of-use assets at the date of initial application of IFRS 16. Right-of-use assets are measured at cost, less any accumulated depreciation. Right-of-use asset is depreciated on a straight-line basis over the lease term. The right-of-use asset is presented under property, plant and equipment.

##### Lease liabilities

At the commencement date of the lease, the Company recognises lease liability measured at the present value of lease payments to be made over the lease term using incremental borrowing rate of 9% at the date of initial application. Lease liability is measured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments.

Interest on the lease liability in each period during the lease term shall be the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.

However, the Company has only lease agreement for rental its Head Office with the Landlord for 10 years with effect from 01 July 2019 has been considered for lease as IFRS 16 and recognized in the financial statements accordingly.

#### 1.28.00 Compliance with Financial Reporting Standards as Applicable in Bangladesh

The Companies complied, as per Para 12 of Securities & Exchange Rule 1987, with the following International Accounting Standards (IASs) as adopted by The Institute of Chartered Accountants of Bangladesh (ICAB) in preparing the financial statements of the Company subject to departure where we have followed :

SN	Standard Number	Title of Standards	Compliance Status
01	IAS 01	Presentation of Financial Statements	Complied
02	IAS 02	Inventories	Complied
03	IAS 07	Statement of Cash Flows	Complied
04	IAS 08	Accounting Policies, Changes in Accounting Estimates and Errors	Complied
05	IAS 10	Events after the Reporting Period	Complied
06	IAS 12	Income Taxes	Complied
07	IAS 16	Property, Plant & Equipment	Complied
08	IAS 19	Employee Benefits	Complied
09	IAS 23	Borrowing Costs	Complied
10	IAS 24	Related Party Disclosures	Complied
11	IAS 33	Earnings per Share	Complied
12	IAS 36	Impairment of Assets	Complied
13	IAS 37	Provisions, Contingent Liabilities and Contingent Assets	Complied
14	IFRS 9	Financial Instruments	Complied
15	IFRS 15	Revenue from Contracts with Customers	Complied
16	IFRS 16	Leases	Complied

#### 1.29.00 Standards issued but not yet effective

In January 2018, the Institute of Chartered Accountants of Bangladesh (ICAB) has adopted International Financial Reporting Standards issued by the International Accounting Standards Board as IFRSs. As the ICAB previously adopted such standards as Bangladesh Financial Reporting Standards without any modification, this adoption does not have any impact on the financial statements of the Company.

A number of new standards are effective for annual periods beginning after 1 April 2020 and earlier application is permitted; however, the Company has not early adopted the new or amended standards in preparing this financial statements.

The following amended standards and interpretations are effective from 1 April 2020

- Amendments To References To Conceptual Framework in IFRS Standards.
- IFRS 17: Insurance Contracts.
- IAS 1 and IAS 8: Definition of Material
- IAS 1: Classification of Liabilities as Current or Non-current
- IAS 16: Proceeds before Intended Use
- IAS 37: Costs of Fulfilling a Contract
- IFRS 9: Fees in the '10 per cent' test for derecognition of financial liabilities
- IAS 41: Taxation in fair value measurements
- IAS 8: Definition of Accounting Estimates

		AMOUNT IN TAKA	
		30-Jun-22	30-Jun-21
<b>2.00</b>	<b>Property, Plant &amp; Equipment (PPE)</b>		
<b>At Cost / Revalued:</b>			
Opening Balance		1,397,455,075	1,398,013,176
Add: Addition during the year		1,697,564	2,961,182
Less: Disposal during the year		-	(3,519,283)
		<b>1,399,152,639</b>	<b>1,397,455,075</b>
<b>Depreciation:</b>			
Opening Balance		453,988,697	400,895,209
Add: Depreciation charged during the year		48,975,456	53,878,288
Less: Disposal during the year		-	(784,800)
		<b>502,964,153</b>	<b>453,988,697</b>
<b>Written Down Value as on 30th June 2022</b>		<b>896,188,486</b>	<b>943,466,378</b>
<b>The details has been shown in "Schedule-01".</b>			
<b>3.00</b>	<b>Capital Work-In-Progress (CWIP)-BMRE</b>		
<b>Opening Balance</b>		786,110,248	318,999,166
Add: Addition during the year		59,878,551	467,111,082
		845,988,799	786,110,248
Less: Adjustment / Transfer to Non-current Assets		-	-
<b>Closing Balance</b>		<b>845,988,799</b>	<b>786,110,248</b>
<b>N.B.</b> It is to be noted that BMRE Project cost will be capitalized after successfully completion of test Production in compliance with the relevant IAS/IFRS.			
<b>4.00</b>	<b>Right-of-Use (ROU) Asset</b>		
<b>Cost</b>			
Opening Balance		7,701,189	7,701,189
Add: Addition during the year		-	-
		<b>7,701,189</b>	<b>7,701,189</b>
<b>Depreciation</b>			
Opening Balance		1,540,239	770,119
Add: Depreciation charged during the year		770,120	770,120
		<b>2,310,359</b>	<b>1,540,239</b>
<b>Written Down Value as on 30th June 2022</b>		<b>5,390,830</b>	<b>6,160,950</b>
<b>5.00</b>	<b>Inventories</b>		
Raw Materials Stock		74,385,513	36,745,940
Finished Goods Stock		8,923,112	8,471,011
Materials-In-Transit	<b>Note: 5.01</b>	89,468,233	60,482,502
Stores & Spares	<b>Note: 28.02</b>	1,315,755	3,540,341
		<b>174,092,613</b>	<b>109,239,794</b>
Raw Materials (M. Ton)		1,282,447	1,707,541
Finished Goods (M. Ton)		435,365	704,895
<b>Total (M. Tons)</b>		<b>1,717,812</b>	<b>2,412,436</b>
a) Raw materials stock with quantity and value are shown in "Schedule-02".			
b) Finished goods stock with quantity and value are shown in "Schedule-03".			
<b>5.01</b>	<b>Materials-In-Transit</b>		
LC Margin Account		65,072,946	37,877,070
Lc No - 0121020320 (3000 MT Sulphur)		(13,750)	
Lc No - 0122020005 (2000 MT Sulphur)		(44,000)	
Lc No - 0122010125 (500 MT Sulphur)		151,138	
Lc No - 0122010192 (500 MT Sulphur)		1,517,638	
Lc No - 0122020020 (1000 MT Sulphur)		164,619	
Lc No - 0122020055 (550 MT Sulphur)		(11,000)	
Lc No - 0122020061 (1000 MT Sulphur)		17,254	
Lc No - 122020100 (945.20 MT Sulphur)		33,097,844	
Lc No - 121020102 (1000 MT Sulphur)		114,540	237,160
Lc No - 122020105 (1000 MT Sulphur)		(22,000)	
Lc No - 122020130 (1000 MT Hydrate)		(13,287,527)	
Lc No - 122020133 (1000 MT Hydrate)		2,168,610	

	AMOUNT IN TAKA	
	30-Jun-22	30-Jun-21
Lc No - 122020153 ( 1000 MT Hydrate )	541,922	401,906
Lc No - 121020107 ( 2000 MT Sulphur )		21,242,851
Lc No - 121020121 ( 1000 MT Sulphur )		340,022
Lc No - 121020153 ( 200 MT LAB )		226,657
Lc No - 121020172 ( 1000 MT Sulphur )		156,837
Lc No - 120020284 ( 1000 MT Hydrate )		
	<b>89,468,233</b>	<b>60,482,502</b>

#### 6.00 Trade Receivables

##### Opening Balance

Add: Sales during the year

Less: Received during the year

##### Closing Balance

(a) Name wise Accounts receivable as on **30th June 2022** are shown in **Schedule-05**.

(b) Classification schedule as required by schedule XI of Companies Act 1994 is as follows:

##### Ageing of the above debtors' balances is as follows:

Below 180 days	626,509,665	434,665,648
Above 180 days	904,512	904,512
	<b>627,414,177</b>	<b>435,570,160</b>

I. Accounts Receivable considered good in respect of which the company is fully secured.

626,509,665

434,665,648

II. Accounts Receivable considered doubtful or bad.

904,512

904,512

**Total = 627,414,177 435,570,160**

The company has also assessed whether there is any significant credit risk involved as per IFRS 9 and the requirement of providing Expected Credit Loss as per the IFRS. However, no such allowance has been provided as more than 99% of the Trade Receivable is recoverable in time and below 180 days aged.

#### 7.00 Advance Income Tax (AIT)

##### Opening Balance

Add : Tax Deduction at Import	17,654,979	23,766,599
Add : Tax Deduction from Sale	27,297,562	10,213,878
Add : Income Tax Paid in Cash	8,692,379	7,454,290
	4,392,900	18,776,270
	<b>58,037,821</b>	<b>60,211,036</b>
Less : Adjustment during this period	22,061,065	(42,556,057)
	<b>35,976,756</b>	<b>17,654,979</b>

#### 8.00 Advances, Prepayments & Deposits

Advance against Salary	Note:-8.01	2,231,164	1,178,311
Advance against Capital Expenditures	Note:-8.02	205,851,459	268,433,846
Bank Guarantee Margin with Agrani Bank		3,387,850	1,919,697
Security & Earnest Money Deposit		11,027,990	4,095,859
FDR at IPDC Finance		10,000,000	10,000,000
VAT Deduction at Import (Not Adjusted)		3,623,230	3,623,230
VAT Deposit Against (10% of Claim)		4,142,790	4,142,790
VAT Deposit	Note:-8.03	8,349,426	1,108,365
		<b>248,613,909</b>	<b>294,502,098</b>

##### 8.01 Advance against Salary

Advance against Salary		513,083	450,083
Advance against Expenses		1,718,081	728,228
		<b>2,231,164</b>	<b>1,178,311</b>

##### 8.02 Advance against Capital Expenditure

Advance payment to suppliers		86,641,028	160,134,966
Asset in Transit		<b>119,210,431</b>	<b>108,298,880</b>
LC No 0120020041 ( LABSA Capital Machinery)		9,357,530	9,357,530
Lc No. 121020380 (Machinery) at Sight.		5,821,756	-
Lc No. 121010411 (Acid Cooler) at Sight		5,066,913	-
Lc No. 122020152 (Machinery) 180d UPAS		22,883	
LC No 119010157 ( Capital Machi & Equipment )		79,401,901	79,401,901
LC No 119010107 ( Acid Resistance Bricks )		1,125,096	1,125,096
LC No 118020228 ( Spare Parts )		7,323,768	7,323,768
LC No 119010132 ( Acid Pump & Blower)		10,058,433	10,058,433
LC No 119010410 ( Adbestor Cement Sheet )		1,032,152	1,032,152
		<b>205,851,459</b>	<b>268,433,846</b>

The details of Advance Payment to Suppliers has been shown in "Schedule-08".

AMOUNT IN TAKA			
<b>8.03 VAT Deposit</b>		30-Jun-22	30-Jun-21
Opening Balance		1,108,365	789,647
<b>Add: Deposit during the year</b>		89,479,839	79,585,763
VAT Cash Deposit		51,150,000	64,500,000
VAT Deduction at Import		13,878,730	4,378,805
AT Deduction at Import		23,303,644	8,979,625
VAT on (Gas & Electricity Bill)		1,147,466	1,727,333
<b>Total Deposit</b>		<b>90,588,204</b>	<b>80,375,410</b>
Less: Adjustment during the year		(82,238,778)	(79,267,045)
<b>Closing Balance</b>		<b>8,349,426</b>	<b>1,108,365</b>
<b>9.00 Cash &amp; Cash Equivalents</b>			
<b>Cash in hand</b>		<b>5,293,028</b>	<b>2,529,646</b>
Cash (Head Office)		337,256	234,272
Cash (Factory)-Current		4,955,772	2,295,374
<b>Cash at Bank</b>		<b>5,826,214</b>	<b>28,838,701</b>
Agrani Bank, Principal Branch, CD A/c No 0200000982200		2,436,892	19,153,713
Agrani Bank, Principal Branch, CD A/c No 0200018008016		165,990	-
BD Krishi Bank CD A/c No. 1001 0210040946		6,450	5,260
Jamuna Bank CD A/c No. 00110210015998		50,842	-
Jamuna Bank CD A/c No. 01030210004758		1,879,070	52,899
Prime Bank A/c No.2127115015947		1,211,992	9,551,851
Basic Bank, A/c-01010069		20,213	20,213
BDBL Account, CD-001133003901		13,947	13,947
BDBL CD A/c 6521111019973		3,014	3,014
Brac Bank Ltd. Asad Gate Br. CD A/c		6,000	6,000
Dutch-Bangla Bank, CD-10123000271		2,434	2,434
Janata Bank Limited-Dilkusha Corporate Br.		24,533	24,533
Uttara Bank, CD-21303		4,838	4,838
		<b>11,119,242</b>	<b>31,368,347</b>

(a) Few Bank accounts are inoperative and carried on accounts for number of years without movement.

#### 10.00 Share Capital

Paid-up Capital (1,620,000 Ordinary Shares of Tk. 10 each)		16,200,000	16,200,000
Add: Issue of Right Share in year 1995		16,200,000	16,200,000
Add: Issue of Bonus Share in year 1997		8,100,000	8,100,000
Add: Issue of Bonus Share in year 2012		8,100,000	8,100,000
Add: Issue of Bonus Share for year 2013		14,580,000	14,580,000
Add: Issue of Bonus Share for year 2014		15,795,000	15,795,000
Add: Issue of Bonus Share for year 2015-2016		7,897,500	7,897,500
Add: Issue of Bonus Share for year 2016-2017		4,343,620	4,343,620
Add: Issue of Bonus Share for year 2017-2018		27,364,830	27,364,830
Add: Issue of Bonus Share for year 2018-2019		29,645,230	29,645,230
		<b>148,226,180</b>	<b>148,226,180</b>

#### 11.00 Share Premium

The above share premium has been carried forward in the financial statements since 1995. This represents premium @ Tk. 200 per share collected on issue of right shares of 162,000.

#### 12.00 Revaluation Reserves

<b>Opening Balance</b>		396,766,745	404,064,937
Less: Depreciation on Revaluation		(5,450,333)	(5,957,708)
Less: Deferred Tax on Revaluation Depreciation		(1,226,325)	(1,340,484)
<b>Closing Balance</b>		<b>390,090,087</b>	<b>396,766,745</b>

(a) One consultant, namely, Dr. Engg. Khurshad-ul-Islam Phd. in Industrial & Process Engineering (Germany) of Bangladesh. Bangladesh Resources Management and Development Company revalued company's Plant & Machinery and Equipment in the Middle of year 2008 on replacement cost basis.

Another civil Engineering Consultant revalued Land at present market price and Building including other civil construction at replacement cost basis in the year 2008.

(b) **Revaluation reserve was taken into accounts as per Board's decision:**

**Details of Revaluation Reserve are as under:**

Machinery and Equipment 483,200,000 483,200,000

Land 89,266,750 89,266,750

Building & Other Civil Construction 80,200,149 80,200,149

**Revaluation Value (Net of Depreciation)** 652,666,899 652,666,899

Other Assets 4,205,463 4,205,463

**Total Revaluation at replacement cost** 656,872,362 656,872,362

Less: Written down value as on 31.12.2008 165,442,789 165,442,789

**Revaluation Reserve** 491,429,573 491,429,573

	AMOUNT IN TAKA	
	30-Jun-22	30-Jun-21
<b>Less: Depreciation Adjustment</b>	<b>91,269,291</b>	<b>85,818,959</b>
For the year 2012	12,978,569	12,978,569
For the year 2013	11,817,372	11,817,372
For the year 2014	10,765,461	10,765,461
For the year 2015	9,812,209	9,812,209
For the period 2016 (6 months)	4,474,096	4,474,096
For the year 2016-2017	8,556,441	8,556,441
For the year 2017-2018	7,809,323	7,809,323
For the year 2018-2019	7,131,491	7,131,491
For the year 2019-2020	6,516,288	6,516,288
For the year 2020-2021	5,957,708	5,957,708
For the year 2021-2022	5,450,333	-
<b>Less: Deferred Tax Adjustment on Depreciation on Revaluation</b>	<b>(10,070,195)</b>	<b>(8,843,870)</b>
<b>Balance as on 30th June 2022</b>	<b>390,090,087</b>	<b>396,766,745</b>

(c) Details of depreciation calculation on revalued assets have been shown in **Schedule-10**  
 (d) Depreciation on Revalued assets had been recognised in statement of profit or loss and other Comprehensive Income in line with Para-41 of IAS-16 and transfer has been made between revaluation reserve and retained earning in compliance with the requirement of the IAS 16 since 2012

#### 13.00 Retained Earnings

Accumulated Profit (Opening Balance)	315,262,094	290,191,550
Net Profit/(Loss) after tax for the period	59,958,120	90,957,313
Cash Dividend for the year 2020-2021	(44,467,854)	(51,879,163)
Adjustment of previous years deferred tax expenses	-	(19,965,313)
Adjustment of Realized Depreciation on Revaluation	5,450,333	5,957,708
	<b>336,202,693</b>	<b>315,262,094</b>

#### 14.00 Long Term Loan

<b>Opening Balance</b>	<b>606,254,739</b>	<b>508,028,074</b>
Agrani Bank Term Loan	558,804,685	508,028,074
Term Loan from IPDC Finance	47,450,054	-
<b>Add: Addition During the period</b>	<b>64,640,735</b>	<b>102,575,149</b>
Agrani Bank Term Loan (Interest)	59,813,096	50,776,611
Term Loan from IPDC Finance Interest	4,827,640	51,798,538
<b>Less: Payment during the period</b>	<b>51,333,982</b>	<b>4,348,484</b>
Agrani Bank Term Loan	38,288,530	-
Term Loan from IPDC Finance	13,045,452	4,348,484
<b>Less: Transferred to Current Liability during the period</b>	<b>116,930,416</b>	<b>112,117,776</b>
Agrani Bank Term Loan	103,884,964	103,884,964
Term Loan from IPDC Finance	13,045,452	8,232,812
<b>Closing Balance</b>	<b>502,631,077</b>	<b>494,136,963</b>
Agrani Bank Term Loan	476,444,287	454,919,721
Term Loan from IPDC Finance	26,186,790	39,217,242

a) Agani Bank sanctioned Project Loan of Tk. 50.91 crore vide letter no. প্রশা/খন/প্রকল্প/ওয়াটা কেমিক্যালস /১১/২০১৮, dated 18 December 2018 for financing BMRE project cost at 70:30 debt equity ratio and repayable in 30 (Thirty) quarterly installment with interest @ of 9% p.a (as per MOU). Considering Corona Virus (Covid - 19) Pandemic effect, Agani Bank revised project loan repayment period and instalment size vide letter no. প্রশা/খন/প্রকল্প/ওয়াটা কেমিক্যালস/২৯/১২০১, dated 06 April 2021 against our proposal, total instalment 28 nos and the 1st instalment will be started 13 / 04 / 2021 each amounting tk,2,59,71,241/- on quarterly basis.

b) IPDC Finance Ltd. sanctioned Project Loan of Tk. 5.00 crore vide letter no. IPDC/WCL/2021/34661 dated February 04, this loan is repayable in 60 (Sixty) monthly installment (each amounting Tk10,87,121/-) with interest @ of 11% p.a (as per MOU) starting from March 10, 2021 upto February 10, 2026.

#### 15.00 Deferred Tax Liability

Deferred tax liability on taxable temporary differences between carrying amount as per accounts and tax base amounts has been calculated into accounts in line with IAS-12.	
a) Deferred Tax Recognised on Taxable Temporary Difference	48,706,392
b) Deferred Tax Recognised on Depreciation of Revaluation Increases	1,226,325
<b>Closing Balance of Deferred Tax Liability</b>	<b>49,932,717</b>
	<b>45,982,632</b>

Computation of deferred tax liability on taxable temporary differences and deferred on revaluation increase are shown at Schedule-09

AMOUNT IN TAKA			
		30-Jun-22	30-Jun-21
<b>16.00 Lease Liability</b>			
<b>Opening Balance</b>		6,914,583	8,094,296
Add: Addition during the period			
Interest Expense		597,760	647,487
		<b>7,512,343</b>	<b>8,741,783</b>
Less: Paid during the period		1,885,600	1,827,200
<b>Closing Balance</b>		<b>5,626,743</b>	<b>6,914,583</b>
Lease Liability-Long Term		4,970,302	6,039,543
Lease Liability-Current		656,441	875,040
		<b>5,626,743</b>	<b>6,914,583</b>
<b>17.00 Bank Overdraft and Loans</b>			
Agrani Bank CC Hypo, Principal Branch		665,705,203	664,089,838
Agrani Bank Incentive Loan, Principal Branch	<b>Note:-17.01</b>	194,365,336	193,564,634
UPAS Loan Liability	<b>Note:-17.02</b>	302,231,309	96,641,389
		<b>1,162,301,848</b>	<b>954,295,861</b>
<b>17.01 Agrani Bank Incentive Loan under Stimulus Package</b>			
During Pandemic Corona Virus (COVID 19) crisis, the Government has declared various Stimulus Packages as working capital loan for industries, SME and other who are affected by COVID 19. Under this package, Agrani Bank has sanctioned working capital loan of Taka 19.00 crore in favor of the Company on 15 June 2020 according to BRPD Circular 08 dated 12 April 2020. This loan carries interest at rate of 9%.			
<b>17.02 Agrani Bank UPAS loan was Tk.302,231,309/- for 180 days deferred to make payment to the consignor against each invoice value with interest &amp; Handlling cost for materials arriving at factory till 30th June 2022.</b>			
<b>18.00 Current Portion of Long Term Loan</b>			
Agrani Bank Term Loan		103,884,964	103,884,964
Term Loan from IPDC Finance		13,045,452	8,232,812
		<b>116,930,416</b>	<b>112,117,776</b>
<b>19.00 Short Term Loan (Unsecured)</b>			
<b>Loan from Managing Director :</b>			
Opening Balance		(916,397)	331,603
Add: Loan received during the year		10,472,800	-
Less : Loan paid during the year		(7,103,000)	(1,248,000)
		<b>2,453,403</b>	<b>(916,397)</b>
<b>20.00 Trade Payables</b>			
<b>Opening Balance</b>		27,776,472	2,615,050
Add: Purchase/addition during the year (local)		301,083,056	481,259,773
		<b>328,859,528</b>	<b>483,874,822</b>
Less: Payment / adjustment during the year		(320,356,787)	(456,098,350)
<b>Closing Balance</b>		<b>8,502,742</b>	<b>27,776,472</b>
The details has been shown in "Schedule-07".			
<b>21.00 Deposit against Sales</b>			
Dohar Chemicals		-	382,747
Dhaka Chemicals		-	658,083
		<b>-</b>	<b>1,040,830</b>
The details has been shown in "Schedule-06".			
<b>22.00 Liabilities for Expenses</b>			
Audit Fee Payable		469,115	411,116
Welfare Expenses Payable		461,645	461,645
Directors Remuneration Payable	<b>Note:-22.01</b>	998,197	1,131,135
Festival Bonus Payable		-	2,053,466
Salaries & Wages Payable (Head Office & Factory)		3,589,491	3,561,951
Utilities Bill Payable		1,354,375	2,461,616
Party Bill Payable / Provision for Exchange Loss		18,765,046	14,687,049
Source VAT & Tax Payable	<b>Note:-22.02</b>	(1,215,741)	434,657
		<b>24,422,127</b>	<b>25,202,635</b>

AMOUNT IN TAKA			
<b>22.01</b>	<b>Directors Remuneration Payable</b>	30-Jun-22	30-Jun-21
Md. Nazrul Islam (Managing Director)	574,571	574,571	
A H M Abdullah	179,671	299,671	
Mahamudul Hasan (Director)	88,893	142,893	
Consultant Remuneration	155,062	114,000	
	<b>998,197</b>	<b>1,131,135</b>	
<b>22.02</b>	<b>Source Tax and VAT Payable</b>		
TDS on Party Bill	2,739,263	(2,954,100)	
TDS on Salary & Remuneration	783	57,479	
VAT Payable on Party Bill	(3,955,787)	3,331,278	
	<b>(1,215,741)</b>	<b>434,657</b>	
<b>23.00</b>	<b>Workers Profit Participation Fund &amp; Welfare Fund</b>		
<b>Opening Balance</b>	40,073,872	35,171,413	
Add: Addition during this period	4,043,992	4,902,459	
	<b>44,117,864</b>	<b>40,073,872</b>	
Less: Paid during this period	-	-	
	<b>44,117,864</b>	<b>40,073,872</b>	
<b>24.00</b>	<b>Provision for Taxation</b>		
<b>Opening Balance</b>	22,061,365	58,269,573	
Add: Provision made during the period	18,197,965	22,061,065	
Less: Provision For Previous Years (Over) / Under	-	(15,726,404)	
	<b>40,259,330</b>	<b>64,604,234</b>	
Less: Adjustment during this period	(22,061,065)	(42,542,869)	
<b>Closing Balance</b>	<b>18,198,265</b>	<b>22,061,365</b>	
<b>25.00</b>	<b>Unclaimed Dividend Account</b>		
1 Dividend Year - 2010	76	75,500	
2 Dividend Year - 2011	92	100,080	
3 Dividend Year - 2014	59	78,746	
4 Dividend Year - 2015 -2016	148	166,186	
5 Dividend Year - 2016 -2017	163	238,707	
6 Dividend Year - 2017 -2018	253,290	280,086	
7 Dividend Year - 2018 -2019	678,495	744,202	
8 Dividend Year - 2019 -2020	965,578	1,047,840	
9 Dividend Year - 2020 -2021	850,750	-	
	<b>2,748,651</b>	<b>2,731,347</b>	
The details has been shown in "Schedule-11".			
<b>26.00</b>	<b>Net Assets Value (NAV) Per Share</b>		
Net Assets Value	<b>Note:-26.01</b>	906,918,960	892,655,019
Number of shares outstanding		14,822,618	14,822,618
<b>NAV Per Share</b>		<b>61.18</b>	<b>60.22</b>
(Previous year's NAV restated on the basis of 14,822,618 shares)			
<b>26.01</b>	<b>Net Assets Value (NAV)</b>		
Total Assets		2,844,784,812	2,624,072,956
Less: Non-Current Liabilities		(557,534,096)	(546,159,138)
Less: Current Liabilities		(1,380,331,756)	(1,185,258,799)
		<b>906,918,960</b>	<b>892,655,019</b>
<b>27.00</b>	<b>Revenue</b>		
Gross Sales	<b>Note:-27.01</b>	1,036,043,378	649,079,365
Less: VAT on Sales	<b>Note:-27.03</b>	(82,238,778)	(79,267,045)
		<b>953,804,600</b>	<b>569,812,320</b>
<b>27.01</b>	<b>Gross Sales</b>		
Sulphuric Acid		451,654,645	453,459,215
Alum Sulphate		178,871,433	154,400,150
Zinc Sulphate		241,988,600	24,750,000
Magnesium Sulphate		163,528,700	16,470,000
		<b>1,036,043,378</b>	<b>649,079,365</b>
(a) Product wise sales with quantity, rate, value and VAT thereon during the years have been shown in "Schedule-04".			
<b>27.02</b>	<b>Per Share Gross Sales</b>		
Gross Sales		1,036,043,378	649,079,365
Number of Shares		14,822,618	14,822,618
Per Share Sales		<b>69.90</b>	<b>43.79</b>
Post effect of Pandemic Corona Virus (COVID - 19) crisis, sales (Market Demand) have been fluctuated regularly. sales of Sulphuric Acid was decreased by Tk. 1,804,570/- against the same period of the previous year though sale of Alum Sulphate, Zinc Sulphate & Magnesium Sulphate were increased by Tk. 24,471,283/-, Tk. 217,238,600/- & 147,058,700/- respectively. But due to post pandemic Corona Virus (COVID - 19) digester which is unavoidable & beyond our control, the company try to continue consistency in sales & production process. Since value of gross sales has been increased and per share sale has also been increased. Price of Raw Materials imported from different countries are increased much more than previous year due to shortage of container, freight of ship, increase of port charge and unavailability of regular liner ship and at last Russia & Ukraine War. These increase huge amount of cost of sales. Since value of gross sales has been increased and per share sale has also been increased.			

	AMOUNT IN TAKA	
	30-Jun-22	30-Jun-21
<b>27.03 VAT on Sales</b>		
VAT on Sulphuric Acid Sale	58,917,342	59,125,107
VAT on Alum Sulphate Sale	23,321,436	20,141,938
VAT on Zinc Sulphate Sale (Exempted)	-	-
VAT on Magnesium Sulphate Sale (Exempted)	-	-
	<b>82,238,778</b>	<b>79,267,045</b>

(a) Product wise Sales with quantity, rate, value and VAT thereon during the period have been shown in "Schedule-04".

<b>28.00 Cost of Sales</b>			
Raw Materials Consumed	<b>Note:-28.01</b>	546,127,130	219,332,107
Carriage Inward		1,903,762	89,840
Store & Spares used	<b>Note:-28.02</b>	11,600,560	4,271,797
Factory Overheads	<b>Note:-28.03</b>	115,487,699	116,284,314
<b>Cost of goods manufactured</b>		<b>675,119,150</b>	<b>339,978,058</b>
Opening Stock of Finished Goods		8,471,011	21,474,961
<b>Cost of goods available for sales</b>		<b>683,590,161</b>	<b>361,453,019</b>
Closing Stock of Finished Goods		(8,923,112)	(8,471,011)
		<b>674,667,049</b>	<b>352,982,008</b>

<b>28.01 Raw Materials Consumed</b>			
Rock Sulphur		445,464,342	159,482,250
Alum Hydrate		56,377,102	45,613,657
Zinc Ash		33,315,110	9,781,201
Magnesium Powder		10,970,575	4,455,000
Linear Alkyl Benzene		-	-
		<b>546,127,130</b>	<b>219,332,107</b>

(a) Movement of raw materials stock showing opening stock, purchased and consumed during the year and closing stock with quantity and value have been shown in "Schedule-02".  
 (b) Raw materials stock had been valued at weighted average purchase price.

<b>28.02 Store &amp; Spares Used</b>			
<b>Opening Balance</b>		3,540,341	1,656,082
Add: Purchase During the year		11,089,664	8,762,275
<b>Store &amp; Spares available for Used</b>		<b>14,630,005</b>	<b>10,418,357</b>
<b>Less: Used during the year</b>		<b>13,314,250</b>	<b>6,878,016</b>
For Production		11,600,560	4,271,797
For BMRE (Capital WIP).		1,713,690	2,606,219
<b>Closing Balance</b>		<b>1,315,755</b>	<b>3,540,341</b>

<b>28.03 Factory Overheads</b>			
Air & Water Test Fee		30,400	22,800
Gas Bill		5,626,973	8,051,236
Electric Bill		7,185,964	9,799,901
Packing Materials		2,167,900	1,866,250
Wages & Salaries including Overtime & Bonus		40,788,558	37,197,484
Chemical Purchase for ETP/ATP/LAB		4,027,480	2,969,695
Daily Labor & Wages (Misc. Work)		580,654	172,884
Fork Lift Expenses		879,790	448,390
Oxygen & L.P Gas Purchase		121,050	166,800
Labor Bill for Alum Breaking		2,955,094	2,446,450
Loading & Unloading charges (Inward & Outward)		1,321,553	977,030
Oil & Lubricant		120,120	99,320
Medical Expenses (Factory)		95,722	272,887
Repairs & Maintenance (General -Factory)		568,128	76,920
Repairs & Maintenance (Plant & Machinery)		1,954,140	334,440
Transport License Fee		360,000	200,000
Factory Depreciation	<b>Note:-28.04</b>	46,704,173	51,181,827
		<b>115,487,699</b>	<b>116,284,314</b>

<b>28.04 Factory Depreciation</b>			
Depreciation on Plant & Machinery		36,883,958	40,839,389
Depreciation on Factory Building		9,771,494	10,285,784
Depreciation on Factory Boundary Wall		20,405	24,006
Depreciation on Laboratory Equipment		28,316	32,648
		<b>46,704,173</b>	<b>51,181,827</b>

	AMOUNT IN TAKA	
	30-Jun-22	30-Jun-21
<b>29.00 Administrative, Selling and Distribution Expenses</b>		
Salaries & Allowances including Eid Bonus (Office)	11,564,182	11,953,770
Annual Subscription to Listed Companies	483,072	548,053
Director Remuneration	9,108,000	9,108,000
Bank Charges and Commission	2,684,872	1,884,518
Business Development Expenses	-	615,480
Car Repairs & Maintenance	2,535,048	1,294,326
CDBL Line Charges	37,800	37,800
Charity & Donation (Factory & Office)	1,185,000	207,500
Computer Operating Expenses	233,842	340,910
Credit Rating Expenses	80,625	80,625
Consultant Remuneration	1,652,000	1,650,000
Conveyance (Office & Factory)	193,130	185,415
Crokers & Cutleries	-	4,465
Dish Bill (Factory & Office)	16,100	15,600
Electric Bill (Office)	603,557	496,195
Entertainment & Lunch Exp. (Office & Factory)	1,837,655	1,280,458
Exchange Loss	18,641,248	2,194,524
Gas Bill (Office)	23,720	25,709
Insurance Expenses	616,688	63,250
Internet Expenses (Factory & Office)	178,800	173,000
Land Survey Expenses	-	23,500
License Renewal Expenses	178,186	150,551
Loan Processing Expenses	-	266,903
Medical Expenses	32,996	586,618
Mobile Expenses (Office & Factory)	416,388	213,855
News Paper & Periodicals (Factory & Office)	11,981	11,100
Office Expenses (Factory & Office)	941,733	545,275
Audit Fee	454,749	396,744
Annual General Meeting & Board Meeting Expenses	575,250	449,900
Office Stationery (Factory & Office)	304,819	246,969
Oil & Fuel Expenses	1,500,123	1,562,843
Parking & Toll Charge	62,900	70,526
Photocopy Charge (Factory & Office)	47,079	69,156
Postage & Courier and Fax Exp.	17,264	10,100
Rates & Taxes	-	128
Renewal of Tax Token & Fitness Certificate	190,181	440,996
Repair & Maintenance-Office Equipment	283,903	74,950
Stamp Purchase	62,381	61,442
Telephone Bill (Office)	8,007	6,462
Travelling Expenses	337,988	6,585
Water Bill (Office & Factory)	21,414	39,403
Fish & Deer Upkeep (Factory)	617,045	394,030
Tree Plantation	7,730	62,610
Carriage Outward	5,198,400	3,490,750
Tender Documentation Charges	101,960	194,647
Advertisement & Publicity	1,076,456	787,551
Fine & Penalty	-	13,188
Loading & Unloading (Outward)	1,403,881	1,260,960
Depreciation (Office)	3,041,403	3,466,582
<b>Note:-29.02</b>	<b>68,569,557</b>	<b>47,063,922</b>
<b>29.01 Director Remuneration</b>		
(i) Md. Nazrul Islam, Managing Director	4,800,000	4,800,000
(ii) Mr. A.H.M Abdullah, Director	2,400,000	2,400,000
(iii) Mr. Mahmudul Hasan, Director	1,080,000	1,080,000
(v) EID Bonus (For Director'S)	828,000	828,000
	<b>9,108,000</b>	<b>9,108,000</b>
<b>29.02 Depreciation (Office)</b>		
Depreciation on Motor Vehicles	1,283,798	1,730,273
Depreciation on Bi-Cycle	236	263
Depreciation on Furniture & Fixture	376,894	406,842
Depreciation on Office Equipment	517,727	460,423
Depreciation on Computer	52,329	53,884
Depreciation on Generator	40,300	44,778
Depreciation on ROU Asset	770,120	770,120
	<b>3,041,403</b>	<b>3,466,583</b>

AMOUNT IN TAKA			
30-Jun-22	30-Jun-21		
<b>30.00 Finance Expenses</b>			
Interest on Agrani Bank C.C (Hypo)	58,034,836	58,177,367	
Interest on Stimulus Package Loan	15,843,023	10,527,265	
Interest on Project Loan	38,890,312	-	
Interest on IPDC Loan	4,827,640	1,798,538	
Interest & Handling Exp. Of Materials Import (UPAS)	11,715,947	2,583,792	
Interest on Lease Liability	597,760	647,487	
	<b>129,909,518</b>	<b>73,734,448</b>	
<b>31.00 Non-operating Income</b>			
Fish Sale	2,713,100	587,250	
Misc. Sales Income	1,552,260	6,332,444	
	<b>4,265,360</b>	<b>6,919,694</b>	
<b>32.00 Income Tax Expenses</b>			
Major component of tax expenses			
In compliance with the requirements of para -79 of IAS-12:Income tax, the major components of tax expenses are given below:			
Current Tax Expense	<b>Note:-32.01</b>	<b>18,197,965</b>	<b>6,334,661</b>
Deferred Tax Expense	<b>Note:-32.02</b>	<b>2,723,760</b>	<b>757,203</b>
		<b>20,921,725</b>	<b>7,091,864</b>
<b>32.01 Reconciliation of Tax Expenses with Accounting Profit and Applicable Effective Tax Rate.</b>			
	%	30-Jun-22	%
<b>Net profit before tax</b>		80,879,845	98,049,177
Statutory Tax Rate	22.5%	18,197,965	22,061,065
Income tax u/s 82C and other adjustment		-	(15,726,404)
<b>Effective Tax Rate</b>	22.5%	<b>18,197,965</b>	<b>6,334,661</b>
<b>Current Tax Expense</b>			
Current tax has been charged at the rate applicable to the company, subject to provision of section 82C taking higher income of- (a) at the rate of 0.60% of total gross receipts,(b) tax deducted at source for corporate sales u/s 52, tax collected at import stage U/S 53; and tax deducted at source of bank interest income u/s 53F, (c) at the applicable tax rate on taxable income. The company recognised current tax expense of BDT 18,197,965 Taka which is also 22.50% of profit before tax.			
<b>32.02 Deferred Tax Expense/(Income)</b>			
Carrying Value of Fixed Assets (WDV) at Balance Sheet Date		896,188,486	943,466,378
Less: Revaluation Increase		(318,010,817)	(322,098,567)
<b>Net carrying Cost</b>		<b>578,177,668</b>	<b>621,367,811</b>
Less: Land Value		(106,402,620)	(106,402,620)
<b>Net Carrying cost (Net of Land &amp; Land Development) (A)</b>		<b>471,775,048</b>	<b>514,965,191</b>
<b>Right-of-Use (ROU) Asset (B)</b>		<b>5,390,830</b>	<b>6,160,950</b>
<b>Lease Liability (C)</b>		<b>(4,313,861)</b>	<b>(5,164,503)</b>
<b>Total Carrying Value at Balance Sheet Date (A+B-C)</b>		<b>472,852,017</b>	<b>515,961,639</b>
Less: Tax Based WDV (Estimated)		(256,379,164)	(317,552,091)
<b>Temporary Taxable Differences</b>		<b>216,472,853</b>	<b>198,409,548</b>
<b>Deferred Tax on Depreciation on Revaluation-Increase</b>			
Deferred Tax Liability on Temporary Taxable @ 22.5%		48,706,392	44,642,148
Deferred Tax on Depreciation on Revaluation Increase through OCI		1,226,325	1,340,484
<b>Deferred Tax Liability on 30th June 2022</b>		<b>49,932,717</b>	<b>45,982,632</b>
Less: Opening Deferred Tax Liability		(45,982,632)	(23,919,632)
Less: Adjustment of Previous years Deferred Tax Expenses		-	(19,965,313)
Less: Deferred Tax on Revaluation Transferred to Revaluation Reserve		(1,226,325)	(1,340,484)
<b>Deferred Tax Expenses (Income) Recognised during the period</b>		<b>2,723,760</b>	<b>757,203</b>
<b>33.00 Earning per share (EPS)</b>			
Basic Earning Per Share , as per IAS - 33 , is calculated as below:			
<b>EPS =</b>			
	Net Profit After Tax		
	Number of Share		
		=	
		59,958,120	90,957,313
		14,822,618	14,822,618
		<b>4.05</b>	<b>6.14</b>

Post effect of Pandemic Corona Virus (COVID - 19) crisis, sales (Market Demand) have been fluctuated regularly. Net sales of Sulphuric Acid was decreased by Tk. 1,596,805/- against the same period of the previous year though net sale of Alum Sulphate, Zinc Sulphate & Magnesium Sulphate were increased by Tk. 21,291,785/-, Tk. 217,238,600/- & 147,058,700/- respectively. But due to post pandemic Corona Virus (COVID - 19) digester which is unavoidable & beyond our control, the company try to continue consistency in sales & production process. Since value of gross sales has been increased and per share sale has also been increased. Price of Raw Materials imported from different countries are increased much more than previous year due to shortage of container, freight of ship, increase of port charge and unavailability of regular liner ship and at last Russia & Ukraine War. The last blow was huge Exchange Loss in foreign payment. These increase huge amount of Cost of Sales. COGS thus increased by Tk. 321,685,041/. As a result Net income after deduction of tax decreased by Tk.30,999,193/- which causes the significant deviation in EPS.

	AMOUNT IN TAKA	
	30-Jun-22	30-Jun-21
<b>34.00 Cash Receipts From Customers and Others</b>		
Gross Sales	1,036,043,378	649,079,365
Non Operating Income	4,265,360	6,919,694
Trade Receivables: Decrease (Increase)	(191,844,017)	(81,702,690)
Loan & Advance - Net of VAT & Tax (Increase)	53,129,250	(10,415,932)
Deposit against Sales Increase / (Decrease)	(1,040,830)	(216,136)
	<b>900,553,142</b>	<b>563,664,302</b>
<b>35.00 Cash paid to Suppliers and Others</b>		
Raw Materials Purchase	583,766,702	164,726,626
Stores & Spares Purchase	9,375,974	10,628,525
Material in Transit: Increase / (Decrease)	28,985,731	33,837,495
Trade Payables-(Increase) / Decrease	(186,316,189)	(22,555,203)
	<b>435,812,218</b>	<b>186,637,443</b>
<b>36.00 Cash paid to Employees and for Other Expenses</b>		
Salaries & Allowances including Eid Bonus (Office)	52,352,740	11,953,770
Carriage Inward	1,903,762	89,840
Factory Overheads (Excl. Wages & Salary and Depreciation)	27,994,968	63,236,237
Administrative & Marketing Exp. (Excd.Salaries, Depr. & Exch. Loss)	35,322,723	29,449,046
Finance costs	129,909,518	73,086,961
Liabilities for Expenses: Decrease (Increase)	999,107	14,770,936
	<b>248,482,817</b>	<b>192,586,791</b>
<b>37.00 Cash paid for VAT &amp; Tax</b>		
<b>(a) Payment of VAT</b>	<b>89,479,839</b>	<b>79,585,763</b>
VAT Deposit in Cash	51,150,000	64,500,000
VAT Paid at Import	13,878,730	4,378,805
AT Paid at Import	23,303,644	8,979,625
VAT on Utility Bill	1,147,466	1,727,333
<b>(b) Payment of Tax</b>	<b>40,382,842</b>	<b>36,444,438</b>
AIT on Import	27,297,562	10,213,878
AIT Deduction from Sale Bill	8,692,379	7,454,290
Payment of Tax in Cash	4,392,900	18,776,270
<b>Total (A+B)</b>	<b>129,862,681</b>	<b>116,030,201</b>
<b>38.00 Acquisition of Non-current Assets</b>		
Addition to Fixed Assets (Net of Adjustment)	1,697,564	2,176,382
Addition for Capital Work in Progress	59,878,551	108,228,966
Payment of Lease Liability	1,069,241	1,179,713
	<b>62,645,356</b>	<b>111,585,061</b>
<b>39.00 Loan Received</b>		
Loan from Agrani Bank	2,416,067	132,941,311
Project Loan from Agrani Bank ( Interest)	59,813,096	100,776,611
Term Loan from IPDC Finance Interest	4,827,640	-
Loan from Managing Director	10,472,800	-
	<b>77,529,603</b>	<b>233,717,922</b>
<b>40.00 Loan Repaid</b>		
Project Loan Payment to Agrani Bank	38,288,530	105,989,319
Term Loan Payment from IPDC Finance	13,045,452	4,348,484
Loan from Managing Director	7,103,000	1,248,000
	<b>58,436,982</b>	<b>111,585,803</b>
<b>41.00 Dividend Paid</b>		
Dividend Paid	44,450,548	54,958,557
Less: Sale of Fraction Share		-
Less: Sale of Fraction Share		(1,732,193)
	<b>44,450,548</b>	<b>53,226,364</b>

Unclaimed Dividend Account balance (Except last three years) amounting Tk. 5,50,450/- has been transferred to **Capital Market Stabilization Fund** ( SND A/c No. 0010311521301 Community Bank Bangladesh Ltd., Gulshan Corporate Branch, Dhaka ) after deducting TDS Compling with the Commission's Directive No. BSEC/CMRRC/2021-386/03 - dated 14 January 2021 during the year.

	AMOUNT IN TAKA	
	30-Jun-22	30-Jun-21
<b>42.00 Net Operating Cash Flow Per Share (NOCFPS)</b>		
Net Operating Cash Flows	86,395,426	68,409,867
Weighted average number of shares	14,822,618	14,822,618
	<b>5.83</b>	<b>4.62</b>

Though Collection from Sales and Trade Debtors was increased by Tk. 336,888,840/-, Payment for Raw Materials & Trade Creditors, Payment for Salaries & Wages & Others Expenses and Payment of VAT and Tax were also increased by Tk.249,174,775/-, Tk.55,896,026/- & Tk.13,832,480/- against the same period of the previous period. As a result Cash Flow from Operating Activities stand at TK.86,395,426/- which causes the significant deviation in NOCFPS.

#### 43.00 Reconciliation of Net Profit with Cash Flows from Operating Activities

<b>Profit before Tax</b>	80,879,845	98,049,177
<b>Adjustment for:</b>		
Add: Depr. on Property, Plant and Equipment	48,975,456	51,363,215
Add: Depreciation of ROU Assets	770,120	770,120
Add: Interest on Lease Liability		647,487
Add: Contribution to WPFF	4,043,992	4,902,459
Add: Exchange Loss	18,641,248	2,194,524
Add /Less: (Incr.) / Decr. in Inventory	(64,852,819)	31,887,677
Add / Less: (Incr.) / Decr. in Trade Receivables	(191,844,017)	(81,702,690)
Add / Less: (Incr.) / Decr. in Loans, Adv. & Deposits (Excl. VAT)	135,368,028	68,851,113
Add / Less: Incr. / (Decr.) in Trade Payables	186,316,189	22,555,203
Add / Less: Incr. / (Decr.) in Deposits against Sales	(1,040,829)	(216,136)
Add / Less: Incr. / (Decr.) in Liabilities for Expenses	(999,107)	(14,862,081)
<b>Cash Generated from Operations</b>	<b>216,258,108</b>	<b>184,440,068</b>
Less: VAT & Income Tax Paid	(129,862,681)	(116,030,201)
<b>Net Cash (used in) / generated from operating activities</b>	<b>86,395,427</b>	<b>68,409,867</b>

#### 44.00 Depreciation of Revaluation Adjustment

Depreciation on Revaluation adjustment	5,450,333	5,957,708
	<b>5,450,333</b>	<b>5,957,708</b>

(a) Depreciation on partial revaluation increase of Plant & Machinery as well as Building had been charged during the period 2021-2022 amounting to Tk. 54,50,333/- and adjusted in statement of Changes in Equity. Details has been shown in "Schedule-10".

#### 45.00 Provision of tax liability between accounts and Final Assessment

Assessment Year	Accounting Year	Tax Provision as per Accounts	Tax Liability as per Final Assessment	Difference of Tax Provision as per Final Assessment	Adjustment of Advance of Tax	Tax Liability Provision
2015-2016	2014	11,017,752	11,017,752	U/s 82BB	-	-
2016-2017	2016	14,853,225	14,853,225	U/s 82BB	-	-
2017-2018	2016-2017	11,633,292	11,633,292	U/s 82BB	-	-
2018-2019	2017-2018	15,697,637	15,697,637	U/s 82BB	-	-
2019-2020	2018-2019	46,838,132	46,838,132	U/s 82BB	-	-
2020-2021	2019-2020	42,542,869	42,542,869	U/s 82BB	-	-
2021-2022	2020-2021	22,061,365	22,061,365	U/s 82BB	22,061,065	300
2022-2023	2021-2022	18,197,965			-	18,197,965
<b>Total =</b>		<b>182,842,237</b>	<b>164,644,272</b>	<b>-</b>	<b>22,061,065</b>	<b>18,198,265</b>

**46.00 Appropriation of Dividend**

(a) Appropriation of cash dividend Tk. 4,44,,67,854/-

Cash dividend has been appropriated on paid-up capital of Tk. 14,822,618/-@ **30%** as per approval in the AGM held on **30 December 2021**.

(b) Appropriation of Stock Dividend of 00/- shares.

Stock dividend has been appropriated on paid-up capital of Tk. 14,822,618/-@ **0%** as per approval in the AGM held on **30 December 2021**.

**47.00 Additional Information as per Requirement of the Companies Act, 1994**

(a) Total number of factory staffs (each received annual salaries & wages Tk. 16,000 & above ) was 84 nos.

(b) Total number of H/O staffs ( each received annual salaries & wages Tk. 16,000 & above) was 17 nos.

(C ) Payment to Directors as Remuneration & Perquisite in the Period has been shown in Note-29.01.

**48.00 Plant Capacity & Utilization**

Name of Products	Attainable Capacity (Oty.M.Ton)		Actual Production	
	Annual	Yearly	(Qty M.Ton)	% of Capacity
Sulphuric Acid	48,000.000	48,000.000	43,612.800	90.86%
Alum Sulphate	18,000.000	18,000.000	6,468.000	35.93%
Zinc Sulphate	6,000.000	6,000.000	3,155.28	52.59%
Magnesium Sulphate	6,000.000	6,000.000	2,420.00	40.33%

**49.00 Payment in Foreign Currency & Foreign Currency Earned**

(a) No payment in foreign currency (except import cost of materials) was made in the Period.

(b) No foreign currency was earned in the Period.

**50.00 Commission, Brokerage & Discount to the Selling Agent**

Company had no selling agent as such no payment of commission, brokerage and discount was made.

**51.00 Contingent Liability**

Commissioner of Customs, Excise and VAT Directorate, Dhaka has raised claim amounting to Tk. 41,427,896 based on their audit objection vide letter dated 11.08.2014. Against this claim, company has filed appeal with Appellate Commissioner on deposit of amount Tk. 4,142,790. The case is still pending with appellate Tribunal. No additional liability had been accounted.

**52.00 Related Parties & Transactions**

Related parties and transactions are considered in line with IAS-24 as under:

Related parties disclosure , details of which are as follows

a) **Short Term Employee Benefit:**

i) **Director Remuneration**

Name	Designation	Amount in taka 30-Jun-22	
		Total	Payable
Md. Nazrul Islam	Managing Director	4,800,000	334,571
Mr. A.H.M. Abdullah	Director	2,400,000	179,671
Mr. Mahmudul Hasan	Director	1,080,000	88,893
Festival Bonus		828,000	240,000

ii) **Top Five Salaried Officers**

Name	Designation	Amount in taka 30-Jun-22	
		Total	Payable
Shamsul Huq	Company Secretary	1,084,680	79,833
Md. Ali Hasan	Chief Financial Officer	1,549,520	110,797
Md. Abu Taher Bhuyan	General Manager ( Factory)	1,412,760	103,741
Md. Ashraful Alam	General Manager ( F & A)	1,384,640	102,500
A S M Farhan Reza	Maintenance Eng. (Civil)	944,320	75,049

- b) Post Employees Benefits : Nil
- c) Others Long-Term Benefits: Nil
- d) Termination Benefits: Nil
- e) Share -Based Payment : Nil
- f) Short Term Loan with Managing Director:  
Short Term loan to Managing Director (Mr. Nazrul Islam) was free of interest.
- g) Apart from the above, the company didn't made any transaction with related parties in normal course of business and or a arm's length basis.

#### 53.00 Recent Events and Trends in our business view:

In the current global scenario, we are also experiencing massive price increase in the purchase ( Import ) of raw materials specially for "Sulphur" .Although the crisis mostly started later due to Corona Virus situation, its increase day by day which is beyond our control. As the raw material is a petroleum bye product, the war between Russia and Ukraine caused prices to raise further. Price of raw materials imported from Middle east and Russia are increased much more than the previous year due to shortage of container, freight of ship, increase of port charges of domestic and transshipment port, unavailability of regular liner vessel. Average price of main raw material sulphur has been increased by about 165% over the previous year. The last blow was huge Exchange Loss in foreign payment. These increased Cost of Goods Sold. As a result net income after deduction of tax decreased by Tk. 30,999,193, which causes the significant deviation in EPS.

#### 54.00 Event after the Reporting Period

- 54.01 Foreign exchange loss includes loss arising from the translation of foreign currency liabilities, mainly comprised of UPAS loan liabilities. Under IAS 21, closing rate has to be used to convert foreign currency assets and liabilities. Consistent with past practice, the BC selling rate of Tk. 93.50/USD as on 30.06.2022 has been used as the closing rate. Subsequently, up to 30 September 2022, the average settlement rate with different banks varied from BDT 98.00/USD to BDT 102.00/USD. Had this rate been used for the translation of the total liabilities the additional translation loss would have been Tk 2.90 Crore.
- 54.02 The Board of Directors in their meeting held on 27 October 2022 have recommended 20% Cash Dividend for General Public / Investor and 10% Cash Dividend for Directors on Paid Up Capital and no stock dividend for the year ended 30 June 2022 subject to approval of the shareholders in the Annual General meeting scheduled to be held on 29 December, 2022. The financial statements for the year ended 30 June 2022 do not include the effect of the dividend which will be accounted for in the next financial year.

There is no other significant events after the reporting date that may affect the reported amounts in the financial statements of the Company for the year ended 30 June 2022.



Razi Uddin Ahmed  
Chairman




Md. Nazrul Islam  
Managing Director



A.H.M. Abdullah  
Director



Md. Ali Ahsan  
Chief Finance Officer



Shamsul Huq  
Company Secretary

Dated: 27 October 2022  
Dhaka, Bangladesh

**WATA CHEMICALS LIMITED**  
**Schedule of Property, Plant & Equipment (PPE)**  
**As at 30th June, 2022**

**Schedule-01**

SL No.	Name of Assets	01.07.2021		Cost / Revaluation		Rate	As on 01.07.2021		Depreciation		As on 30.06.2022	Written Down Value
		As at 01.07.2021	Addition this period	Adjustment this period	Total 30.06.2022		As on 30.06.2022	Addition this year	Depreciation this year	Adjustment this year		
01	Land & Land Development	106,402,620	-	-	106,402,620	-	363,562,995	-	-	-	400,446,953	106,402,620
02	Plant & Machinery & Equip.	982,922,829	742,540	-	983,665,369	10%	67,880,444	9,771,494	-	-	77,651,938	583,218,416
03	Factory Building	263,310,331	-	-	263,310,331	5%	648,435	20,405	-	-	668,840	185,658,393
04	Boundary Wall	784,468	-	-	784,468	15%	341,737	28,316	-	-	370,053	115,628
04	Laboratory Equipment	526,744	45,200	-	571,944	15%	-	-	-	-	370,053	201,891
05	Motor Vehicles	28,241,826	-	-	28,241,826	10%	15,403,848	1,283,798	-	-	16,687,646	11,554,180
06	Bi-Cycle	5,200	-	-	5,200	10%	2,837	236	-	-	3,073	2,127
07	Furniture & Fixture	6,199,964	46,200	-	6,246,164	10%	2,469,524	376,894	-	-	2,846,418	3,399,746
08	Office Equipment	7,181,100	863,624	-	8,044,724	10%	2,725,170	517,727	-	-	3,242,897	4,801,827
09	Computer & Software	890,158	-	-	890,158	10%	366,873	52,329	-	-	419,202	470,957
10	Generator	989,835	-	-	989,835	10%	586,834	40,300	-	-	627,134	362,701
	<b>Total</b>	<b>1,397,455,075</b>	<b>1,897,564</b>	<b>-</b>	<b>1,399,152,639</b>		<b>453,988,697</b>	<b>48,975,436</b>	<b>-</b>	<b>-</b>	<b>502,964,153</b>	<b>896,188,486</b>

**NB:** (a) Depreciation has been charged following reducing balance method.

(b) Depreciation on addition has been charged for the period from the date of acquisition.

(c) Depreciation has been charged on Plant & Machinery which were in use as under:

Particulars	WDV	Addition	Depreciable	Value	Rate	Depreciation
Depreciation on Sulfuric Acid Plant Unit-1	53,026,055	-	53,026,055	x	10%	=
Depreciation on Sulfuric Acid Plant Unit-2	231,916,144	-	231,916,144	x	10%	23,191,614
Depreciation on Alum Sulphate Plant Unit-1	19,261,358	-	19,261,358	x	10%	=
Depreciation on Zinc Plant	17,258,433	-	17,258,433	x	10%	1,926,136
Depreciation on Magnesium Plant	30,274,143	-	30,274,143	x	10%	=
Depreciation on Utilities Plant	16,823,702	742,540	17,566,242	x	10%	1,725,843
<b>Total</b>	<b>368,559,835</b>	<b>742,540</b>	<b>369,302,375</b>			<b>3,027,414</b>
						<b>1,710,344</b>
						<b>36,883,958</b>

**WATA CHEMICALS LIMITED**  
**Movement of Raw Materials Stock**  
**For the Year Ended 30th June 2022**

Particulars	Opening Stock		Purchased during the period		Adj. during the period		Consumption		Closing Stock	
	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka
Rock Sulphur	1,645.820	35,142,822	14,342.070	433,947,860	-	-	15,264.480	445,464,342	723.410	23,626,340
Alumina Hydrate	40.607	1,015,175	2,146.830	70,355,515	-	-	1,875.720	56,377,102	311.717	14,993,587
Zinc Ash	6.644	190,018	1,195.000	34,177,000	-	-	1,164.864	33,315,110	36.780	1,051,908
Magnesium Powder	14.470	397,925	395.000	10,862,500	-	-	398.930	10,970,575	10.540	289,850
Linear Alkyl Benzene			200.000	34,423,828	-	-	-	-	200.000	34,423,828
<b>Total</b>	<b>1,707.541</b>	<b>36,745,940</b>	<b>18,278,900</b>	<b>583,766,702</b>	<b>-</b>	<b>-</b>	<b>18,703,994</b>	<b>546,127,130</b>	<b>1,282,447</b>	<b>74,385,513</b>

Raw Materials consumption in relation with production (Input Ratio)

For the Year Ended 30th June 2022

Product Name	Raw Materials Used		Production		Input Ratio (Per Ton)		Consumption of RM		Value of Consumed Materials	
	Qty. (M.Ton)	Production	Qty. (M.Ton)	Purchased Materials	Own Product Internal used	Purchased Raw Materials used	Own Product Internal used	Purchased Raw Materials used	Own Product Internal used	Average rate (Per M.Ton)
Sulphuric Acid	43,612.80	0.350	15,264.480	-	-	445,464,342	-	-	-	29,183
Aluminum Sulphate	6,468.00	0.290	1,875.720	-	-	56,377,102	-	-	-	30,056
Do	6,468.00	0.600	-	3,884.916	-	-	-	-	-	8,969
Zinc Ash	3,155.28	0.380	1,164.864	-	-	-	-	-	-	28,600
Sulphuric Acid	3,155.28	0.620	-	1,956.324	-	-	-	-	-	8,969
Magnesium Powder	2,420.00	0.180	398.930	-	-	-	-	-	-	-
Sulphuric Acid	2,420.00	0.820	-	1,984.400	-	-	-	-	-	8,969
<b>Total</b>	<b>67,699.36</b>	<b>-</b>	<b>18,703,994</b>	<b>7,825,640</b>	<b>535,156,555</b>	<b>-</b>	<b>70,184,963</b>	<b>-</b>	<b>-</b>	<b>-</b>

**Movement of Raw Materials Stock**  
**For the Year Ended 30th June 2021**

Particulars	Opening Stock		Purchased during the period		Adj. during the period		Consumption		Closing Stock	
	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka
Rock Sulphur	4,738.451	55,974,802	12,162.619	138,650,270	-	-	15,255.250	159,482,250	1,645.820	35,142,822
Alumina Hydrate	1,002.538	30,144,476	633,889	16,484,356	-	-	1,595.820	45,613,657	40.607	1,015,175
Zinc Ash	128.644	3,679,219	220.000	6,292,000	-	-	342.000	9,781,201	6.644	190,018
Magnesium Powder	56.470	1,552,925	120.000	3,300,000	-	-	162.000	4,455,000	14.470	397,925
<b>Total</b>	<b>5,926.103</b>	<b>91,351,422</b>	<b>13,136,508</b>	<b>164,726,626</b>	<b>-</b>	<b>-</b>	<b>17,355.070</b>	<b>219,332,107</b>	<b>1,707.541</b>	<b>36,745,940</b>

**WATA CHEMICALS LIMITED**  
**Movement of Finished Goods Stock**  
**For the Year Ended 30th June 2022**

Schedule-03

Particulars	Opening Stock		Production during the period	Internal Used during the period	Sale during the period	Closing Stock	
	1-Jul-20	Qty. M.Ton	1-Jul-20	Qty. M.Ton	30-Jun-22	Qty. M.Ton	30-Jun-22
Sulphuric Acid	357.255	4,322,089	43,612,800	-	36,128,700	15.715	140,945
Alumina Sulphate	203.500	2,411,475	6,468,000	3,884,916	6,316,850	354,650	7,607,243
Zinc Sulphate	66.720	973,311	3,155,280	1,956,324	3,157,000	65,000	1,174,925
Magnesium Sulphate	77.420	764,135	2,420,000	1,984,400	2,497,420	-	-
<b>Total</b>	<b>704.895</b>	<b>8,471,011</b>	<b>55,656,080</b>	<b>7,825,640</b>	<b>48,099,970</b>	<b>435,365</b>	<b>8,923,112</b>

**WATA CHEMICALS LIMITED**  
**Movement of Finished Goods Stock**  
**For the Year Ended 30th June 2021**

Particulars	Opening Stock		Production during the period	Internal Used during the period	Sale during the period	Closing Stock	
	1-Jul-20	Qty. M.Ton	1-Jul-20	Qty. M.Ton	30-Jun-21	Qty. M.Ton	30-Jun-21
Sulphuric Acid	1,956.822	15,200,779	43,015,000	-	40,031,767	357.255	4,322,089
Alumina Sulphate	361.000	4,505,280	5,478,000	3,286,800	5,635,500	203.500	2,411,475
Zinc Sulphate	66.720	985,721	90.000	558,000	900,000	66.720	973,311
Magnesium Sulphate	77.420	783,181	90.000	738,000	900,000	77.420	764,135
<b>Total</b>	<b>2,461.962</b>	<b>21,474,961</b>	<b>50,293.000</b>	<b>4,582,800</b>	<b>47,467.267</b>	<b>704.895</b>	<b>8,471,011</b>

**WATA CHEMICALS LIMITED**  
**Sales (Net of VAT)**  
**For the Year Ended 30th June 2022**

Schedule-04

Particulars	Jul'21-Jun'22			
	Quantity (M. Ton)	Gross Sale Value (Including VAT) In Taka	VAT on Sale In Taka	Sale Value (Net of VAT) In Taka
Sulphuric Acid	36,128.700	451,654,645	58,917,342	392,737,303
Alumina Sulphate	6,316.850	178,871,433	23,321,436	155,549,997
Zinc Sulphate (VAT Exempted)	3,157.000	241,988,600	-	241,988,600
Magnesium Sulphate (VAT Exempted)	2,497.420	163,528,700	-	163,528,700
<b>Total</b>	<b>48,099.970</b>	<b>1,036,043,378</b>	<b>82,238,778</b>	<b>953,804,600</b>

**WATA CHEMICALS LIMITED**  
**Sales (Net of VAT)**  
**For the Year Ended 30th June 2021**

Particulars	30-Jun-21			
	Quantity (M. Ton)	Gross Sale Value (Including VAT) In Taka	VAT on Sale In Taka	Sale Value (Net of VAT) In Taka
Sulphuric Acid	40,031.767	453,459,215	59,125,107	394,334,108
Alumina Sulphate	5,635.500	154,400,150	20,141,938	134,258,212
Zinc Sulphate (VAT Exempted)	900.000	24,750,000	-	24,750,000
Magnesium Sulphate (VAT Exempted)	900.000	16,470,000	-	16,470,000
<b>Total</b>	<b>47,467.267</b>	<b>649,079,365</b>	<b>79,267,045</b>	<b>569,812,320</b>

**WATA CHEMICALS LIMITED**  
**Trade Receivables**  
**As at 30th June, 2022**

Schedule-05

Sl. No	Name of Customers	Amount in Taka	
		30-Jun-22	30-Jun-21
1	M/S Asad Trading	156,737,206	159,086,611
2	Afil Paper Mills Ltd.	18,991	55,201
3	Ashugong Fertilizer Chemical Co. Ltd.	-	3,283,000
4	Basundhara Paper Mills	384,512	384,512
5	BSK Chemical Industries Ltd.	703,950	3,673,950
6	Dhaka Chemicals	16,250	
7	Friends Chemicals	1,888,075	1,661,525
8	Green Dot.Com Ltd.	215,275	474,188
9	H.K Enterprise	1,607,614	-
10	Leather Net BD	67,137	67,137
11	Modunaghat Water Treatment Plant	656,339	656,339
12	Mohara Division (CWASA)	1,824,966	-
13	M/s. Asad Trading Unit-2	115,779,424	60,755,672
14	M/s Aysha Trading Corporation	1,428,027	-
15	M/s. Dewan Enterprise	3,377,250	-
16	Dohar Chemicals	81,536	
17	M/s. HH Enterprise	44,758	-
18	M/s. Jaman Enterprise.	736,997	736,997
19	M/S Masud Auto Parts & Chemicals	326,861	63,943
20	M/s. M.R. Chemicals	59,287,385	44,898,975
21	M/s Munshi Chemicals	50,612	63,580
22	M/s Tarek Enterprise	437,190	221,345
23	M/s. Zharna Chemical Supply Co.	8,038,638	10,413,535
24	Zharna Traders	12,094,364	9,235,739
25	Nazrul & Brothers	442,463	
26	N.M. Corporation	381,890	1,599,390
27	Raima Chemicals Industry	2,000,234	2,000,234
28	Rajshahi WASA	-	89,516
29	Refa Chemicals	520,000	520,000
30	Rone Chemical/Trading House	8,877	15,361
31	Saidabad Water Treatment Plant.	58,881,000	35,432,000
32	Sheik Russel Pani Sodhonagar	14,372,600	6,508,032
33	Sheik Hasina Water Treatment Plant	8,394,623	6,520,079
34	SIM Fabrics	447,276	447,276
35	SM Chemicals	160,152,461	71,221,555
36	Sonali Chemicals	90,250	90,250
37	SS Chemicals Industries Ltd	167,580	167,580
38	Tamim Enterprise	23,790	123,790
39	Traigon International	19,465	19,465
40	Uttara Chemicals	15,599,961	14,975,033
41	Waste Chem International	108,353	108,353
Total		627,414,177	435,570,160

**Deposit against Sales**  
**As at 30th June, 2022**

Schedule-06

SL. No	Name of Customers	Amount in Taka	
		30-Jun-22	30-Jun-21
1	Dohar Chemicals	-	382,747
2	Dhaka Chemicals	-	658,083
Total		-	1,040,830

**WATA CHEMICALS LIMITED**  
**Trade Payables**  
**As at 30th June, 2022**

Schedule-07

Sl. No	Particulars	Amount in Taka	
		30-Jun-22	30-Jun-21
1	Abir Shiping Limited ( C & F )	6,744,407	15,148,259
2	Adarsh Furnace & Refractory Works	-	26,250
3	Amber IT Limited	-	76
4	Arthosuchak . Com	5,000	5,000
5	Bismillah Engineering Workshop	-	64,725
6	Bismillah Enterprise	-	31,858
7	Care Consultant	-	20,000
8	Electromach Engineering	231,880	312,228
9	Executive Technology Solution	-	251,024
10	Inovative Technology International	-	190,000
11	Kazi Enterprise	-	348,215
12	MM Corporation ( C & F )	-	9,216,425
13	Mozid Engineering Workshop	-	260,718
14	M/s. Faiza Thai Glass Center	-	8,412
15	M/s Habib Enterprise	565,000	-
16	M/s Harun Rong Bitan	-	5,500
17	M/s Monowara Enterprise	270,008	
18	M/s Nazrul Enterprise	-	206,300
19	Rongdhonu Industrial Engineering	-	48,000
20	Shawon Engineering	-	346,961
21	Sobuj Enterprise (Tiles Work)	-	11,339
22	Tara Beebi International	397,004	290,960
23	Technomax Engineering	-	132,421
24	Univision Engineering	-	146,000
25	Waterchem Technology	289,442	404,100
26	Water Ion Exchange	-	301,700
<b>Total</b>		<b>8,502,741</b>	<b>27,776,472</b>

**WATA CHEMICALS LIMITED**  
**Advance to Suppliers**  
**As at 30th June, 2022**

**Schedule-08**

Sl. No	Particulars	Amount in Taka	
		30-Jun-22	30-Jun-21
1	Abhishek Engineering & Chemicals	-	29,000
2	Achol Enterprise	-	53,680
3	Aesthetic Engineering Services	60,000	
4	Azmira Enterprise	278,560	
5	Akram Mill Store	2,000,000	2,000,000
6	Ambient Steel Ltd.	2,638,600	
7	Atik Chemicals	2,000,000	
8	BBS Cables Ltd.	138,014	138,014
9	Bengal Interior	1,200,488	1,200,488
10	Binary Kraft	2,951,488	2,951,488
11	BSRM Steel Ltd	1,302,400	1,302,400
12	Daily Share Bazar	12,000	12,000
13	Dhaka Engineering Works (Md. Shihab)	11,755,982	627,982
14	Didar Construction	-	404,500
15	Energytech Power Solution	374,000	374,000
16	Executive Technology Solution	73,962	-
17	F. Rahman Construction ( Fazlur Rahman )	12,721,566	8,431,566
18	Jahangir Stone Corporation Ltd.	-	520,000
19	Jamuna Trading Corporation	5,123,996	1,068,216
20	Kazi Enterprise	234,785	-
21	Khakan SS & Thai Glass	200,000	-
22	Md. Marwar Eha Hashem (F. Beautification Work)	50,000	50,000
23	Marvelous IT	15,000	
24	Md.Mojnu (Tree Plantation Work)	211,700	211,700
25	Md. Najmul (Sanitary Engr.)	-	18,000
26	Md. Rezaul Karim (Turbine Consultant)	-	150,000
27	Meghna Seeds Crushing Mills Ltd.	-	802,000
28	MM Corporation ( C & F )	313,066	
29	M/s. Amzad & Brothers	938,470	938,470
30	M/s Fahim Transport Agency	676,524	1,000,882
31	M/s. Joynal & Sons	837,750	487,750
32	M/s. LRD Enterprise	2,326,400	447,100
33	M/s. Moklesur Rahman & Brothers	1,825,700	1,825,700
34	M/s Nizam Enterprise	535,400	
35	M/s Noor Enterprise	1,933,275	
36	M/S Reza Construction	831,000	
37	M/S Shawon Enterprise	-	410,000
38	M/s. Sohel & Brothers (Pipe House)	720,000	
39	National Tradings.	333,300	333,300
40	New Boiler Museum	645,300	645,300
41	New Progaty Iron Traders	779,618	779,618
42	Nis Chemical	9,252,261	117,166,261
43	Nitol Motors Limited	300,000	300,000
44	Omad International	200,000	200,000
45	Pran RFL Group	140,000	20,000
46	Rajshahi Travels & Tours	352,000	-
47	Rangs Workshop Limited.	22,317	22,317
48	Rooftec Trade	6,767,811	5,747,241
49	Rudro International	225,000	225,000
50	Ruhul Amin / Contractor	2,956,800	2,956,800
51	S A Marine Collection	430,000	430,000
52	Serve & Solve Corporation	269,554	269,554
53	Shorifuddin ( Pond Digging )	201,000	201,000
54	Sino Well Sailing Chemical Co. (BD) Ltd.	4,144,140	4,144,140
55	Soudi Radiator Engineering Works	170,000	170,000
56	Technaf Engineering Pvt. Limited.	-	186,000
57	Technomax Engineering	150,000	
58	Turbo Technology Ltd.	981,500	831,500
59	Water Ion Exchange	116,300	
60	Unique Cement Industries Ltd.	3,872,000	
61	Uttara Creadoor	52,000	52,000
Total		86,641,028	160,134,967

**WATA CHEMICALS LIMITED**  
**Calculation of Deferred Tax Liability**  
**For the Year Ended 30th June 2022**

Schedule-09

**(a) Carrying amount at Balance Sheet date**

i) **Carrying Cost of Fixed Assets-WDV (Net of Land Value & Revaluation increase):**

Particulars	Amount in Taka			
	30-Jun-22	30-Jun-21	30-Jun-20	30-Jun-19
Written Down Value (As per Schedule-1)	896,188,486	943,466,378	997,117,967	1,049,091,731
<b>Less: Revaluation Increase</b>	<b>318,010,817</b>	<b>322,098,567</b>	<b>407,814,137</b>	<b>407,814,137</b>
Plant & Machinery Increase	353,253,863	353,253,863	353,253,863	353,253,863
Factory Building Increase	54,663,662	54,663,662	54,663,662	54,663,662
Other Assets Value (Decrease)	-	-	(103,388)	(103,388)
Less: Depreciation of Revaluation	(89,906,708)	(85,818,958)	-	-
	<b>578,177,668</b>	<b>621,367,811</b>	<b>589,303,830</b>	<b>641,277,594</b>
Less: Land Value	(106,402,620)	(106,402,620)	(106,402,620)	(106,402,620)
<b>Net WDV (Except Land Value &amp; Revaluation)</b>	<b>471,775,048</b>	<b>514,965,191</b>	<b>482,901,210</b>	<b>534,874,974</b>
ii) <b>Carrying value of Right-of-use (ROU) asset</b>	<b>5,390,830</b>	<b>6,160,950</b>	<b>6,931,070</b>	-
iii) <b>Carrying value of Lease Obligation</b>	(4,313,861)	(5,164,503)	(5,189,269)	-
<b>Total Carrying value at Balance Sheet date (i+ii+iii)</b>	<b>472,852,017</b>	<b>515,961,639</b>	<b>484,643,011</b>	<b>534,874,974</b>

**(b) Carrying amount as Tax Base**

**Tax Based Fixed Assets-WDV as on 30th June 2022**

**As per Tax Depreciation Schedule as shown below (Including addition during year):**

Particulars	Amount in Taka			
	30-Jun-22	30-Jun-21	30-Jun-20	30-Jun-19
Plant & Machinery	162,914,507	202,900,594	251,546,743	313,624,364
Factory Building	78,469,561	98,086,951	122,608,689	153,141,811
Motor Vehicle & Bi-cycle	5,965,999	7,457,499	12,056,357	12,309,082
Furniture & Fixture	3,339,230	3,664,056	3,902,123	2,080,180
Office Equipment (including computer)	5,255,651	4,975,988	4,815,743	4,258,885
Laboratory Equipment	415,708	443,868	522,198	614,350
Generator	18,508	23,135	28,919	36,149
	<b>256,379,164</b>	<b>317,552,091</b>	<b>395,480,771</b>	<b>486,064,821</b>
(c) <b>Temporary Taxable Difference (a-b)</b>	<b>216,472,853</b>	<b>198,409,548</b>	<b>89,162,240</b>	<b>48,810,153</b>
(d) <b>Deferred Tax Liability on Temporary Taxable Difference (C*22.5%)</b>	<b>48,706,392</b>	<b>44,642,148</b>	<b>22,290,560</b>	<b>12,202,538</b>
(e) <b>Deferred Tax Recognised on Depreciation of Revaluation Charged for the Period @22.5% (Schedule-10)</b>	<b>1,226,325</b>	<b>1,340,484</b>	<b>1,629,072</b>	<b>1,782,873</b>
(f) <b>Deferred Tax Liability as on 30th June' 2022 (d+e)</b>	<b>49,932,717</b>	<b>45,982,632</b>	<b>23,919,632</b>	<b>13,985,411</b>

**Computation of Tax Based WDV of Fixed Assets**  
**As on 30th June 2022 (As per 3rd Schedule of ITO, 1984)**  
**Assessment Year-2022-2023**

Description of Assets	Opening WDV as on 1-Jul-21	Addition during the year	Total	Rate of Dep.	Depreciation for the period	Closing WDV
						30-Jun-22
Plant & Machinery	202,900,594	742,540	203,643,134	20%	40,728,627	162,914,507
Factory Building	98,086,951	-	98,086,951	20%	19,617,390	78,469,561
Motor Vehicles & Bi-Cycle	7,457,499	-	7,457,499	20%	1,491,500	5,965,999
Furniture & Fixture	3,664,056	46,200	3,710,256	10%	371,026	3,339,230
Office Equipment (Including Computer)	4,975,988	863,624	5,839,612	10%	583,961	5,255,651
Laboratory Equipment	443,868	45,200	489,068	15%	73,360	415,708
Generator	23,135	-	23,135	20%	4,627	18,508
<b>Total</b>	<b>317,552,091</b>	<b>1,697,564</b>	<b>319,249,655</b>		<b>62,870,491</b>	<b>256,379,164</b>

**WATA CHEMICALS LIMITED**  
**Depreciation Adjustment with Revaluation Reserve**

Schedule-10

Particulars	Plant & Machinery	Factory Building	Total
<b>Revaluation Increase</b>	353,253,863	54,663,662	407,917,525
<b>Depreciation Charged on Revaluation Increase</b>	102,453,863	54,663,662	157,117,525
<b>Rate of Depreciation</b>	<b>10%</b>	<b>5%</b>	
For the Year 31.12.2012	10,245,386	2,733,183	12,978,569
For the Year 31.12.2013	9,220,848	2,596,524	11,817,372
For the Year 31.12.2014	8,298,763	2,466,698	10,765,461
For the Year 31.12.2015	7,468,887	2,343,323	9,812,209
For the Period 30.06.2016 (6 Months)	3,360,999	1,113,097	4,474,096
For the Year 30.06.2017	6,385,899	2,170,542	8,556,441
For the Year 30.06.2018	5,747,308	2,062,015	7,809,323
For the Year 30.06.2019	5,172,577	1,958,914	7,131,491
For the Year 30.06.2020	4,655,320	1,860,968	6,516,288
For the Year 30.06.2021	4,189,788	1,767,920	5,957,708
For the Year 30.06.2022	3,770,809	1,679,524	5,450,333

- (a) Depreciation on Plant & Machinery had been charged on partial revaluation increase amounting to Tk. 102,453,863 against total revaluation increase of Tk. 353,253,863 which is equal to 29% of total revaluation increase on Plant & Machinery value.
- (b) Adjustment in respect of depreciation on revaluation increase for the year 2021-2022 for total amount of Tk.5,450,333/- had been made through "**Change in Equity Statement**".

**WATA CHEMICALS LIMITED**  
**Statement of Yearwise Unclaimed Dividend Account**

Schedule-11

SL No.	Year of Dividend	Amount of Taka		
		Demat	Non Demat	Total
		Schedule-11 (A)	Schedule-11 (B)	
1	Dividend Year - 2010	-	73,626	73,626
2	Dividend Year - 2011	9,480	88,352	97,832
3	Dividend Year - 2014	19,856	57,428	77,284
4	Dividend Year - 2015 -2016	18,961	143,571	162,532
5	Dividend Year - 2016 -2017	76,760	157,928	234,688
6	Dividend Year - 2017 -2018	93,532	159,757	253,290
7	Dividend Year - 2018 -2019	59,834	618,661	678,495
8	Dividend Year - 2019 -2020	63,365	902,213	965,578
9	Dividend Year - 2020 -2021	76,131	774,619	850,750
Subtotal (A)		417,919	2,976,155	3,394,074

**Yearwise Statement of Transfer to ICB**

SL No.	Year of Dividend	Amount of Taka		
		Demat	Non Demat	Total
		Schedule-11 (A)	Schedule-11 (B)	
1	Dividend Year - 2010		73,550	73,550
2	Dividend Year - 2011	9,480	88,260	97,740
3	Dividend Year - 2014	19,856	57,369	77,225
4	Dividend Year - 2015 -2016	18,961	143,423	162,384
5	Dividend Year - 2016 -2017	76,760	157,765	234,525
Unclaimed Dividend Transferred Subtotal (B)				645,423
Less: TDS on Dividend				(94,973)
Unclaimed Dividend Account Net Transferred Subtotal (A)				550,450
Unclaimed Dividend Account Balance (A-B) = C				2,748,651

**WATA CHEMICALS LTD**  
**Statement of Yearwise Unclaimed Dividend Account (Demat)**

Schedule-11 (A)

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
<b>Dividend Year - 2010</b>			
1	115	MR. MAHMUDUL KARIM	600.00
2	929	MR. ANWAR HOSSAIN	240.00
3	947	MR. MD. NURUL ISLAM	600.00
4	1268	BRIG(RTD) A.S. MAHMUD	300.00
5	1340	MRS LAILA AZAD	960.00
6	1466	MR. ZAFRUL HASSAN	900.00
7	1839	MR. SANJIB KUMAR SARKER	240.00
8	1867	MR. MOHAMMAD MOFAZZAL HOSSAIN	240.00
9	2031	MR. SK. TOWHIDUL ISLAM	540.00
10	2053	MR. KAZI EYEAR AHAMED	300.00
11	2059	DR. MD. REZAUL ISLAM	60.00
12	2492	MRS MOMATAZ BEGUM	600.00
13	2526	MRS. SHAMIM RRA BEGUM	480.00
14	2527	MRS. HOSNE ARA BEGUM	480.00
15	2531	MR. MD. TALIBUR RAHMAN	300.00
16	2628	MR. MD. ABDUL HANNAN	300.00
17	2894	M/S GRAMEEN SECURITIES MANAGEMENT LTD	240.00
18	3060	MRS RANA DEY & LINA DEY	60.00
19	3130	MR. SUKUMAR SAHA & DEEPTI SAHA	240.00
20	3309	MRS ROKEYA MUSTAFA	1,200.00
21	3899	MR. SIRAJUL ISLAM	60.00
22	4052	MR. ABM TAJ RIFAT RAHMAN	60.00
23	4054	MR. ABM ZIAUR RAHMAN SIDDIQUE	120.00
24	4055	MRS KAMRUN NAHAR ZIA	60.00
25	1416	MR. ANWAR HOSSAIN	300.00
<b>Dividend Year - 2010 Total</b>			<b>9,480.00</b>
<b>Dividend Year - 2014</b>			
1	1201510014710691	MD. KAMRUZZAMAN	50.00
2	1201510021598012	MD. JAHIRUL ISLAM	400.00
3	1201560041126772	SYED ALMAMUN FERDOUS	250.00
4	1201580004127538	MONZURUL HAQ SHOAIB	145.00
5	1203020028523450	HOSNE ARA BEGUM	300.00
6	1201590050426375	MD. ASLAM DEWAN	50.00
7	1201590051862887	SHAMIMA NASRIN	50.00
8	1203020029935552	MD. MATIOR RAHMAN	150.00
9	1201630045555367	MD. MOSHIN BHUIYAN	150.00
10	1201640016732895	MD. MONIRUZZAMAN	130.00
11	1203260035235210	ANWAR HOSSAIN	200.00
12	1201720005541440	MD. ROWNOK HOSSAIN	200.00
13	1203040039208129	MD. MOBARAK MIAH	250.00
14	1201770004506089	MD. REFAUL HAQUE	156.00
15	1201920003792892	MD. REZAUL HOQUE	156.00
16	1201920004180382	MD. KHORSHID ALAM	78.00
17	1201920016544249	MD. SIRAJUL HAQUE	500.00
18	1202000000510321	MR. TUHIN SAHA	200.00
19	1202000000746831	SYED AZIZUDDIN HOSSAIN	390.00
20	1202030051416940	MD. SAIFUL ALAM	200.00
21	1202050014238609	MD. ISMAIL HOSSAIN	620.00
22	1202090052018791	REZZAUL HASSAN BHUIYAN	500.00
23	1202150034889796	MRS. TAHMINA KHATUN	200.00
24	1202160026345022	A.K.M SHAKHAWAT HOSSAIN	500.00
25	1201530051727223	SAMIR KUMAR DAS	500.00
26	1202400021519308	TARIQUL AHAMMED	500.00
27	1202450049443661	MD. NAZIB MAHMUD SHAJIB	700.00
28	1202550034335073	MD. KHAIRUZZAMAN BARBHUIYAN	337.50
29	1202630034422084	MOHAMMED ALAM	400.00

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
30	1202790004130279	KAZI TOHIDUL ISLAM	430.00
31	1202800033993929	SABITA MAJUMDER	50.00
32	1202820001863729	MD. MASUD ALI KHAN	250.00
33	1202820005793012	EMRAN ALI MUNSHI	162.50
34	1202820055023821	MD. NAZMUL HAQUE	405.00
35	1202830012300560	MD. ALI AKBAR	200.00
36	1202830036339521	MOHAMMED HEDAYET ULLA	200.00
37	1202890055939133	TASMIN HAQUE	150.00
38	1202980004963993	MD. SAYED AHMED	200.00
39	1203020021006566	ASHIS KUMAR SARKER	120.00
40	1203020033812170	KAMRUN NAHAR	120.00
41	1203110027165487	MD. NASIR HOSSAIN (RIAZ)	150.00
42	120318000218186	MOHAMMAD HABIB ISMAIL BHUIYAN	500.00
43	1203180026465676	MUNSHI MOSHIUR RAHMAN	250.00
44	1203250009640481	MD. GOLAM MUSTAFA PATWARY	250.00
45	1203280024343477	MD. SAIFUL ISLAM	800.00
46	1203410004962541	MOHAMMAD SK.SALIM	300.00
47	1203490040399606	MD AMJAD HOSSAIN MOJUMDER	300.00
48	1203510040303421	SONIA PARVIN	500.00
49	1203650011829016	MD. TASIN KADIR	500.00
50	1203680020541138	MD. SAIFUL ISLAM	600.00
51	1203880028619778	SYED A.K.M SALIM	1,000.00
52	1204310032213428	MD ANWAR HUSSAIN	500.00
53	1204310044231270	BADRUN NAHAR JOLLY	200.00
54	1204490033483479	KHAIRUNESSA AHMED	150.00
55	1205790056101973	MD. MIZANUR RAHMAN	700.00
56	1202030039342132	LAILA AKTER	150.00
57	1202320004124237	SUKUMAR SAHA	156.00
58	1202380015314652	MD. MUZIBUR RAHMAN	156.00
59	1202410041024124	MD. SERAZUL ISLAM	130.00
60	1202060021112783	MD. NAZMUL HUDA	303.50
61	1203630043576651	HASINA ZAHAN	805.00
62	1204490038099344	MD. HAFIJUR RAHAMAN	365.00
63	1203680056604220	BISHWAJIT PAUL	425.00
64	1203140005122842	FIROZ AHAMED	26.00
65	1203730055704503	SHIRIN AKTER	89.00
Dividend Year - 2014 Total			19,855.50

**Dividend Year - 2015 -2016**

1	1202280031977251	SUMAN SAHA	10.00
2	1202060022072884	MD. JAHIR UDDIN MALLICK	250.10
3	1202020000276552	MR. TAPAN CHANDRA BHOWMIK	202.14
4	1202030017628510	M. ANISUR RAHMAN RAJIB	32.04
5	1202160015301686	MOSAMMATH ANJUMANARA BEGUM	128.16
6	1202140016197110	HASAN MD. SHAHARIAR ALAM	32.04
7	1202150000883541	MD. SHAHJAHAN KAZI	30.00
8	1202090000370235	MR MD RUHUL AMIN	400.00
9	1202090006416897	MRS JENY HAZRA	90.10
10	1202090033242807	S.M. HABIBUL HASAN	20.00
11	1202140021332940	MD. AMJAD HOSSAIN KHAN SOHEL	96.12
12	1202140000222060	MR. ABUL BASHER KHAN	202.14
13	1202820001358022	PILOO MIAH	390.00
14	1202720027309786	EXCELLENT INVESTMENT LTD.	180.10
15	1202840004183774	MD. ABUL HASHAM	202.14
16	1201510014710691	MD. KAMRUZZAMAN	200.10
17	1202200032506780	MD. SAIFUL ISLAM	80.10
18	1202250021689238	MR. BADAL CHANDRA BHADRA	90.10
19	1202200010746881	KAMRUN NAHAR	210.10
20	1202370025689468	MOUSUMI JASMIN	242.14
21	1202320004124327	SUKUMAR SAHA	390.00
22	1202370009654541	PARVIN SULTANA	500.00
23	1202160014856756	UMA RANI DAS	390.00
24	1204490044971698	MD. SHAH ALAM	330.00

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
25	1203500030291431	MD. IMRAN SHARIF	210.00
26	1203730059169358	SHASAN BARUA	30.00
27	1203610019206904	BIPLOB KUMAR BISWAS	224.18
28	1203650042930417	ALAMGIR	60.00
29	1203020034742759	MD. MAMUN	210.00
30	1203210021482164	MD. HABIBUR RAHMAN MOLLA	260.10
31	1203630055342568	MD. NURUS SALAM	170.00
32	1203630055343024	MD. NURUS SALAM	100.00
33	1203520010424504	MD. FAYSAL	250.00
34	1203450004122139	MD. RASED ALI	300.10
35	1203410044843426	ANOWER ALI	500.00
36	1202800033993953	HAZERA KHATUN	488.16
37	1202640004301300	BILKIS AKTER	1,350.00
38	1203270013245461	MD. DAIN ISLAM	100.00
39	1203280048614271	MD. ARIF BILLAH	500.00
40	1203040040294561	MS. NASIMA AKTER	272.14
41	1203040048604887	SUNZEDA SULTANA	930.00
42	1203060008131578	RASHID IQBAL	200.00
43	1203080001334260	ME. ASADUZZAMAN TALUKDER	550.00
44	1201580018634032	MR. MASUDUZZAMAN	300.00
45	1201900046492328	MD. KAMAL KHAN	450.00
46	1202000000030326	MR. KAZI SHAHIDUL ISLAM	250.00
47	1201890061184321	MD. YONUS MIA	32.04
48	1201900000105976	PRODIP KUMAR DAS	10.00
49	1202020000451453	MR MD YEASIN MOLLA	500.00
50	1201560000768916	HASIN AHMED	592.14
51	1201480026343074	DELOWAR HOSSAIN	532.14
52	1201850020959682	MR MD. ARIF	700.10
53	1204760020513691	SYED ABDUL NOOR	550.00
54	1202270049765251	BEAUTY AHMED	200.00
55	1201640000137356	MOSADDEQUL HUQ	500.00
56	1201480020672759	KAZI ABUL KASHEM	1,000.00
57	1201940041253327	MD. SHAHABUDDIN	250.00
58	1203670060527870	HARU LAL DAS	400.00
59	1203350001131152	AZAD RAHMAN KHAN	390.00
60	1202630017977283	MD. EYASHIR ARAFAT	50.00
61	1202820000193584	MURAD ALI KHAN	322.04
62	1203680059822716	MOHAMMAD HOSSEN	260.10
63	1202420025474289	MD. MASUDUR RAHMAN	100.00
64	1202420025474297	MD. MASUDUR RAHMAN	40.00
65	1202840041494991	NIGAR SULTANA	50.00
66	1203520058588136	SHAH MUNTASIR MAMUN	80.00

Dividend Year - 2015 -2016 Total

18,961

**Dividend Year - 2016 -2017**

1	1201470000429811	MD. MOHIBUL ISLAM CHOWDHURY	223.38
2	1201470038352716	MD. SHAJAHAN MIAH	83.38
3	1201510009709592	MD. FIRDOUS ALAM	603.38
4	1201510023333625	MD. MAHBUBUR RAHMAN POLASH	1,000.00
5	1201540023371081	SHAH MOHAMMAD IBRAHIM	163.38
6	1201580004093403	MD. FARID UDDIN	60.00
7	1201720004510758	MD. ELIAS	2,500.00
8	1201770003494098	2046 - MD. ANWAR HOSSAIN	343.38
9	1202050001719501	MR. MD. MAHFUZUR RAHMAN BHUIYAN	1,601.65
10	1202080016703044	MD. TAZ UDDIN	200.15
11	1202160017261331	MD. MAHABUBUR RAHMAN	360.00
12	1202450000749908	MOKHLES ALAM	100.00
13	1202580032662095	ZIAUL ASHRAF	481.50
14	1202640011144253	M. BAZLUR RASHID	342.70
15	120287000093671	MAKSUD OMAR	201.80
16	1203040035532558	MD. JAHANGIR ALAM NASIM	1,000.00
17	1203100045440850	MD. ASHRAFUL ISLAM	40.45
18	1203140040410212	MRS. SHARDA ZAMAN	100.00
19	1203370005242561	MD. ELIAS	2,200.00

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
20	1203510015413164	MOHAMMAD ABDUR ROB	222.25
21	1203680043602101	KHONDOKER FARID HASSAN	1,000.00
22	1203880016928552	HENRY BOWER	2,102.70
23	1203880030410709	BILKIS BEGUM PARUL	1,900.00
24	1203880035355813	RASMA BEGUM	2,000.00
25	1204090032342239	ABURI INTERNATIONAL	4,581.50
26	1204430022313969	SUSHANTA BANIK	100.00
27	1204500044710328	MST. NURUNNAHAR	320.00
28	1204880051582393	MD. KAMRUZZAMAN MASUM	900.00
29	1205780040480537	RIAZ UDDIN AHMED	80.00
30	1205780062840091	MR. ASADUZZAMAN	1,000.00
31	1301020000991905	RUPALI BANK LTD. F. EX.CORP.BR.	7,021.80
32	1605310047501168	SUSPENSE ACCOUNT BONUS SHR	7,021.80
33	1201720016118034	DR.MD.SHAMSUL ALAM	279.00
34	1201720019673740	MD.ABDUR RASHID	218.10
35	1201720026263107	MD.ABU HANIF	200.00
36	1201720026537601	MD.ABU HANIF	393.00
37	1201720029919275	HASINA AKTER	300.00
38	1201720039377129	SURAIYA AKTER	1,000.00
39	1201720053881433	MD. GOLAM SAROAR	1,000.00
40	1201720054888263	TASLIMA HAQUE	151.00
41	1201720062992992	SWAPAN KUMAR PAUL	662.00
42	120173000096766	MR SK. FAZLUL KARIM	173.00
43	1201730001138526	MR.MOHAMMAD JAHIRUL QUAYUM.	547.00
44	1201730001138550	MR.RASHEDUL QUAYUM.	1,095.00
45	1201730045715702	MD.ALAMGIR HOSSEN	202.00
46	1201730053847605	SYED MOKBUL AHMED	345.00
47	1201730061373477	MD ZAKIR HOSSAIN	6,420.00
48	1201730062365545	MD.SHAHID MIA	70.75
49	1201740021933409	DR.MD.GIASH UDDIN	499.00
50	1201740040197270	GOL AFROZ BEGUM	300.00
51	1201740049177917	MD. ABDUR ROB JOMADDER	6,691.00
52	1201740062593272	MD.SHAHEENUR REZA TALUKDER	540.00
53	1201740063021086	ADNAN FORHAD	1,342.00
54	1201750000136054	MD. AMIRUL ISLAM	382.00
55	1201770004506089	3003 - MD. REFAUL HAQUE	547.00
56	1201770045625821	12335-MODON KUMAR SHEN	2,482.00
57	1201810000020139	AHMED MAHMUDUR RAHMAN KHAN	28.30
58	1201810000024137	S.M. ABU HASSAN	1,095.00
59	1201810005247190	MOSHER REF HOSSAIN BHUIYAN	1,229.80
60	1201810018456965	SHARMIN NAHAR	7,400.00
61	1201820015772793	MD.ELIAS	572.00
62	1201820025691931	MAHMUD HASSAN	470.00
63	1202010041752355	MD. KAMRUZZAMAN	60.00
64	1202030045726506	MOHAMMAD SAFIQU RAHMAN	20.00
65	1202080056428649	MD. BILLAL HOSSAIN	90.75
66	1202090000596748	M.A KAMAL UDDIN	100.00

Dividend Year - 2016 -2017 Total

76,760

**Dividend Year - 2017 -2018**

1	1201480003801374	MD. ABDUL MOIEZ	800.00
2	1201510009928150	TAPAN CHANDRA MALLIK	100.00
3	1201530037652758	UMME AMARA SHATHI	890.00
4	1201530064669531	MD. JAHID HOSSAIN	200.00
5	1201540062892659	MD.MASUM	50.00
6	1201540064004962	HASIB AHMED	50.00
7	1201540064677016	ARPITA BARUA	50.00
8	1201560000014437	MUSFIQUR RAHMAN	400.00
9	1201560017562958	MD. FAZLUL HAQUE	100.00
10	1201560043472526	MD.AMIR HOSSAIN	100.00
11	1201570000158687	NASREEN JAHAN	570.00
12	1201570010363026	MOMTAZ BEGUM	10.00
13	1201570010346068	MOMTAJ BEGUM	10.00

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
14	120158000054883	MR. MD. BAZLUR RAHMAN	10.00
15	1201580000332567	MR. MOHAMMAD ABDUL AZIZ	182.00
16	1201580000332947	MRS.RAHMAT-A-KHODA	450.00
17	1201580007732987	MD ZAHID HOSSAIN	98.00
18	1201580007732995	MD ZAHID HOSSAIN	98.00
19	1201580020961361	MRS.MAHTABA HASAN	1,000.00
20	1201580023349051	KHANDOKER AHSAN HABIB	456.00
21	1201580026277956	MD. ABDUS SALAM FARAZI	260.00
22	1201580036213002	ENAETH HOSSAIN	250.00
23	1201580038401462	MD. AKRAM ULLAH KHAN	60.00
24	1201580039363404	SUMAN HOSSAIN	490.00
25	1201580062031686	H.M.ELIUS ASHMOAL	250.00
26	1201580066432920	MD.MAMUNUR RASHID	190.00
27	1201590000369022	MR. SUDHIR KUMAR ROY	100.00
28	1201590018577968	MOHAMMED MAHABUBUR RAHMAN	314.00
29	1201590018643591	SABERA BEGUM	1,000.00
30	1201590019495019	SUKDEB BANIK	1,000.00
31	1201590020610028	MD SHAH ALAM SIDDIQUE	900.00
32	1201590021784370	MD BELAL HOSSAIN	100.00
33	1201590024920695	MD. ATIKUR RAHMAN	1,160.00
34	1201590025249373	BIDDUT DEY	350.00
35	1201590026014084	MD. ISTIAK ALAM	50.00
36	1201590033204253	MD. ARMAN ALI	10.00
37	1201590033438087	KAZI MOHAMMED JASHIM UDDIN	310.00
38	1201590034088717	MD. BAHAUDDIN FAHIM	200.00
39	1201590060549478	JAMIUL ISLAM BISWAS	240.00
40	1201590062893711	PRITHWI RAJ ACHARJEE	1,000.00
41	1201600021440356	KAMRUN NAHAR	350.00
42	1201630020517612	MD. KAMRUL ISLAM	500.00
43	1201630048600000	SIDDIQUE HOSSAIN	120.00
44	1201630051692097	KOHINOOR AKTER	200.00
45	1201630053351251	NAYAR SULTANA	200.00
46	1201690012317163	MD.ABDULLAHEL KAFI	100.00
47	1201700005866168	MITRA BHATTACHARJEE	370.00
48	1201700042343143	BONY ISRAEL	200.00
49	1201700058109210	MD. IQBAL HASAN	100.00
50	1201700062425368	MOHAMMED MOSLEM MIAZI	100.00
51	1201700067099974	MD. SHAHNEWAZ ISLAM	10.00
52	1201710000920918	MD. SALEH ABDULLAH	450.00
53	1201710002551632	ABU BAKER SIDDIQUE	100.00
54	1201710018121512	MD. ABDUR RAZZAQUE	300.00
55	1201710029114521	MD. DIDARUL ALAM	600.00
56	1201720020177796	KAZI SAIDUL HAQUE	300.00
57	1201720027179367	MD.ABDULLAH	50.00
58	1201720039377129	SURAIYA AKTER	50.00
59	1201730000017093	MD. AMDADUL HAQUE	270.00
60	1201730040440166	SHAH MD. MAMUN-OR-RASHID	50.00
61	1201730058783794	SHAH MD.MAMON OR RASHID	150.00
62	1201740016764208	SHAHIDA AFROZ	1,000.00
63	1201740020688771	K.M. ASHADUZZAMAN	1,000.00
64	1201740060729339	TOWFIQUE RAHMAN	800.00
65	1201740060802111	MD. HAMIDUL ISLAM	500.00
66	1201740064858677	ARIFUR RAHMAN	100.00
67	1201770003494098	2046 - MD. ANWAR HOSSAIN	476.00
68	1201810000780617	MD. NASIR UDDIN HOWLADER	200.00
69	1201820006052801	SAIFUDDIN AHMED	1,000.00
70	1201820017388449	JIBAN KRISHNA BHOWMIK	1,000.00
71	1201820018090713	MDNEYAMUL HAQUE	990.00
72	1201820026062113	GOPAL CHANDRA PAUL	260.00
73	1201820026698248	SHEIKH MD. SARWAR HOSSAIN	1,000.00
74	1201820028183658	MD. FARUQL ALAM BHUIYAN	750.00

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
75	1201820030364311	ABU NAHID EBNE HASHEM RIAN	1,000.00
76	1201820030813948	ABU NAHID EBNE HASHEM RIAN	1,086.00
77	1201820032307928	ANUP KANTI DAS	100.00
78	1201820042281166	MD.KUTUB UDDIN	300.00
79	1201820044758208	MD. ABU TAREQ	830.00
80	1201820045605281	MD. ABDUS SATTAR	100.00
81	1201820049696345	SHANKAR CHADRA ROY	900.00
82	1201820051704431	S.M ABU SAYEM HIMEL	100.00
83	1201820052500644	COMPUTER NETWORK SYSTEMS LTD.	270.00
84	1201820052929992	MOHAMMAD BORHAN UDDIN	239.25
85	1201820053315962	JASIM MOHAMMAD	400.00
86	1201820062543763	MOHAMMAD SARWAR ALAM	100.00
87	1201820062549637	SIDDIQUR RAHMAN	1,000.00
88	1201820062756598	MD. ABUL MOHSIN	100.00
89	1201820062771407	MEER MONIRUZZAMAN	300.00
90	1201820062962733	MD HUMAYUN KOBIR SHAHEEN	282.00
91	1201900021292851	K.B. AZGAR AHMED	200.00
92	1201900046492328	MD. KAMAL KHAN	94.00
93	1201910063653948	MIR ASRAFUL ISLAM	480.00
94	1201910064124208	MD. SHAHADAT HOSEN	10.00
95	1201910067068140	SYED IMRAN AHMED	230.00
96	1201920064421727	PANKAJ ROY CHOWDHURY	550.00
97	1201930062731574	ISHTIAQ HYDER KHAN	100.00
98	1201940016242123	DEWAN MUHTANEK FAHIM	240.00
99	1201940034093871	SHETOL IGNATIOUS GONSALVES	10.00
100	1201940060184726	ASHRAF ALI KHAN	100.00
101	1201950000342151	ABDUS SALAM ARIF	602.00
102	1201950005103818	WORLD. COM LTD.(UNIT-1)	500.00
103	1201950006719859	GAZI MARUF HASAN	100.00
104	1201950007057341	MASUK AHMED PATWARY	50.00
105	1201950011592595	KAZI RAHILA FERDOUSI	350.00
106	1201950011738007	NOORJAHAN BEGUM	190.00
107	1201950062213752	FARUK AHMED	758.00
108	1201950062614114	MD. IBRAHIM HOSSAIN	200.00
109	1201950062708566	ABUL KASEM MD ASADUZZAMAN	500.00
110	1201950064814059	KAMAL UDDIN	100.00
111	1201950065364835	ZOHURA KHATUN	500.00
112	1201960003775238	JANNATUL AFROZ	320.00
113	1201960030170059	MD RAKIBUL HASSAN	64.00
114	1201960030330785	MD GIAS UDDIN	270.00
115	1201960039682159	TULSHI CHANDRA SARKER	300.00
116	1201960058567343	PARVIN ISLAM	100.00
117	1201960063836406	GAZI ABUL KASHEM	580.00
118	1201960064482411	MD ABBAS UDDIN	720.00
119	1201960064554397	RAJIB DEB NATH	426.00
120	1201960065371863	MAJUMDER TRADERS	1,080.00
121	1201980001612225	MUKTA AKTER	560.00
122	1201980003833720	MOHAMMAD SHAH ALAM	250.00
123	1201980032144190	FATEMA KHANAM	650.00
124	1201990002305166	FARIDA YASMIN	324.00
125	1202000016415571	S M SHFIQL AMIN FERDAUSI	260.00
126	1202010062981388	SHOPNO BILASH CO-OPERATIVE LTD	100.00
127	1202020017934909	MD.LITON	226.00
128	1202020044604614	KAMOL SARKER	130.00
129	1202020055388473	MD. ABU SUFIAN MOZUMDER	440.00
130	1202020058311101	RASHEDUL ISLAM	100.00
131	1202020058383955	ELMI BINTA SHAWKAT	30.00
132	1202020062579738	KHALED HASAN	80.00
133	1202050010850066	MR. MD. SIDDIQUR RAHMAN	200.00
134	1202050017237104	MD SAMIUL ISLAM	600.00
135	1202060000131086	MD. MUZAMMEL HAQUE	334.00
136	1202060015308447	MD. SALIM MOLLA	300.00
137	1202060015492829	MD. TAYABUR RAHMAN	280.00

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
138	1202060024800710	MD. TAYEBUR RAHMNA	142.00
139	1202060024800729	MST. ROKIYA	284.00
140	1202060063762077	MD. RUBEL HOSSAIN	50.00
141	120209000050601	ADVOCATE S K SEN	284.40
142	1202090006416897	MRS JENY HAZRA	392.00
143	1202090021484751	SM MASUDUL HAQUE	630.00
144	1202090040791291	MR. ABU BAKAR SIDDIK	200.00
145	1202090045220104	MD. MOFAJJAL HOSSAIN	40.00
146	1202090050231231	MUHAMMED SHAMSUDDIN	100.00
147	1202120065940652	MD. SHOHAG	428.00
148	1202130048740849	MD MOKDED MOLLAH	60.00
149	1202140016294592	MD ANWARUL MALEK	600.00
150	1202140055267304	MD. ATIQUR RAHMAN	530.00
151	120215000209662	MR. IFTEKHAR AHMED	54.00
152	1202150006167292	SHEFALI AKTAR	50.00
153	1202150007465550	FABIAN S. GOMES	500.00
154	1202160015955641	K.B AZGAR AHMED	410.00
155	1202160016673729	MD. SYEDUR RAHMAN	10.00
156	1202160062450631	SAYED AHMED KHAN	100.00
157	1202190042843513	KHALEDUN NAHAR	300.00
158	1202190056240071	SHORIFA ISLAM	408.00
159	120220000097265	S M KOWSAR	1,000.00
160	1202200000395216	MD. MOHIUDDIN (MOHIN)	50.00
161	1202200012099772	MUHAMMAD SHOWKAT IMRAN	300.00
162	1202200022402995	MUHAMMAD MIZANUR RAHMAN	280.00
163	1202200023977252	RABEYA KHATUN	110.00
164	1202200062574818	MUHAMMAD ABUL FAZAL SHARKAR	60.00
165	1202210005091829	MIR ASGAR ALI	390.00
166	1202220060635872	SHARIF MUHAMMED FAZLAE ELAHI	1,000.00
167	1202220062018509	MD. HUMAYUN KABIR PATWARY	1,000.00
168	1202240043148895	MUHAMMAD MIZANUR RAHMAN	260.00
169	1202240053836887	MD. ABIDUZZAMAN	100.00
170	1202260016303007	MOSTAFA KAMAL UDDIN	392.00
171	1202280017412966	MD. MASUM KABIR	100.00
172	1201470044290625	MD. AMDADUL HAQUE	100.00
173	1201510040013792	AMINUR RAHMAN	390.72
174	1201510052140119	MR. MD. ABDUL MATIN	425.00
175	1201580000413429	MR. MD. SHAHJAHAN ALI	1,000.00
176	1201590043543150	MOHAMMAD ALI ZINNAH	1,000.00
177	1201590065754527	MD. MONIRUL ISLAM	142.00
178	1201630015273623	MD. MAHBUB MUSA	1,020.00
179	1201710048338977	LEENA SULTANA	654.00
180	120172000010083	S.M. MONIRUZZAMAN	269.00
181	1201730012454807	SAYED JISHAN	100.00
182	1201770004506089	MD. REFAUL FAQUE	450.00
183	1201810000024137	S.M. ABU HASSAN	900.00
184	1201820025958355	MANISHA BANERJEE	929.00
185	1201820028591104	JINNATH ARA	200.00
186	1201820040805587	MD. JALAL HOSSAIN	409.00
187	1201820064727297	HAFIZA BEGUM	849.20
188	1202000016415588	BEGUM HANUFA KHANAM	50.00
189	1202020055363286	H. A. FATTAH	500.00
190	1202030001491280	HANNAN SHIKDER	350.00
191	1202090016909892	MAHAMUDA ANWAR	400.00
192	1202150021893963	MD. ANISUZZAMAN	300.00
193	1202240062726636	AZM OBAIDUR RAHMAN	500.00
194	1202400059020908	MOHAMMAD ALI	54.00
195	1202400059020916	MOHAMMAD ALI	54.00
196	1202400059803098	GOLAM FARUQ CHOWDHURY	294.00
197	1202400060282019	MD. MOSLIM UDDIN	180.00
198	1202400060309399	MASHUKAT TABASSUM	100.00
199	1202400060825912	MST. ZARINA BEGUM	30.00

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
200	1202400062903212	MD. MAHABUBUL ISLAM PATWARY	100.00
201	1202580004121359	ABDUR RAHIM MOLICK	10.00
202	1202620003924269	SHAKWAT HOSSAIN CHOWDHURY	30.00
203	1202830004996822	MS. HELEN IMRAN	10.00
204	1202830049597471	MD. SHAMSUJJAMAN	289.20
205	1202840039367967	DIPU KUMAR BARUA	315.00
206	1202840061199123	MD. SOHEL HOSSAIN	144.00
207	1202850022451475	MOHAMMED MIZANUR RAHMAN	98.00
208	1202960016990217	MUHAMMAD MAKSDUR RAHMAN	120.00
209	1203020054906682	ABDUL OHAB	90.00
210	1203060027285616	MST. MASUM JAHAN	313.04
211	1203060058506931	MD. ABDUL MALAK	1,000.00
212	1203140040932728	SOHEL AHMED	1,085.00
213	1203150031058257	MD HALIM MIAH	259.00
214	1203150043475016	ATAUR RAHMAN	200.00
215	1203180028694524	MD.ARIFUL ISLAM	249.20
216	1203180066038139	SHADMAN SAKIB NOOR	1,000.00
217	1203320007137704	MD. A. KADER	500.00
218	1203360049818881	ABU TAMIM MUHAMMAD JAHIR IMAM	330.00
219	1203510023287254	HOSNEARA BEGUM	104.00
220	1203520010562607	MD. FAZAL AHMED	500.00
221	1203620064808314	SHAHERA BEGUM	461.00
222	1203630019313069	MD. SAIDUR RAHMAN	475.00
223	1203650059460315	YEASMIN SHARMIN	100.00
224	1203730044477621	MD. ABDUL QUADER KHONDAKER	475.00
225	1203780032827144	MD. NUR ISLAM MINAR CHODURI	94.00
226	1203780036007131	MAMUNUR RASHID	200.00
227	1203780044544221	NAZRUL ISLAM RIPON	50.00
228	1203780044601372	ABU FOYEZ	40.00
229	1203810013051230	MD. HANNAN BISWAS	431.00
230	1203940001584652	MR.MOHD ALI XAHANGIR	168.00
231	1204050038831097	MIZANUR RAHMAN	500.00
232	1204070066462823	ABDUR RAB	1,000.00
233	1204220014583322	MD. FARUK HOSSAN	200.00
234	1204220058583117	MOHAMMAD AKRAM HOSSAIN	90.00
235	1204340032171410	MD. NURUL HAQUE	518.00
236	1205690062264788	MD. TANVER AHMED	200.00
237	1205690062655134	MOHAMMAD KAMRUZZAMAN	124.00
238	1601880027509823	MD SADAK AHMED	200.00
239	1602170046045411	A.R. CONSULTATION	255.36
240	1605220046887775	RIL-I/A:R0598	50.00
241	1201540023371081	SHAH MOHAMMAD IBRAHIM	426.60
242	1201540066432757	SALMA BEGUM	70.00
243	1201590046703684	NARGIS AKTHER KHANOM	342.80
244	1201590046703716	MD. REZAUL KARIM	161.40
245	1201820015136905	AHSANUL ALAM	269.00
246	1202080056428649	MD. BILLAL HOSSAIN	400.40
247	1202150000494009	KAMRUN NAHAR	450.00
248	120240000011286	MD.SHAHIDUL ISLAM	600.00
249	1202420038830274	BILLAL HOSSAIN	141.40
250	1202640011144253	M. BAZLUR RASHID	251.40
251	1202850044451976	MOHAMMED BABUL	20.00
252	1203060048514301	HABIB ULLAH	167.60
253	1203110016505517	MD.KHORSHED ALAM DHALI	127.60
254	1203150062820865	MD ABDUR RASHID	250.00
255	1204170028015826	MD.ABUL HASNAT BHUIYAN	1,000.00
256	1204390041516796	SHEIKH MD. KALA MIAH	100.00
257	1204570026085039	HAMIDA BEGUM	191.40
258	1301020025720820	MD. BILLAL HOSSAIN	420.40
259	1602170020158076	ABDUR RAHIM	245.20

Dividend Year - 2017 -2018 Total

93,532.47

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
<b>Dividend Year - 2018 -2019</b>			
1	1201500017673573	MD. NAZIMUDDIN	210.00
2	1201510018278367	MAKHAM CHANDRA GINE	330.00
3	1201510052140119	MR. MD. ABDUL MATIN	279.00
4	1201530000256649	SHARIFUL MOSLEMIN KHAN	1,845.00
5	1201580027132721	MD. BILLAL HOSSAIN	92.55
6	1201580028051016	IFFAT ARA IRIN	546.00
7	1201580028058663	IFFAT ARA IRIN	666.00
8	1201600021885841	AFZAL HOSSAIN	186.00
9	1201700058727100	RAHONUMAYA RAHMAN	954.00
10	120172000010083	S.M. MONIRUZZAMAN	225.00
11	1201720025773881	MD. SHAMAUN ALI	12.00
12	120173000096766	MR SK. FAZLUL KARIM	276.00
13	1201730018669152	JESMIN AKTER	1,110.00
14	1201770004506089	MD. REFAUL HAQUE	1,845.00
15	1201820015136905	AHSANUL ALAM	225.00
16	1201820015355755	GOLAM DASTAGIR	105.00
17	1201820040805587	MD. JALAL HOSSAIN	801.00
18	1201820045585722	MR. PINTU DEY	234.00
19	1201820068186192	MD. ISMAIL	600.00
20	120183000068316	MD. A. AZIZ MIAH	600.00
21	1201830037729695	MD. ASHIK UZZAMAN	300.00
22	1201830039764537	SHUVA DAS	246.00
23	1201840043175462	M MOHIBUR RAHMAN	570.00
24	1201890018214697	MD. ALI AKBAR KHAN	360.00
25	1201890062003335	MOHAMMAD ERFAN UDDIN	210.00
26	1201900025234879	MD. SANOWAR HOSSAIN	102.00
27	1201910062702981	PLACID GOMES	192.00
28	1201950005432329	MD. KAMAL HOSSAIN	102.75
29	1201950046125940	CHANDAN KUMAR KUNDO	270.00
30	1202020020096693	MR AREF BARKAT	600.00
31	1202020021463734	KHOKON CHANDRA DASH	750.00
32	1202020022958847	MUHAMMAD ALAMGIR HOSSAIN	165.00
33	1202080056428649	MD. BILLAL HOSSAIN	189.00
34	1202090016478245	SK. NASIR UDDIN	330.00
35	120212000086916	ASM RUBAIYAT FARMAN	300.00
36	1202120046580424	MST. NAZMA	93.00
37	1202140062434461	SHAHANA BEGUM	510.00
38	1202150000209662	MR. IFTEKHAR AHMED	117.00
39	1202150015007492	MD. SHAHIDUL HASAN	93.00
40	1202240050172710	MOHAMMAD SAIFUR RAHMAN	210.00
41	1202280017884275	ABUL HOSEN	330.00
42	1202400001337320	MOHAMMAD ANSAR UDDIN	750.00
43	1202400019484116	MD LITON AKTER	786.00
44	1202400059020908	MOHAMMAD ALI	117.00
45	1202400059020916	MOHAMMAD ALI	117.00
46	1202400060331252	MD. AWAL BHUIYAN	117.00
47	1202400060337134	MD. AWAL BHUIYAN	117.00
48	1202400061028191	MD. ZAHURUL ISLAM	315.00
49	1202400061028215	CHAMPA BEGUM	303.00
50	1202400068794505	TABUSSUM AKTER	141.00
51	1202420038830274	BILLAL HOSSAIN	93.00
52	1202450018342618	MR. RIZWAN FERDOUS RAHMAN	1,440.00
53	1202450046145043	DAWoudur RAHMAN	600.00
54	1202450053579490	MST. RABEYA KHATUN	93.00
55	1202450053765286	MD. ASHRAFUL ALAM CHOWDHURY	300.00
56	1202460058403331	REAZUL HAQUE	291.00
57	1202580004121359	ABDUR RAHIM MOLICK	185.10
58	1202580015208210	MR. FARID UDDIN AHMED	186.00
59	1202630007871977	REZAUL HAQ	300.00
60	1202640011144253	M. BAZLUR RASHID	432.00
61	1202650035762549	MAHABUB UDDIN AHMED	210.00
62	1202760003928995	MD. SHAMSUZZAMAN	12.00

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
63	1202810004232429	MD. SALIM ULLAH	96.00
64	1202820005793012	EMRAN ALI MUNSHI	93.00
65	1202830004996822	MS. HELEN IMRAN	300.00
66	1202830044722621	MAHADI HASSAN BHUIYAN	900.00
67	1202830054919956	BIPUL KUMAR GOSWAMI	1,230.00
68	1202900000014595	K. J. CHOWDHURY	3,000.00
69	1202950022039879	MD. ABDUL BARI	287.10
70	1203000046244125	MAHFUJA MIZAN	1,590.00
71	1203000054877461	MD ABDUL LATIF	117.00
72	1203010017953165	ABDULLAH-AL- MAMUN	1,467.00
73	1203010019017090	MARY SARKAR	510.00
74	1203020014783940	MONJERA TASMIN	717.00
75	1203060049579292	SHAMIM AHMED	360.00
76	1203110032199786	MD. IBRAHIM KHALIL	117.00
77	1203110048712185	BEAUTI SULTANA	186.00
78	1203120067536701	MD. HAFIZ AHMED	60.00
79	1203150043475016	ATAUR RAHMAN	120.00
80	1203210045516370	MD. ABUL HOSSAIN	300.00
81	1203210048464594	MD. ALAMGIR HOSSAIN	93.00
82	1203210064162810	MD. MOSHIUR RAHMAN MAZUMDER	186.00
83	1203260004150305	ALI KAUSAR MUHAMMAD FIROZ	234.00
84	1203370001145977	MRS. SHAMIMA ALAMGIR	600.00
85	1203370003275438	ZAHIDUL ISLAM	1,500.00
86	1203490062694725	MD. ALI AKBER	750.00
87	1203510007942577	MD. ABDULLAH AL-MAMUN	300.00
88	1203510023287254	HOSNEARA BEGUM	402.00
89	1203570064426449	MONOWARA BEGUM	93.00
90	1203680048779113	MD. MOHI US SUNNAT CHOWDHURY	60.00
91	1203730044477621	MD. ABDUL QUADER KHONDAKER	1,302.00
92	1203730068133151	MD. NURER NOBI	1,500.00
93	1203780041625444	SAMIA FERDOWSI	546.00
94	1203800013052045	MD. ZAKIR HOSSAIN	102.75
95	1203800024282461	ZAKIA SULTANA CHOWDHURY	153.00
96	1203810008459280	MR SHAHJAHAN	287.85
97	1203850060115871	MATIUR RAHMAN KHAN	72.00
98	1203850060117689	MATIUR RAHMAN KHAN	270.00
99	1203940001584652	MR. MOHD ALI XAHANGIR	288.00
100	1204070040489115	RAZU AHAMED	2,400.00
101	1204070067190024	D. M. SAKHAWAT HOSSAIN	2,700.00
102	1204340063406964	MD. MAHMUDUL HAQUE	900.00
103	1204440062111669	MD RASHID AHMED	630.00
104	1204570039437313	MD. SAIFUL ISLAM	180.00
105	1205670019722454	ZAHID MALEQUE	1,890.00
106	1205890068334285	MR. SHAHARIA	1,170.00
107	1301860001230119	MD MODU MIAH	338.85
108	1601880019854440	MD. TAWHIDUL ISLAM	300.00
109	1601880037421042	MD MOGAFFER RAHAMAN	2,049.00
110	1602170000519510	SHAILA RAHMAN	3,000.00

Dividend Year - 2018 -2019 Total **59,833.95**

**Dividend Year - 2019 -2020**

1	1201510033830267	SHAHANAJ AKTER	77.00
2	1201510052140119	MR. MD. ABDUL MATIN	10.50
3	1201510067935022	KAMRUN NAHAR BEGUM	1,750.00
4	1201560015202842	MD. SAIYOD ALI	812.00
5	1201580009232618	FATEMA AKTHER	87.50
6	1201580027132721	MD. BILLAL HOSSAIN	2.97
7	1201600021885841	AFZAL HOSSAIN	35.00
8	1201700052288953	SHIPLU CHANDRA MALAKER	87.50
9	120172000010083	S.M. MONIRUZZAMAN	196.00
10	1201720023285908	RAKHI DAS PURKAYASTHA	1,575.00
11	1201770003494098	2046 - MD. ANWAR HOSSAIN	1,634.50
12	1201780016015821	Md. Faizullah	148.75

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
13	1201820040805587	MD.JALAL HOSSAIN	1,036.00
14	1201820045585722	MR. PINTU DEY	77.00
15	1201870001708063	SAZZADUN NESSA	35.00
16	1201890068096361	KASHFIA JAHAN	35.00
17	1201900025234879	MD. SANOWAR HOSSAIN	157.67
18	1201900037329476	SUJIT CHANDRA SAHA	182.00
19	1201940000174715	MD.HELAL UDDIN	35.00
20	1202020011902527	ABDUL JALIL	52.50
21	1202030039342132	LAILA AKTER	2,625.00
22	1202050000043469	MD. GOLAM MOSTAFA	70.00
23	1202050020751499	MD. MANGAL MIA	175.00
24	1202120046580424	MST. NAZMA	59.50
25	1202130020903986	MD MOHIUDDIN	350.00
26	1202150000209662	MR. IFTEKHAR AHMED	38.50
27	1202150015007492	MD.SHAHIDUL HASAN	3.50
28	1202150018934480	RAJIYA BEGUM	28.00
29	1202250060732813	AMENA BEGUM	280.00
30	1202250060732831	AMENA BEGUM	164.50
31	1202250062283986	SHUBHA MIA	238.00
32	1202260016303007	MOSTAFA KAMAL UDDIN	87.50
33	1202260034212684	NUR MOHAMMAD	350.00
34	1202270042128369	MD HASAN	28.00
35	1202270045467509	MD. SANOWAR HOSSAIN	24.50
36	1202280017884275	ABUL HOSEN	126.00
37	1202320062481363	FAHMIDA PARVIN	28.00
38	1202400000011286	MD.SHAHIDUL ISLAM	227.50
39	1202400020408731	MD. SHAFIQUL ISLAM (BITU)	8,403.50
40	1202400025933837	MD. SAIFUL ISLAM	175.00
41	1202400061028191	MD. ZAHURUL ISLAM	63.00
42	1202400062560161	MD. MOSAROF HOSSEN	154.00
43	1202420038830274	BILLAL HOSSAIN	3.50
44	1202460058403331	REAZUL HAQUE	35.00
45	1202490027037330	BHANU BEGUM	105.00
46	1202530062033337	GAZI TAMIM HOSSAIN	52.50
47	1202550034335073	MD. KHAIRUZZAMAN BARBHUIYAN	350.00
48	1202580035234232	SHAMIM AHMED	525.00
49	1202640011144253	M. BAZLUR RASHID	630.00
50	1202760053740966	SAMIR KUMAR BISWAS	245.00
51	1202820005793012	EMRAN ALI MUNSHI	3.50
52	1202830016163287	MRS. HELANA PARVIN SOOMA	1,050.00
53	1202890026577494	MOHAMMAD ABDUL QUDDUS	787.50
54	1202960066709509	MD. MASUM	1,750.00
55	1203000010714607	MD. ABDUL BATEN MOLLAH	8,596.00
56	1203010019017090	MARY SARKAR	479.50
57	1203020014783940	MONJERA TASMIN	913.50
58	1203040032344270	JALAL UDDIN AHMED	259.00
59	1203060028692964	ONE MUTUAL TRUST (MCS) LTD	7,000.00
60	1203060039783510	MD. MORSHED ALAM	42.00
61	1203110034452292	MD.ABDUL KHALIK	87.50
62	1203110048712185	BEAUTI SULTANA	7.00
63	1203180058528951	MD. ABDUR RAB	70.00
64	1203190020223736	MD. HARUN	70.00
65	1203370000173796	MUNNI BEGUM	700.00
66	1203370003275438	ZAHIDUL ISLAM	2,145.50
67	1203570034090793	MANJUARA AZAD	49.00
68	1203570064426449	MONOWARA BEGUM	3.50
69	1203650059756027	NARGIS LAILA	49.00
70	1203680055257382	NAKIBA SULTANA	560.00
71	1203730044477621	MD. ABDUL QUADER KHONDAKER	1,634.50
72	1203800013052045	MD.ZAKIR HOSSAIN	17.85
73	1203850060115871	MATIUR RAHMAN KHAN	98.00
74	1203850060117689	MATIUR RAHMAN KHAN	129.50

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
75	1203910034764752	WALIUL BARI CHOWDHURY	2,302.65
76	1203940001584652	MR.MOHD ALI XAHANGIR	420.00
77	1203940027369086	RUSDANA BEGUM	969.50
78	1203980039904699	RAZIN IMRAN	35.00
79	1204090029654634	MD. NASIR UDDIN SARDER	17.50
80	1204310027739129	BIKASH CHANDRA CHANDA	17.50
81	1204340063406964	MD. MAHMUDUL HAQUE	1,312.50
82	1204490062192562	TAMIZ UDDIN AHMED	1,158.50
83	1204570039437313	MD. SAIFUL ISLAM	262.50
84	1204570046295284	ABU KHAER	350.00
85	1204820036556967	MD. SAIFUL ISLAM	7.00
86	1205150032410349	A. T. M. SHOEB	175.00
87	1205690000372475	MAJOR TOWHID BIN AHMED	1,249.50
88	1205690055236332	A.F.F.M JAKIR HOSSAIN	164.50
89	1205720058964866	MAHMUDA AKTER	350.00
90	1206000004434111	MAHBUBA AKTER	2,800.00
91	1601880024966171	MOHAMMAD KHORSHED ALAM	252.00
92	1601880043165802	RANJIT PAUL	17.50
93	1602170045260020	SAKHWAT HOSSAIN	105.00
94	1605280067341774	LBIL - L8307	350.00
95	1201820068186192	MD. ISMAIL	175.00
96	1203060005251348	IMTIAZ AHMED	350.00
97	1605170068844082	CBCRL CLIENT A/C- CN242	350.00

Dividend Year - 2019 -2020 Total

63,365.39

Dividend Year - 2020 -2021

1	1201510052140119	MR. MD. ABDUL MATIN	7.65
2	1201560034965232	SHAHNAJ PRAVIN	255.00
3	1201580000037518	MR. SHAKIL AHMED	510.00
4	1201580021169326	TANIA BINTE QURAISHI	12.75
5	1201580021169417	TANIA BINTE QURAISHI	15.30
6	1201580032541258	MD. ASSADUZZAMAN	15.30
7	1201730068497714	SEWLI AKTER	255.00
8	1201820040805587	MD.JALAL HOSSAIN	754.80
9	1201820045585722	MR. PINTU DEY	38.25
10	1201820060708878	AZIM SHAH	75.60
11	1201830048968721	MD. ALI AHSAN	2,700.00
12	1201890068066432	MD.ZUBAER ALAM	25.50
13	1201900025234879	MD. SANOWAR HOSSAIN	84.15
14	1201940059439041	MD. MOZAHIDUL ISLAM	117.30
15	1201950005081955	MD.DELWAR HOSSAIN	7.65
16	1202050000043469	MD. GOLAM MOSTAFA	54.00
17	1202270074019591	MD. YAKUB ALI	765.00
18	1202320062481363	FAHMIDA PARVIN	20.40
19	1202550065445863	MAHBUBA BEGUM	877.50
20	1202720020840902	MD. AMIR HOSSAIN	51.00
21	1202760065100231	FARUK HOSSAIN	38.25
22	1202850012450461	SYEDA SAYELA ASMA	331.50
23	1202850045428753	MD. HABIBUR RAHMAN	252.45
24	1203040032344270	JALAL UDDIN AHMED	188.70
25	1203040042848071	IQBAL AHMED KHAN	387.60
26	1203060028692964	ONE MUTUAL TRUST (MCS) LTD	6,000.00
27	1203110034452292	MD.ABDUL KHALIK	17.85
28	1203110073689003	EBAZAAR ALLIANCE LTD.	684.00
29	1203510023287254	HOSNEARA BEGUM	234.60
30	1203520058400534	MD. KAIRUL	45.90
31	1203520058400542	MOKTER MIA	45.90
32	1203520073800614	EASMIN AKTER	5.10
33	1203520073800705	EASMIN AKTER	5.10
34	1203520073800903	BITI BEGUM	5.10
35	1203520073801199	MD. AYETHULLAH	20.40
36	1203630021248363	MOHAMMAD JAMAL HOSSAIN SHAHJI	2.55
37	1203680037686931	OLI ULLAH	765.00

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
38	1203680038045141	SYED MOHAMMED HOSSAIN	739.50
39	1203680055257382	NAKIBA SULTANA	892.50
40	1203730016095051	MOHD MAZBAH UDDIN AKTHER	51.00
41	1203830037928133	MD. NAJRUL ISLAM	127.50
42	1203880029199274	MAKSUDA AKTER	51.00
43	1204040051011266	ABU TORAB ALI	38.25
44	1204390023243439	MOHAMMAD ABDUL MAZID	25.50
45	1204450073180981	YASIN MIA	188.70
46	1204450073180991	YASIN MIA	188.70
47	1204450073181009	MD.MOHIUDDIN	188.70
48	1204450073181017	MD.MOHIUDDIN	188.70
49	1204450073181025	ABU MOHAMMAD ADNAN	188.70
50	1204450073181033	ABU MOHAMMAD ADNAN	188.70
51	1204450073181068	MD.ABDULLAH AL MAMUN	188.70
52	1204450073181076	MD.ABDULLAH AL MAMUN	188.70
53	1204450073181084	MESKATUL MOSTAFA TAZAL	188.70
54	1204450073181092	MESKATUL MOSTAFA TAZAL	188.70
55	1204450073181108	MOHAMMED TAREK	188.70
56	1204450073181116	MOHAMMED TAREK	188.70
57	1204450073181124	AMIR HOSSAIN	188.70
58	1204450073181132	AMIR HOSSAIN	188.70
59	1204450073181140	MD.IQBAL HOSSAN	188.70
60	1204450073181159	MD.IQBAL HOSSAN	188.70
61	1204450073181167	MD.MILON HOSSEN	188.70
62	1204450073237525	AMINUL ISLAM	188.70
63	1204450073237533	AMINUL ISLAM	188.70
64	1204500065045031	MD. ABU MORSHED KHAN	1,751.85
65	1205210045491819	MRS. POPY CHAKRABORTY	68.85
66	1205300062657521	MD ZOYNAL ABEDIN	2.55
67	1205590058445892	NEWTECH ENTERPRISE LIMITED	32,400.00
68	1601880052725812	MOHAMMAD NAZRUL ISLAM	173.40
69	1601880052725839	MOHAMMAD NAZRUL ISLAM	173.40
70	1201580019898670	MRS NILUFA AKHTER	86.70
71	1201580027132721	MD. BILLAL HOSSAIN	2.55
72	1201590066720588	MOSHARAF HOSSEN	63.75
73	1201590066720761	MOHAMMAD SALA UDDIN	63.75
74	1201590066721186	MOHAMMAD SALA UDDIN	63.75
75	1201590068026631	WAHED MAHBUB CHOWDHURY	63.75
76	1201590068026641	WAHED MAHBUB CHOWDHURY	63.75
77	1201640001226691	NURUN NESSA	67.50
78	120172000010083	S.M. MONIRUZZAMAN	142.80
79	1201770003494098	2046 - MD. ANWAR HOSSAIN	1,190.85
80	1201780016015821	SHAMSU UDDIN	127.50
81	1201820033866231	MD. ABDUL HYE	30.60
82	1201890019855091	MD. ABDUS SALAM	280.50
83	1201900037329476	SUJIT CHANDRA SAHA	5.10
84	1201950006884231	MD. SHAHA ALAM	7.65
85	1201960043538701	MD. ABDUL KAHAR	270.00
86	1202050016091187	MR. MD. TOFAZZAL HOSSAIN	255.00
87	1202060056391041	MD. NUR NABI	107.10
88	1202150018934480	RAJIYA BEGUM	20.40
89	1202400020408731	MD. SHAFIQL ISLAM (BITU)	6,122.55
90	1202420038830274	BILLAL HOSSAIN	2.55
91	1202460058403331	REAZUL HAQUE	43.35
92	1202470019761764	MD. ABDUL QUADER	255.00
93	1202550008822249	MRS. ANJUMAN ARA	2,550.00
94	1202550034335073	MD. KHAIRUZZAMAN BARBHUIYAN	255.00
95	1202550037834551	MD. SHAHROZ ANAM	810.00
96	1202640011144253	M. BAZLUR RASHID	459.00
97	1202650014010402	MD. SAIFUL HOQUE	2.55
98	1202930070399210	FULMATI	25.50

SL No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
99	1202950022039879	MD. ABDUL BARI	132.60
100	1203020014783940	MONJERA TASMIN	665.55
101	1203110041771842	RUMANA RASHID MINA	499.80
102	1203120012307993	MD. SOLAYMAN	12.75
103	1203260019480118	MOHAMMAD SALIM MIA	45.90
104	120337000173796	MUNNI BEGUM	153.00
105	1203460037735471	MONOWARA BEGUM	318.75
106	1203600036922431	TUSHAR AHMED	86.70
107	1203810008459280	MR SHAHJAHAN	20.40
108	1204490062192562	TAMIZ UDDIN AHMED	893.70
109	1204570039437313	MD. SAIFUL ISLAM	150.45
110	1204680045971871	MD. IBRAHIM HOSSAIN	153.00
111	1204690063603778	MD. MASUDUR RAHMAN HOWLADER	550.80
112	1206130000190050	SHIRAN SYLVESTER GOMES	981.75
113	1201580009232618	FATEMA AKTHER	63.75
114	1202820005793012	EMRAN ALI MUNSHI	2.55
115	1605640000242587	MAHMUDA KHATUN	701.25
116	1201950007137811	MOSHA RABEYA AKHTER	612.00
117	1201950007137870	MOSHA RABEYA AKHTER	739.50
118	1202140048766436	FORHAD HOSSAIN MAHMUD	86.70
119	1202850008760815	KHAN MOHAMMAD REZAUL KARIM	2.55
120	1201960020876928	ABU NASER MD. TOHA	66.30
Dividend Year - 2020 -2021 Total			76,131.00

**WATA CHEMICALS LTD**  
**Statement of Yearwise Unclaimed Dividend Account (Non Demat)**

Schedule-11 (B)


SL No.	Folio No.	Name	2010		2011		2014		2015 2016		2016 2017		2017 2018		2018 2019		2019 2020		2020 2021		Amount in Taka	
			2010	2011	2014	2015 2016	2016	2017	2017 2018	2018	2018 2019	2019	2020	2020 2021	2021	2021	2021	2021	2021	2021	2021	2021
1	115	MR. MAHMUDUL KARIM	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
2	164	MR. ABDUS SOBHAN MIAH	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02										
3	203	K.F. CORPORATION (PVT). LTD	17,200.00	20,640.00	13,416.00	33,540.00	36,894.00	38,738.70	151,080.93	220,326	188,851	720,687.15										
4	275	MR. SUMIT RAHMAN	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
5	302	MR. HARJUN-AR-RASHID	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04										
6	318	MR. TAPAN SANKAR HAZRA	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06										
7	319	MRS. JENY HAZRA	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06										
8	322	MOHD. HARISUL HOQUE	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02										
9	316(B)	MRS. HOSSNE ARA BEGUM	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
10	396	MD. DELVAR HOSSAIN BHUIYAN	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
11	537	MR. NAYYAR MIRZA BAIG	1,600.00	1,920.00	1,248.00	3,120.00	3,432.00	3,603.60	14,054.04	20,495	17,568	67,040.67										
12	554	MRS. BITHI RAY	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
13	555	MR. APURBA KUMAR RAY & MRS. BITHI RAY	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
14	558	MOSMUM HABIB CHOWDHURY	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
15	828	MRS. HOSSNE ARA BEGUM	600.00	720.00	468.00	1,170.00	1,287.00	1,351.35	5,270.27	7,686	6,588	25,140.25										
16	829	MR. ANISUR RAHMAN	1,000.00	1,200.00	780.00	1,950.00	2,145.00	2,252.25	8,783.78	12,810	10,980	41,900.42										
17	886	MR. MIRZA ABOO MANSUR	1,000.00	1,200.00	780.00	1,950.00	2,145.00	2,252.25	8,783.78	12,810	10,980	41,900.42										
18	893	MR. ABDUR RAUF & MRS. HIRA	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10										
19	947	MR. MD. NURUL ISLAM	400.00	480.00	312.00	780.00	858.00	900.90	3,513.51	5,124	4,392	16,760.17										
20	954	MR. M. FARHAD HUSSAIN	400.00	480.00	312.00	780.00	858.00	900.90	3,513.51	5,124	4,392	16,760.17										
21	963	MR. SYED WASEQUE MD. ALI	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
22	978	MR. A.B.M. ANWARUL ISLAM	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02										
23	1004	MRS. NAZMA HUQ	400.00	480.00	312.00	780.00	858.00	900.90	3,513.51	5,124	4,392	16,760.17										
24	1045	MRS. SHAMSUN NAHAR RAUF	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02										
25	1046	MR. SIRAJ-UD-DAWLA	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10										
26	1047	MR. NARAYAN CHANDRA SARKAR	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06										
27	1101	MR. MONZURUL HUQ	300.00	360.00	234.00	585.00	643.50	675.68	2,635.13	3,843	3,294	12,570.12										
28	1108	MR. MD. REZWANUL KARIM	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
29	1110	MR. PIJUSH KANTI CHOWDHURY	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10										
30	1158	MR. IMTIAZ AHMED	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04										
31	1167	MR. MD. MOHIUDDIN IA-16411	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02										
32	1198	MR. SHAFI AHMED	2,400.00	2,880.00	1,872.00	4,680.00	5,148.00	5,405.40	21,081.06	30,743	26,351	100,561.00										
33	1202	MRS. JASMIN AHMED	1,400.00	1,680.00	1,092.00	2,730.00	3,003.00	3,153.15	12,297.29	17,934	15,372	58,660.58										
34	1203	MR. MOINUL AKBAR MUNNA	2,600.00	3,120.00	2,028.00	5,070.00	5,577.00	5,855.85	22,837.82	33,305	28,547	108,941.08										
35	1233	MRS. SUFIYA AKHTAR KHATUN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10										
36	1235	MRS. MANJU RANI SARKER	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										
37	1241	MR. MASHUQUR RAHMAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10										
38	1242	MRS. MAHMUDA RAHMAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10										
39	1243	MR. MD. NURUL HOQUE	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08										

SL No.	Folio No.	Name	2010	2011	2014	2015 2016	2016 2017	2017 2018	2018 2019	2019 2020	2020 2021	Amount in Taka
40	1244	MR. DEEPTI PRASANNA CHOWDHURY	750.00	900.00	585.00	1,462.50	1,608.75	1,689.19	6,587.83	9,607	8,235	31,425.31
41	1251	MRS. SABRINA KHAN	400.00	480.00	312.00	780.00	858.00	900.90	3,513.51	5,124	4,392	16,760.17
42	1268	BRIG.A.S. MAHMOOD	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
43	1285	MR. MD. IKRAMUL BARI	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
44	1348	MR. MASUD REZA BHUIYAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
45	1349	MRS. YASMIN RAHMAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
46	1420	MR. SHARIF ATAUR RAHMAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
47	1459	MR. AMINUL ISLAM KHAN	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06
48	1463	DR. TOFAIL AHMED CHOWDHURY	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06
49	1468	MR. HASIB-BIN-AKBAR	200.00	240.00	156.00	390.00	429.00					1,415.00
50	1469	MRS. HAZERA AKBAR	200.00	240.00	156.00	390.00	429.00					1,415.00
51	1470	MR. S.M. AKBAR HOSSAIN	200.00	240.00	156.00	390.00	429.00					1,415.00
52	1482	MR. MD. RABIUL ISLAM	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
53	1533	Mr. Syed Ashraf Ali Bonus paid									2,196	2,195.94
54	1534	MR. MD. ABU TAHER MIA	750.00	900.00	585.00	1,462.50	1,608.75	1,689.19	6,587.83	9,607	8,235	31,425.31
55	1547	MR. S.M. ASFAQUZZAMAN	600.00	720.00	468.00	1,170.00	1,287.00	1,351.35	5,270.27	7,686	6,588	25,140.25
56	1559	MR. MD. FARUK HOSSAIN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
57	1561	MRS. NAYAR SULTANA	1,000.00	1,200.00	780.00	1,950.00	2,145.00					7,075.00
58	1564	MR. MD. ABUL HOSSAIN	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
59	1600	MRS. TANZIA AFRIN	200.00	240.00	156.00	390.00	429.00					1,415.00
60	1608	MR. MUJIBUR RAHMAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
61	1644	MR. MD. SAYEDUR RAHMAN	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
62	1650	MR. MD. ALAMGIR	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
63	1708	MR. GRACY ROBERT KHAN	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
64	1753	MR. IFTEKHAR-UL-ISLAM	400.00	480.00	312.00	780.00	858.00	900.90	3,513.51	5,124	4,392	16,760.17
65	1773	MR. MD. ABDULLAH	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
66	1777	MR. MD. SHAHIDUR RAHMAN	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
67	1805	MR. M.A. SAMAD MAH	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
68	1822	MR. MD. MOHIUDDIN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
69	1839	MR. SANJIB KUMAR SARKER	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
70	1844	MR. MD. SHAHADAT HUSSIAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
71	1846	MR. M.A. TAHER	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
72	1859	MR. IMDADUL HOQUE	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
73	1860	MR. SHAMSUDDIN AHMED	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
74	1882	MR. MD. SHAFKAT HOSSAIN	500.00	600.00	390.00	975.00	1,072.50	1,126.13	4,391.89	6,405	5,490	20,950.21
75	1898	MR. TOFAZZAL HOSSAIN	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06
76	1899	MR. MD. SOLAIMAN MIAH	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
77	1905	MR. MD. JUBAIR- BIN-AMIR (RUMI)	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
78	1908	MR. SYED RIZWANUR RAHMAN	500.00	600.00	390.00	975.00	1,072.50	1,126.13	4,391.89	6,405	5,490	20,950.21
79	1909	MR. MOHAMMAD ALI	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
80	1914	MR. BADIUZZAMAN SARDER	50.00	60.00	39.00	97.50	107.25					353.75
81	1917	MR. NIKHLI KRISHNA SAHA	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
82	1928	MR. NAHIDUL HAQUE	1,000.00	1,200.00	780.00	1,950.00	2,145.00	2,252.25	8,783.78	12,810	10,980	41,900.42

SL No.	Folio No.	Name	2010	2011	2014	2015 2016	2016 2017	2017 2018	2018 2019	2019 2020	2020 2021	Amount in Taka
83	1929	MR. A.M. GHULAM WAHEED	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
84	1952	MR. NESAR UDDIN AHMED	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
85	1957	MR. MD. MOMINUR RASHID	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
86	1958	MR. MD. SHAFIQUL ISLAM	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
87	1962	MR. RAQIB UDDIN CHOWDHURY	200.00	240.00	156.00	390.00	429.00					1,415.00
88	1970	MR. MD. KAMAL UDDIN	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640.48	548.99	2,095.02
89	1979	MR. MD. SAIDUR RAHMAN	1,850.00	2,220.00	1,443.00	3,607.50	3,968.25	4,166.66	16,249.98	23,698	20,312	77,515.77
90	1984	MR. ZEHADUL ISLAM	500.00	600.00	390.00	975.00	1,072.50	1,126.13	4,391.89	6,405	5,490	20,950.21
91	2001	MR. MD. AKBAR HOSSEN	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06
92	2002	MR. MD. MONIR HOSSEN DULAL	600.00	720.00	468.00	1,170.00	1,287.00	1,351.35	5,270.27	7,686	6,588	25,140.25
93	2008	MRS. MAHBUB ARA BEGUM	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
94	2009	MR. KAZI ADIL AHMED SHAFI	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
95	2011	MR. MOHD. AMZAD HOSSAIN	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
96	2015	MR. BABUL BISWAS	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
97	2019	MRS. BASANA DAS	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
98	2020	MR. PRIYA LAL DAS	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
99	2029	MR. MD. HARUN-UR-RASHID	1,250.00	1,500.00	975.00	2,437.50	2,681.25	2,815.31	10,979.72	16,012	13,725	52,375.52
100	2035	MR. MD. ALAUDDIN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
101	2043	MR. ZAHIRUL HAQUE	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
102	2047	MR. MD. SAIFUL ISLAM	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
103	2048	MR. OBAIDULLAH	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
104	2049	MR. MD. REZAUL ISLAM	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
105	2053	MR. KAZI EYEYEAR AHAMED	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
106	2059	DR. MD. REZAUL ISLAM	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
107	2062	MR. S.M. NURUL ALAM	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
108	2064	MR. MD. MEHER UDDIN	900.00	1,080.00	702.00	1,755.00	1,930.50	2,027.03	7,905.40	11,529	9,882	37,710.37
109	2065	DR. SUKUR ALAM KHAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
110	2077	MR. MANJUR MORSHEED KOBIR	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
111	2079	MR. HUMAYUM KABIR	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
112	2096	MR. MD. MOAZZEM HOSSAIN	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06
113	2097	MR. MD. BAHAUDDIN MRIDHA	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
114	2099	DR. MASUDA SALMA	400.00	480.00	312.00	780.00	858.00	900.90	3,513.51	5,124	4,392	16,760.17
115	2102	MR. HAMIM CHOWDHURY	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
116	2116	MR. MD. QUAMRUZZAMAN KHAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
117	2125	MR. MD. ABUL HOSSAIN	450.00	540.00	351.00	877.50	965.25	1,013.51	3,952.70	5,764	4,941	18,855.19
118	2127	MR. SHAH JALAL UDDIN KHAN	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
119	2152	MR. IMTIAZ AHMED	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
120	2157	MR. SK. TALUKDER	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
121	2158	MR. ANWARUL HASAN	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
122	2168	MR. MOZAMMEL HAQUE	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
123	2177	MR. RAFIQUL ISLAM	500.00	600.00	390.00	975.00	1,072.50	1,126.13	4,391.89	6,405	5,490	20,950.21
124	2181	MR. A.H.M. SHAMSUL ALAM	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02

SL No.	Folio No.	Name	2010	2011	2014	2015 2016	2016 2017	2017 2018	2018 2019	2019 2020	2020 2021	Amount in Taka
125	2187	MRS. SELIMA AKHTER NILUFA BANU	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
126	2190	MR. MD. IFTEKHAR ALI	100.00	120.00	78.00	195.00	214.50	536.25	563.06	2,195.94	3,202	2,745
127	2195	MR. UTPAL DHAR	250.00	300.00	195.00	487.50	214.50	225.23	878.38	1,281	1,098	10,475.10
128	2196	MRS. NINA ISLAM	100.00	120.00	78.00	195.00	214.50	107.25	112.61	439.19	640	549
129	2197	MR. MD. LIAKAT ALI SARKER	50.00	60.00	39.00	97.50	536.25	563.06	2,195.94	3,202	2,745	4,190.04
130	2199	MR. A.K.M. MAHMUDUR RAHMAN	400.00	480.00	312.00	780.00	858.00	1,072.50	1,126.13	4,391.89	6,405	5,490
131	2210	MR. KHUSHI MOHAN PAUL	500.00	600.00	390.00	975.00	585.00	1,462.50	1,608.75	6,587.83	9,607	8,235
132	2213	MRS. MEHERUN HOSSAIN	750.00	900.00	585.00	1,462.50	1,608.75	1,689.19	6,587.83	9,607	8,235	31,425.31
133	2215	MR. MD. MOSHARRAF HOSSAIN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	2,095.02
134	2218	MR. ABDUL WAHAB	350.00	420.00	273.00	682.50	750.75	788.29	3,074.32	4,483	3,843	14,665.15
135	2227	MR. MD. ABAKAR SIDDIQUE	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
136	2263	MRS. REZIA BEGUM IA-28113	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
137	2282	MR. TOUHEED SHAJUJAHAN IA-30520	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
138	2301	MR. MD. TASLIM HOSSAIN IA-30827	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
139	2345	MR. M.A. QUASEM	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
140	2346	MR. MD. SARWAR HOSSAIN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
141	2463	MR. SHEIKH ABDUR RAHMAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	2,095.02
142	2464	MR. MUNIR HASAN	1,250.00	1,500.00	975.00	2,437.50	2,681.25	2,815.31	10,979.72	16,012	13,725	52,375.52
143	2469	MR. MD. NAZMUL ALAM CHOWDHURY	500.00	600.00	390.00	975.00	1,072.50	1,126.13	4,391.89	6,405	5,490	20,950.21
144	2470	MR. AZIZUL HOQUE SIKDER	400.00	480.00	312.00	780.00	858.00	900.90	900.90	3,513.51	5,124	4,392
145	2474	MR. MD. MONIR HOSEN	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
146	2477	MR. MAJEENUL ISLAM	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
147	2492	MRS. MOMOTAZ BEGUM	500.00	600.00	390.00	975.00	1,072.50	1,126.13	4,391.89	6,405	5,490	20,950.21
148	2505	MR. KANCHAN ALI HOWLADER	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
149	2520	MR. MD. SHAMSUDDIN	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08
150	2526	MRS. SHAMIM ARA BEGUM	400.00	480.00	312.00	780.00	858.00	900.90	900.90	3,513.51	5,124	4,392
151	2527	MRS. HOSNE ARA BEGUM	400.00	480.00	312.00	780.00	858.00	900.90	900.90	3,513.51	5,124	4,392
152	2528	MRS. FARHANA BEGUM	400.00	480.00	312.00	780.00	858.00	900.90	900.90	3,513.51	5,124	4,392
153	2532	MR. DEWAN ABDUL HAI	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
154	2533	MR. MANSOOR AHMED	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
155	2534	MR. ABU SALEH	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
156	2543	MR. ASHEEQUR RASUL	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
157	2567	MR. MD. MOZIBUR RAHMAN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
158	2568	MR. HABIB ULLAH	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06
159	2573	MR. MD. MOSTAFA KAMAL	300.00	360.00	234.00	585.00	643.50	675.68	2,635.13	3,843	3,294	12,570.12
160	2574	MR. SANWAR HOSSAIN	150.00	180.00	117.00	292.50	321.75	337.84	1,317.57	1,921	1,647	6,285.06
161	2582	MR. MD. TAZIRUL ISLAM	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
162	2585	MR. MD. SHAH ALAM	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
163	2590	MR. MD. NURUZZAMAN	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
164	2593	MR. MD. BAHAUDDIN	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10
165	2622	MR. MD. ASRAFUZZAMAN	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02
166	2626	MR. MOHMIM HASSAN	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04
167	2628	MR. MD. ABDUL HANNAN	50.00	60.00	39.00	97.50	107.25	112.61	439.19	640	549	2,095.02

SL No.	Folio No.	Name	2010	2011	2014	2015	2016	2017	2018	2019	2020	2021	Amount in Taka
168	2632	MR. EMADUR RAHMAN CHOWDHURY	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04	
169	2633	MR. MD. MANSUR ELAHI	100.00	120.00	78.00	195.00	214.50	225.23	878.38	1,281	1,098	4,190.04	
170	2640	MRS. ARJUMAN ARA BEGUM	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
171	2653	MR. SHAH ALAM ZAHIRUDDIN	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
172	2703	MRS. AFROZA AHSAN	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
173	2706	MR. MD. SHAHIDUL ISLAM	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
174	2707	MR. MD. SALIM	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
175	2748	MR. MD. ABDUS SALAM	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
176	2915	MR. SAYEED	400.00	480.00	312.00	780.00	858.00	900.90	3,513.51	5,124	4,392	16,760.17	
177	3055	MR. KLINTON SARKAR	1,200.00	1,440.00	936.00	2,340.00	2,574.00	2,702.70	10,540.53	15,372	13,176	50,280.50	
178	3076	BRAC	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
179	3089	MR. MD. MOYNUL HAQUE MOLLAH	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
180	3090	MR. MOHAMMAD SHOWKAT ALI KHAN	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
181	3094	MRS. MAHBUBA BEGUM	250.00	300.00	195.00	487.50	536.25	563.06	2,195.94	3,202	2,745	10,475.10	
182	3258	MR. A.H.M. DAULUDIN	100.00	120.00	78.00	195.00	214.50					707.50	
183	3259	MR. SYED JAMILUP RAB	50.00	60.00	39.00	97.50	107.25					353.75	
184	3260	MR. SYED ABDUR RAB	50.00	60.00	39.00	97.50	107.25					353.75	
185	3261	MR. S.M. ASHRAF HOSSAIN	50.00	60.00	39.00	97.50	107.25					353.75	
186	3304	MRS. SULTANA SHIRIN	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
187	3307	MR. NIAZ UDDIN AHMED	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
188	3391	DR. M.A. HALIM	200.00	240.00	156.00	390.00	429.00	450.45	1,756.76	2,562	2,196	8,380.08	
189	3454	MR. MONIR HOSSAIN	200.00	240.00	156.00	390.00	429.00					1,415.00	
190	3455	MR. MONSUR ALI	200.00	240.00	156.00	390.00	429.00					1,415.00	
191	3546	MR. A.N.M. SHAFIQUL HASAN KHAN	50.00	60.00	39.00	97.50	107.25					549	2,095.02
192	3778	MRS. ZAKIA SULTANA	50.00	60.00	39.00	97.50	107.25					549	2,095.02
193	3791	MR. SHAH ALAM (BABU)	50.00	60.00	39.00	97.50	107.25					549	2,095.02
194	3792	MR. BADAL KHAN	50.00	60.00	39.00	97.50	107.25					549	2,095.02
195	3880	MRS. SYEDA SONIA ALI, IA-12030	600.00	720.00	468.00	1,170.00	1,287.00	1,351.35	5,270.27	7,686	6,588	25,140.25	
196	890	MR. AGHA YUSUF	106.25	127.50	82.88	207.19	227.91	252.90	985.50	1,436		3,426.52	
197	2138	MR. MD. RAISUL KARIM	170	204	133	332	365					1,126.13	
198	4118	MR. MD. AZIZUL ISLAM	73,626	88,352	57,428	143,571	157,928	159,757	618,661	902,213	774,619	2,976,155	



## PHOTOGRAPHS OF WATA CHEMICALS LIMITED

# Photograph Factory Premises



# Photograph Factory Premises



## Photograph of Under Construction Mosque At Factory Premises



# Photograph Factory Premises



# Photograph Factory Premises



# Photograph Factory Premises



# Photograph Factory Premises



# Photograph Factory Premises



# Photograph Finished Products



ALUMINIUM SULPHATE



ZINC SULPHATE



## Photograph Finished Products



BASIC CHROME SULPHATE



MAGNESIUM SULPHATE

## Photograph RAW Materials



## Photograph Raw Materials



## Photograph VISIT BY SREDA OFFICIALS



# Photograph of 39th AGM



## PROXY FORM



17/B (3rd FLOOR), MONIPURIPARA, SANGSHAD  
AVENUE, DHAKA-1215, PHONE: 58152001,  
58155206 Fax: +880 2 58155091

I/We.....of.....

..... being a member of WATA Chemicals Limited, do hereby appoint  
Mr. /Ms.....of..... to attend and vote on my/our  
behalf at the 40th Annual General Meeting (AGM) of the Company to be held on 4:00 PM, Thursday, December- 29' 2022 at  
Virtual Platform and at any adjournment thereof.

As witness my / our hand this.....Day of December, 2022

.....  
Signature of Proxy



.....  
Signature of the Member

BO ID No.

BO ID No.

Notes:

No. of Shares held .....

01. A member entitled to attend and vote in the AGM may appoint a Proxy to attend and vote on his/her behalf.
02. The Proxy Form, duly filed and stamped must be deposited, not later than 48 (Forty Eight) hours before the time fixed for the meeting.
03. Signature of the Member(s) must be in accordance with the Specimen Signature recorded with the Company.
04. As per Article of Association of the Company, no person shall act as a proxy unless he himself is a shareholder of the company.

(Authorized Signature)  
WATA CHEMICALS LTD.

.....  
Signature Verified)

## ATTENDANCE SLIP



17/B (3rd FLOOR), MONIPURIPARA, SANGSHAD  
AVENUE, DHAKA-1215, PHONE: 58152001,  
58155206 Fax: +880 2 58155091

I/We do hereby record my/our attendance at the 40th Annual General Meeting (AGM) of the Company being held on 4:00 AM,  
Thursday, December- 29' 2022 at Virtual Platform. Name of the Member (s)/Proxy:.....  
.....

BO ID No of Member:

BO ID No of Proxy Holder:

No. of Shares held .....

.....  
Signature of member(s)/Proxy

**HEAD OFFICE:**

17/B (3rd Floor), Monipuripara  
Sangshad Avenue, Dhaka-1215

**FACTORY:**

Murapara, Rupgonj, Narayanganj.

H/Line

: +88 01643249460

Tel : 02-58152001, 02-58155206

Fax : 880-2-58155091

website : [www.watachemicals.com](http://www.watachemicals.com)

e-mail : [watachemicals@gmail.com](mailto:watachemicals@gmail.com)